0001193125-23-173796.txt : 20230623 0001193125-23-173796.hdr.sgml : 20230623 20230623160329 ACCESSION NUMBER: 0001193125-23-173796 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20230623 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230623 DATE AS OF CHANGE: 20230623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enliven Therapeutics, Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 231037629 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-647-8519 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: IMARA Inc. DATE OF NAME CHANGE: 20160419 8-K 1 d514661d8k.htm 8-K 8-K
false0001672619CO 0001672619 2022-12-31 0001672619 2021-12-31 0001672619 2022-01-01 2022-12-31 0001672619 2021-01-01 2021-12-31 0001672619 2023-06-23 2023-06-23 0001672619 2020-06-30 0001672619 2020-06-01 2020-06-30 0001672619 2023-02-23 2023-02-23 0001672619 2021-02-28 0001672619 2021-03-01 0001672619 2022-01-31 0001672619 2021-03-01 2021-03-31 0001672619 2022-01-01 2022-01-31 0001672619 2022-04-01 2022-04-30 0001672619 2023-02-23 0001672619 2020-01-01 2020-12-31 0001672619 2020-12-31 0001672619 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 elvn:UnvestedRestrictedStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-01-01 2022-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0001672619 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001672619 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember 2022-01-01 2022-12-31 0001672619 us-gaap:DividendPaidMember 2022-01-01 2022-12-31 0001672619 us-gaap:DividendDeclaredMember 2022-01-01 2022-12-31 0001672619 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001672619 us-gaap:AccountsPayableMember 2022-01-01 2022-12-31 0001672619 us-gaap:AccruedLiabilitiesMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:TaxYearTwoThousandAndThirtyNineMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember elvn:ColoradoTaxAuthorityMember elvn:TaxYearTwoThousandFortyOneMember 2022-01-01 2022-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:InternalRevenueServiceIRSMember elvn:TaxYearTwoThousandFortyOneMember us-gaap:ResearchMember 2022-01-01 2022-12-31 0001672619 us-gaap:ResearchMember 2022-01-01 2022-12-31 0001672619 elvn:TheTaxCutsAndJobsActMember elvn:PostTaxYearTwoThousandAndTwentyOneMember 2022-01-01 2022-12-31 0001672619 elvn:TaxYearTwoThousandTwentyOneAndPriorMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:LaboratoryEquipmentMember 2022-12-31 0001672619 us-gaap:ComputerEquipmentMember 2022-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember elvn:MergerAgreementMember 2022-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:IPOMember 2022-12-31 0001672619 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0001672619 us-gaap:RestrictedStockMember 2022-12-31 0001672619 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember elvn:NotExpirableMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:TaxYearTwoThousandAndThirtyNineMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember elvn:ColoradoTaxAuthorityMember elvn:TaxYearTwoThousandFortyOneMember 2022-12-31 0001672619 srt:MinimumMember 2022-12-31 0001672619 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember elvn:TaxYearTwoThousandFortyOneMember us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:NotExpirableMember us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:LaboratoryEquipmentMember 2021-12-31 0001672619 us-gaap:ComputerEquipmentMember 2021-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember elvn:MergerAgreementMember 2021-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0001672619 us-gaap:RestrictedStockMember 2021-12-31 0001672619 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 elvn:UnvestedRestrictedStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:AccountsPayableMember 2021-01-01 2021-12-31 0001672619 us-gaap:AccruedLiabilitiesMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-12-31 0001672619 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001672619 us-gaap:ResearchMember 2021-01-01 2021-12-31 0001672619 srt:MaximumMember elvn:EnlivenIncMember elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2019-07-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-04-30 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-04-01 2020-04-30 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-12-01 2020-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2020-08-01 2020-08-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2020-08-31 0001672619 elvn:StockOptionRepricingMember 2022-08-09 2022-08-09 0001672619 elvn:StockOptionRepricingMember elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2022-08-09 2022-08-09 0001672619 elvn:EnlivenIncMember us-gaap:RestrictedStockMember 2019-06-01 2019-06-30 0001672619 us-gaap:RestrictedStockMember elvn:EnlivenIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-06-01 2019-06-30 0001672619 srt:MinimumMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 srt:MaximumMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 elvn:EmployeesAndConsultantsMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2020-12-31 0001672619 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001672619 us-gaap:CommonStockMember 2022-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001672619 us-gaap:RetainedEarningsMember 2022-12-31 0001672619 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001672619 us-gaap:CommonStockMember 2020-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001672619 us-gaap:RetainedEarningsMember 2020-12-31 0001672619 us-gaap:RestrictedStockMember 2020-12-31 0001672619 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001672619 us-gaap:CommonStockMember 2021-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001672619 us-gaap:RetainedEarningsMember 2021-12-31 iso4217:USD utr:sqft xbrli:shares utr:Year xbrli:pure utr:Month iso4217:USD xbrli:shares elvn:DIRECTOR elvn:Segment elvn:Vote
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 23, 2023
 
 
Enliven Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
  
001-39247
  
81-1523849
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
6200 Lookout Road
    
Boulder, CO
  
80301
(Address of principal executive offices)
  
(Zip Code)
(720)
647-8519
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
 
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
 
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol
  
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
  
ELVN
  
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company  
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
☐
 
 
 
 
Item 5.07
Submission of Matters to a Vote of Security Holders.
Enliven Therapeutics, Inc. (the “
Company
”) held its Annual Meeting of stockholders (the “
Annual Meeting
”) on June 23, 2023. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of two Class III Directors
 
Name of Director
   
For
     
Withheld
     
Broker Non-Votes
Richard Heyman, Ph.D.
   
 
30,518,067
 
   
 
385,508
 
   
1,641,388
Samuel Kintz, M.B.A.
   
 
30,900,278
 
   
 
3,297
 
   
1,641,388

Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
 
For
  
Against
  
Abstain
32,543,338
  
1,460
  
165
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
 
Item 8.01
Other Events.
As previously reported, on February 23, 2023, the Company effected a
1-for-4
reverse stock split of its common stock (the “
Reverse Stock Split
”) in connection with its merger with Enliven Inc. (formerly, Enliven Therapeutics, Inc.) (“
Former Enliven
”). In connection with such merger, the Company issued common stock to Former Enliven stockholders based on an exchange ratio of approximately 0.2951 shares of common stock for each share of Former Enliven capital stock (which exchange ratio reflects the Reverse Stock Split) (the “
Exchange Ratio
”). To reflect the Reverse Stock Split and the Exchange Ratio, the audited financial statements of Former Enliven as of December 31, 2022 and 2021 and for the years then ended have been recasted and are filed herewith as Exhibit 99.1. There have been no other changes to such financial statements.
The unaudited pro forma financial information of the Company as of March 31, 2023 and for the year ended December 31, 2022 and three-month period ended March 31, 2023 are filed herewith as Exhibit 99.2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
ENLIVEN THERAPEUTICS, INC.
   
By:
  
/s/ Samuel Kintz
   
Samuel Kintz
   
President and Chief Executive Officer
Date: June 23, 2023
EX-23.1 2 d514661dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-254978 on Form S-3 and Registration Statements Nos. 333-237117, 333-258538, 333-263554 on Form S-8 of Imara Inc. and Registration Statement No. 333-270188 on Form S-8 of Enliven Therapeutics, Inc. (formerly Imara Inc.) of our report dated March 21, 2023, (June 23, 2023, as to the effects of the exchange ratio described in Note 1) relating to the financial statements of Enliven Inc. (formerly Enliven Therapeutics, Inc.), appearing in this Current Report on Form 8-K of Enliven Therapeutics, Inc. dated June 23, 2023.

/s/ DELOITTE & TOUCHE LLP

San Jose, California

June 23, 2023

EX-99.1 3 d514661dex991.htm EX-99.1 EX-99.1
P4YP3Yhttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate201912Member1-for-4
Exhibit 99.1
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO FINANCIAL STATEMENTS
ENLIVEN THERAPEUTICS, INC.
 
    
Page
  
Report of Independent Registered Public Accounting Firm
   
 
F-2
 
Financials Statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021
   
 
F-3
 
Balance Sheets
   
 
F-3
 
Statements of Operations and Comprehensive Loss
   
 
F-4
 
Statements of Convertible Preferred Stock and Stockholders’ Deficit
   
 
F-5
 
Statements of Cash Flows
   
 
F-6
 
Notes to Financial Statements
   
 
F-7
 
 
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of Enliven Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Enliven Inc. (formerly Enliven Therapeutics, Inc.) (the “Company”) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ deficit, and cash flows, for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Deloitte & Touche LLP
San Jose, California
March 21, 2023 (June 23, 2023, as to the effects of the exchange ratio described in Note 1)
We have served as the Company’s auditor since 2020.
 
F-2
ENLIVEN THERAPEUTICS, INC.
BALANCE SHEETS
(in thousands, except share and per share amounts)
 
 
  
As of December 31,
 
 
  
2022
 
 
2021
 
ASSETS
  
 
CURRENT ASSETS
  
 
Cash and cash equivalents
   
$
75,536
 
  
$
110,024
 
Prepaid expenses and other current assets
   
 
2,217
 
  
 
646
 
    
 
 
    
 
 
  
Total current assets
   
 
77,753
 
  
 
110,670
 
Property and equipment, net
   
 
890
 
  
 
492
 
Right of use asset
   
 
626
 
  
 
462
 
Deferred offering costs
   
 
3,975
 
  
 
1,651
 
Restricted cash
   
 
54
 
  
 
54
 
    
 
 
    
 
 
  
TOTAL ASSETS
   
$
83,298
 
  
$
113,329
 
 
 
 
 
 
 
 
 
 
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
                
CURRENT LIABILITIES
               
 
Accounts payable, net
   
$
3,438
 
  
$
2,521
 
Accrued expenses and other current liabilities
   
 
6,277
 
  
 
3,232
 
    
 
 
    
 
 
  
Total current liabilities
   
 
9,715
 
  
 
5,753
 
LONG TERM LIABILITIES
                 
Other
non-current
liabilities
   
 
659
 
  
 
714
 
    
 
 
    
 
 
  
Total liabilities
   
 
10,374
 
  
 
6,467
 
    
 
 
    
 
 
  
COMMITMENTS AND CONTINGENCIES (Note 7)
            
Convertible preferred stock, $0.0001 par value; 61,730,064 shares authorized, issued and outstanding at December 31,
2022 and December 31, 2021, liquidation preference of $140,520 at December 31, 2022 and December 31, 2021
   
 
149,749
 
  
 
149,749
 
STOCKHOLDERS’ EQUITY
                 
Common stock $0.0001 par value; 26,264,364 shares authorized at December 31, 2022 and December 31, 2021;
3,570,019 and 3,435,014 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively
   
 
1
 
  
 
1
 
Additional
paid-in
capital
   
 
6,038
 
  
 
2,314
 
Accumulated deficit
   
 
(82,864
) 
  
 
(45,202
) 
    
 
 
    
 
 
  
Total stockholders’ deficit
   
 
(76,825
) 
  
 
(42,887
) 
    
 
 
    
 
 
  
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
   
$
83,298
 
  
$
113,329
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of these financial statements
 
F-3
ENLIVEN THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
 
    
Year Ended December 31,
  
    
2022
 
 
2021
  
Operating expenses:
     
Research and development
   
$
31,022
 
  
$
20,474
 
General and administrative
   
 
7,769
 
  
 
4,288
 
  
 
 
    
 
 
  
Total operating expenses
   
 
38,791
 
  
 
24,762
 
  
 
 
    
 
 
  
Loss from operations
   
 
(38,791
) 
  
 
(24,762
) 
Other income (expense), net
     
Interest income
   
 
1,129
 
  
 
22
 
  
 
 
    
 
 
  
Total other income, net
   
 
1,129
 
  
 
22
 
  
 
 
    
 
 
  
Net loss and comprehensive loss
   
$
(37,662
) 
  
$
(24,740
) 
  
 
 
    
 
 
  
Net loss per share attributable to common stockholders, basic and diluted
   
$
(12.05
) 
  
$
(10.73
) 
  
 
 
    
 
 
  
Weighted-average number of shares outstanding used in computing net loss per common share, basic and diluted
   
 
3,124,274
 
  
 
2,306,110
 
  
 
 
    
 
 
  
The accompanying notes are an integral part of these financial statements
 
F-4
ENLIVEN THERAPEUTICS, INC.
STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(in thousands, except share amounts)
 
    
Convertible
         
 
 
  
 
 
  
Additional

Paid-in

Capital
 
  
Accumulated

Deficit
 
 
Total

Stockholders’

Deficit
  
    
Preferred Stock
         
Common Stock
  
    
Shares
 
  
Amount
          
Shares
 
  
Amount
  
Balance - January 1, 2021
   
 
61,730,064
 
   
$
149,749
 
  
 
   
 
3,257,927
 
   
$
1
 
   
$
157
 
   
$
(20,462
) 
  
$
(20,304
) 
Exercise of common stock options
   
 
—  
 
   
 
—  
 
  
 
   
 
177,087
 
   
 
—  
 
   
 
136
 
   
 
—  
 
  
 
136
 
Vesting of restricted stock and stock options
   
 
—  
 
   
 
—  
 
  
 
   
 
—  
 
   
 
—  
 
   
 
97
 
   
 
—  
 
  
 
97
 
Stock-based compensation
   
 
—  
 
   
 
—  
 
  
 
   
 
—  
 
   
 
—  
 
   
 
1,924
 
   
 
—  
 
  
 
1,924
 
Net loss
   
 
—  
 
   
 
—  
 
  
 
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
(24,740
) 
  
 
(24,740
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance - December 31, 2021
   
 
61,730,064
 
   
 
149,749
 
  
 
   
 
3,435,014
 
   
 
1
 
   
 
2,314
 
   
 
(45,202
) 
  
 
(42,887
) 
Exercise of common stock options
   
 
—  
 
   
 
—  
 
  
 
   
 
135,005
 
   
 
—  
 
   
 
246
 
   
 
—  
 
  
 
246
 
Vesting of restricted stock and stock options
   
 
—  
 
   
 
—  
 
  
 
   
 
—  
 
   
 
—  
 
   
 
287
 
   
 
—  
 
  
 
287
 
Stock-based compensation
   
 
—  
 
   
 
—  
 
  
 
   
 
—  
 
   
 
—  
 
   
 
3,191
 
   
 
—  
 
  
 
3,191
 
Net loss
   
 
—  
 
   
 
—  
 
  
 
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
(37,662
) 
  
 
(37,662
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance - December 31, 2022
   
 
61,730,064
 
   
$
149,749
 
  
 
   
 
3,570,019
 
   
$
1
 
   
$
6,038
 
   
$
(82,864
) 
  
$
(76,825
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The accompanying notes are an integral part of these financial statements
 
F-5
ENLIVEN THERAPEUTICS, INC.
STATEMENTS OF CASH FLOWS
(in thousands)

 
 
  
Year Ended
 
 
  
December 31,
 
 
  
2022
 
 
2021
 
Cash flows from operating activities:
                 
Net loss
   
$
(37,662
) 
  
$
(24,740
) 
Adjustments to reconcile net loss to net cash used in operating activities:
                 
Depreciation
   
 
215
 
  
 
115
 
Stock-based compensation
   
 
3,191
 
  
 
1,924
 
Write-off
of deferred IPO costs
   
 
1,741
 
  
 
—  
 
Changes in operating assets and liabilities:
                 
Prepaid expenses and other assets
   
 
(1,590
) 
  
 
(563
) 
Right-of-use
asset
   
 
4
 
  
 
133
 
Accounts payable
   
 
411
 
  
 
1,734
 
Accrued expenses and other liabilities
   
 
1,613
 
  
 
2,263
 
    
 
 
    
 
 
  
Net cash used in operating activities
   
 
(32,077
) 
  
 
(19,134
) 
    
 
 
    
 
 
  
Cash flows from investing activities:
                 
Purchases of property and equipment
   
 
(612
) 
  
 
(191
) 
    
 
 
    
 
 
  
Net cash used in investing activities
   
 
(612
) 
  
 
(191
) 
    
 
 
    
 
 
  
Cash flows from financing activities:
                 
Issuance of convertible preferred stock, net of issuance costs
   
 
—  
 
  
 
(226
) 
Deferred issuance costs related to merger / initial public offering
   
 
(2,390
) 
  
 
(1,480
) 
Issuance of common stock
   
 
591
 
  
 
690
 
    
 
 
    
 
 
  
Net cash used in financing activities
   
 
(1,799
) 
  
 
(1,016
) 
    
 
 
    
 
 
  
Net decrease in cash, cash equivalents and restricted cash
   
 
(34,488
) 
  
 
(20,341
) 
Cash, cash equivalents and restricted cash at the beginning of the period
   
 
110,078
 
  
 
130,419
 
    
 
 
    
 
 
  
Cash, cash equivalents and restricted cash at the end of the period
   
$
75,590
 
  
$
110,078
 
    
 
 
    
 
 
  
Components of cash, cash equivalents and restricted cash:
                 
Cash and cash equivalents
   
$
75,536
 
  
$
110,024
 
Restricted cash
   
 
54
 
  
 
54
 
    
 
 
    
 
 
  
Total cash, cash equivalents and restricted cash
   
$
75,590
 
  
$
110,078
 
    
 
 
    
 
 
  
Supplemental disclosure of
non-cash
operating activities:
                 
Deferred issuance costs related to initial public offering included in accounts payable
   
$
—  
 
  
$
131
 
    
 
 
    
 
 
  
Deferred issuance costs related to initial public offering included in accrued liabilities
   
$
—  
 
  
$
39
 
    
 
 
    
 
 
  
Deferred merger costs included in accounts payable
   
$
656
 
  
$
—  
 
    
 
 
    
 
 
  
Deferred merger costs included in accrued liabilities
   
$
1,190
 
  
$
—  
 
    
 
 
    
 
 
  
Lease liability obtained in exchange for right of use asset
   
$
387
 
  
$
491
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of these financial statements
 
F-6
ENLIVEN THERAPEUTICS, INC.
NOTES TO FINANCIAL STATEMENTS
In connection with the closing of the Merger (as defined below) Enliven Therapeutics, Inc. changed its name to Enliven Inc. on February 23, 2023. For the purposes of these Notes to the Financial Statements, Enliven Therapeutics, Inc. is referring to the company prior to the Merger (as defined below).
1. Organization, Description of Business and Liquidity
Business
Enliven Therapeutics, Inc. (the Company) was incorporated in the State of Delaware on June 12, 2019 and is headquartered in Boulder, Colorado. The Company is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. The Company aims to address emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Its discovery process combines deep insights in clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs.
Since its inception, the Company has devoted substantially all of its efforts to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities. To date, the Company has funded its operations primarily through private placements of its convertible preferred stock.
On October 13, 2022, the Company entered into an agreement and plan of merger (Merger Agreement) with Imara Inc. (Imara), a Delaware corporation and Iguana Merger Sub, Inc., a wholly-owned subsidiary of Imara (Merger Sub). Pursuant to the Merger Agreement, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the merger (the Merger). Immediately prior to the closing of the Merger, certain new and current investors subscribed for the purchase of an aggregate of approximately $164.5 million of common stock of Enliven (the Financing). On February 23, 2023, Enliven closed the Merger with Imara Inc. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc.
Risks and uncertainties
The Company is subject to risks common to development-stage companies in the biotechnology industry including, but not limited to, risks of failure of preclinical studies and clinical trials, new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on third-party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, compliance with government regulations and the need to obtain additional financing.
The Company continues to closely monitor macroeconomic and geopolitical developments, including the global
COVID-19
pandemic, the Russia- Ukraine conflict and inflation. The extent of the impact of these developments on the Company’s business, operations and research and development timelines and plans remains uncertain, and will depend on numerous factors, including the impact, if any, on the Company’s personnel, responses of governmental entities, and the responses of third parties such as contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties with whom the Company does business. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s development activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the potential impact of these developments on its business and financial statements. To date, the Company has not experienced material business disruptions or incurred impairment losses in the carrying values of its assets as a result of these developments, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these financial statements.
 
F-7
Liquidity considerations
In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional capital. Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we may seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our capital requirements. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, that will occur.
The Company has incurred significant losses and negative cash flows from operations since inception. As of December 31, 2022, the Company had an accumulated deficit of $82.9 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $37.7 million and $24.7 million for the years ended December 31, 2022 and 2021, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash and cash equivalents of $75.5 million as of December 31, 2022 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.
Merger Agreement and Exchange Ratio
On October 13, 2022, the Company entered into the Merger Agreement with Imara, a Delaware corporation and Merger Sub. Pursuant to the Merger Agreement, among other matters, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the Merger. The Merger was intended to qualify for U.S. federal income tax purposes as a tax-free “reorganization” under the provisions of Section 368(a) of the Code and, in the event that former Enliven stockholders, including stockholders that participate in the Enliven
pre-closing
financing, are in “control” of Imara immediately after the effective time of the Merger (within the meaning of Section 368(c) of the Code), as a
non-taxable
exchange of shares of Enliven common stock for shares of Imara common stock within the meaning of Section 351(a) of the Code, with the result that Enliven stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes upon the exchange of Enliven common stock for Imara common stock pursuant to the Merger, except with respect to cash received in lieu of a fractional share of Imara common stock.
Upon the closing of the Merger on February 23, 2023, (a) each outstanding share of Company common stock (including common stock issued upon the conversion of the Company’s preferred stock, and shares issued in the Financing) was converted into the right to receive a number of shares of Imara common stock (Imara Common Stock) (after giving effect to the
1-for-4
reverse stock split of Imara Common Stock in connection with the Merger) equal to the exchange ratio per the Merger Agreement; and (b) each of the then outstanding Company stock option that had not previously been exercised prior to the closing of the Merger was assumed by Imara.
Immediately prior to the closing of the Merger, and in order to provide the Company with additional capital for its development programs, certain new and current investors purchased an aggregate of approximately $164.5 million of common stock of Enliven.
The Merger and Financing were completed on February 23, 2023. The Merger has been accounted for as a reverse recapitalization under U.S. GAAP because the assets of Imara as of the effective date of the Merger are primarily cash and other
non-operating
assets. Enliven was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (1) Enliven stockholders own a substantial majority of the voting rights in the combined company; (2) Enliven designated a majority (eight of nine) of the initial members of the board of directors of the combined company; and (3) Enliven’s senior management holds all positions in senior management
of
the combined company.
 
F-8
2. Summary of Significant Accounting Policies
Basis of presentation
The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB).
Use of estimates
The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and
stock-based
compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate.
Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations.
Restricted cash
The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets.
 
F-9
Concentrations of credit risk and
off-balance
sheet risk
The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances.
Fair value measurements
Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are as follows:
 
  •  
Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
 
  •  
Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and
 
  •  
Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.
The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities.
Deferred offering costs
Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively.
 
F-10
Property and equipment, net
Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.
The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of three to
five years
.
Impairment of long-lived assets
The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements.
Leases
The Company elected to early adopt ASU
No. 2016-02,
Leases (ASC 842) and its associated amendments as of January 1, 2020. In June 2020, the Company entered into a sublease agreement under which it leased laboratory and office facilities which the Company determined to be an operating lease. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding
right-of-use
asset (ROU) upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding
right-of-use
assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. As the Company’s lease does not provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and
non-lease
components.
Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other
non-current
liabilities.
Convertible preferred stock
The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur.
 
F-11
Research and development expenses
The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and
non-clinical
studies, costs to acquire, develop and manufacture supplies for preclinical and clinical testing and other studies, expenses incurred under agreements with contract research organizations, and salaries and related costs, including equity-based compensation, as well as depreciation and other allocated facility-related and overhead expenses. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.
The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and
non-clinical
study materials are manufactured by contract manufacturing organizations. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company’s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
Stock-based compensation
The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur.
The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified.
Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:
 
  •  
Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock.
 
  •  
Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the
mid-point
between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.
 
F-12
  •  
Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. 
 
  •  
Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards.
 
  •  
Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero.
The assumptions underlying these valuations represented the Company’s board and management’s best estimates,
which
involved inherent uncertainties and the application of management’s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its stock-based compensation expense could be materially different.
Income taxes
Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.
The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
Net loss per share
The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the
two-class
method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. The net loss attributable to common stockholders is not allocated to the convertible preferred shares as the holders of convertible preferred shares do not have a contractual obligation to share in losses. Cumulative dividends on preferred shares are added to net loss to arrive at net loss available to common stockholders.
Under the
two-class
method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted common stock as these shares are considered contingently issuable shares until they vest.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.
 
F-13
Segments
The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance.
Comprehensive income (loss)
Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. The Company did not have any items that required classification as other comprehensive income (loss).
Emerging growth company status
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently issued accounting pronouncements adopted
In December 2019, the FASB issued ASU
2019-12,
Simplifying the Accounting for Income Taxes (ASU
2019-12).
ASU
2019-12
eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance was effective for fiscal years beginning after December 15, 2021. The Company
adopted
ASU 2019-12
on
January 1, 2022
, and the adoption did not have a material impact.
 
F-14
3. Fair Value Measurements
The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):
 
    
As of December 31, 2022
  
    
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
  
Assets:
            
US Treasury backed money market funds
   
$
74,523
 
   
$
74,523
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total financial assets measured at fair value
   
$
74,523
 
   
$
74,523
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
As of December 31, 2021
 
    
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
Assets:
            
US Treasury backed money market funds
   
$
106,768
 
   
$
106,768
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total financial assets measured at fair value
   
$
106,768
 
   
$
106,768
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy.
 
F-15
4. Leases
Facility lease
In June 2020, the Company leased office and laboratory space under a sublease agreement for 6,782 square feet, which was set to expire on December 30, 2021. In March 2021, the Company amended its sublease agreement, increasing its leased space by 2,495 square feet to 9,277 square feet and monthly rent to $12,000. Upon the extension of the lease in March 2021, the lease was automatically extended to December 30, 2024. Additionally, in January 2022 the Company amended its sublease, which increased the leased space by an additional 8,893 square feet commencing on May 1, 2022, and the rental payments increased by an equally proportionate amount to reflect the increase in floor space. Further, in April 2022 the Company amended the sublease, which deferred the expansion for the additional space to July 1, 2022. The monthly rent is subject to annual increases through the lease term. The Company is required to pay base rent expense as well as its proportionate share of the facilities operating expenses. The
non-lease
components, consisting primarily of common area maintenance, are paid separately based on actual costs incurred. Therefore, the variable
non-lease
components were not included in the right of use asset and lease liability and are reflected as expense in the period incurred. The incremental borrowing rate used to calculate the Company’s right of use asset and lease liability is 4%. The incremental borrowing rate was estimated based on the Company’s estimated borrowing rate on a collateralized loan. As of December 31, 2022, the remaining lease liability and right of use asset were $0.6 million and $0.6 million, respectively. As of December 31, 2021, the remaining lease liability and right of use asset were $0.5 million and $0.5 million, respectively.
 
F-16
The Company recognized rent expense under the facility sublease for the years ended December 31, 2022 and 2021 of $0.2 million. As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands):

 
 
  
As of

December 31, 2022
 
Year ending December 31,
         
   
2023
   
$
329
 
2024
   
 
341
 
    
 
 
  
Total minimum lease payments
   
 
670
 
Less: amount representing interest
   
 
26
 
    
 
 
  
Present value of lease liabilities
   
 
644
 
Less: current portion of lease liabilities
   
 
323
 
    
 
 
  
Lease liabilities, noncurrent
   
$
321
 
    
 
 
  
During the years ended December 31, 2022 and 2021, the Company recognized $0.3 million and $0.2 million in variable lease costs, respectively.
5. Property and Equipment, Net
Property and equipment, net consisted of the following (dollars in thousands):
 
    
Estimated Useful Life
 
  
As of December 31,
 
    
in Years
 
  
2022
 
  
2021
 
Laboratory equipment
   
 
5
 
   
$
1,191
 
   
$
614
 
Computer equipment
   
 
3
 
   
 
73
 
   
 
38
 
             
 
 
     
 
 
  
             
 
1,264
 
   
 
652
 
Less: accumulated depreciation
            
 
(374
) 
   
 
(160
) 
             
 
 
     
 
 
  
Property and equipment, net
            
$
890
 
   
$
492
 
             
 
 
     
 
 
  
Depreciation expense for the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively.
6. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
 
    
As of December 31,
 
    
2022
 
  
2021
 
Accrued employee compensation costs
   
$
2,130
 
   
$
1,027
 
Accrued research and development costs
   
 
1,918
 
   
 
1,637
 
Accrued deferred offering costs
   
 
1,190
 
   
 
39
 
Lease liabilities
   
 
323
 
   
 
159
 
Accrued legal and professional fees
   
 
269
 
   
 
176
 
Other
   
 
447
 
   
 
194
 
    
 
 
     
 
 
  
Accrued expenses and other current liabilities
   
$
6,277
 
   
$
3,232
 
 
 
 
 
 
 
 
 
 
 
F-17
7. Commitments and Contingencies
Lease commitments
—The Company’s commitments related to lease agreements are disclosed in Note 4.
Litigation
—From time to time, the Company may be involved in legal proceedings or be subject to claims arising in the ordinary course of our business. The Company was not currently a party to any legal proceedings. Regardless of outcome, any proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.
Indemnification agreements
—In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company among other things to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its financial statements as of December 31, 2022 or 2021.
8. Common Stock
As of December 31, 2022 and 2021, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 26,264,364 shares of $0.0001 par value common stock, of which 3,570,019 and 3,435,014 shares were issued and outstanding, respectively. As of December 31, 2022 and 2021, there were 252,652 and 703,092 shares which were subject to repurchase, respectively. The liability related to shares subject to repurchase totaled $0.6 million as of December 31, 2022 and 2021, of which $0.3 million and $0.4 million were recorded as other
non-current
liabilities as of December 31, 2022 and 2021, respectively.
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any, subject to the preferential dividend rights of any convertible preferred stock. No dividends have been declared or paid by the Company through December 31, 2022.
In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any convertible preferred stock.
The Company had the following shares of common stock reserved for future issuance:
 
    
As of December 31,
  
    
2022
 
  
2021
  
Conversion of preferred stock
   
 
18,216,847
 
   
 
18,216,847
 
Issuance of common stock upon exercise of stock options
   
 
3,316,671
 
   
 
3,075,403
 
Options available for grant under stock plan
   
 
906,265
 
   
 
403,680
 
    
 
 
     
 
 
  
Total common stock reserved for future issuance
   
 
22,439,783
 
   
 
21,695,930
 
    
 
 
     
 
 
  
 
F-18
9. Convertible Preferred Stock
As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following:

 
 
  
 
 
  
 
 
  
 
 
  
Aggregate
 
  
Proceeds Net
 
 
  
 
 
  
Shares
 
  
Per Share
 
  
Liquidation
 
  
of Issuance
 
 
  
Authorized
 
  
Issued and
 
  
Liquidation
 
  
Amount
 
  
Costs
 
 
  
Shares
 
  
Outstanding
 
  
Preference
 
  
(in thousands)
 
  
(in thousands)
 
Series Seed convertible preferred stock
   
 
14,507,038
 
   
 
14,507,038
 
   
$
0.71
 
   
$
10,300
 
   
$
10,211
 
Series A convertible preferred stock
   
 
25,114,089
 
   
 
25,114,089
 
   
$
1.80
 
   
 
45,300
 
   
 
45,170
 
Series B convertible preferred stock
   
 
22,108,937
 
   
 
22,108,937
 
   
$
3.84
 
   
 
84,920
 
   
 
84,689
 
    
 
 
     
 
 
              
 
 
     
 
 
  
Total convertible preferred stock
   
 
61,730,064
 
   
 
61,730,064
 
            
$
140,520
 
   
$
140,070
 
    
 
 
     
 
 
              
 
 
     
 
 
  
No shares of convertible preferred stock were issued during the years ended December 31, 2022 and 2021.
 
F-19
The Company’s convertible preferred stock have the following rights, preferences, privileges and restrictions:
Voting
—On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of convertible preferred stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of convertible preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matters. Except as provided by law or by the other provisions of the Company’s Amended and Restated Certificate of Incorporation, holders of convertible preferred stock shall vote together with the holders of common stock as a single class and on an
as-converted
to common stock basis.
Dividends
—The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) in any calendar year unless the holders of the convertible preferred stock then outstanding shall first receive, or simultaneously receive, dividends on each outstanding share of convertible preferred stock in an amount for such calendar year equal to the greater of (i) the applicable dividend rate of $0.0426, $0.108226 and $0.2305 per share for the Series Seed, Series A and Series B, respectively, subject to adjustment in the event of any stock splits, stock dividends or similar changes in capitalization with respect to such class or series, and (ii) that dividend per share of such series of convertible preferred stock as would equal the product of (A) the dividend payable on each share of such series determined, if applicable, as if all shares of such series had been converted into common stock and (B) the number of shares of common stock issuable upon conversion of such series, in each case calculated on the record date for the determination of holders entitled to receive such dividend. The right to receive dividends on shares of convertible preferred stock shall not be cumulative, and no right to dividends shall accrue to holders of the convertible preferred stock by reason of the fact that dividends on such shares are not declared or paid.
Liquidation preference
—In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of the convertible preferred stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, and in the event of a deemed liquidation event, the holders of shares of convertible preferred stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such deemed liquidation event or out of the available proceeds, as applicable, on a pari passu basis among each other and before any payment shall be made to the holders of the common stock by reason of their ownership hereof, an amount equal to the greater of (i) one times the applicable original issue price of $0.71 per share of Series Seed, $1.803768 per share of Series A and $3.84098 per share of Series B, plus any dividends declared, but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of the convertible preferred stock had been converted into common stock immediately prior to such liquidation, dissolution, winding up or deemed liquidation event. If upon any such event, the assets of the Company available for distribution to the stockholders shall be insufficient to pay the holders of the convertible preferred stock the full amount, they shall be entitled to share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would be otherwise payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
After payment of the liquidation preference to the holders of convertible preferred stock, the remaining assets of the Company shall be distributed ratably to the holders of common stock on a fully converted basis.
Redemption
—The shares of convertible preferred stock shall not be redeemable by any holder.
Voluntary conversion
—Each share of convertible preferred stock shall be convertible, at the option of the holder thereof at any time and from time to time, without the payment of additional consideration by the holder thereof, into such number of fully paid and
non-assessable
shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price in effect at the time of conversion. The original issue price of the Series Seed, Series A and Series B convertible preferred shares is $0.71, $1.803768 and $3.84098, respectively. Such conversion price, and at the rate at which the convertible preferred shares may be converted into shares of common stock, shall be subject to adjustment for occurrences such as stock splits, certain dividends, mergers and distributions.
 
F-20
Automatic conversion
—Each share of convertible preferred stock will automatically be converted into shares of common stock, at the
then-effective
conversion rate of such shares upon either (i) the closing of the sale of shares of the Company’s common stock to the public in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, with proceeds of at least $75.0 million, or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the requisite holders, then all outstanding shares of convertible preferred stock shall automatically be converted into shares of common stock, at the then effective conversion rate.
10. Stock-Based Compensation
Equity Incentive Plan
—In July 2019, the Company adopted the 2019 Equity Incentive Plan (the 2019 Plan) pursuant to which the Company’s board of directors may grant
non-statutory
stock options, stock appreciation rights, restricted stock, and restricted stock units to employees and
non-employees
and incentive stock options only to employees. The 2019 Plan initially authorized grants of awards of up to 374,076 shares. In April 2020, the board of directors increased the number of shares of the Company’s common stock authorized for issuance under the 2019 Plan by 2,210,062 to 2,584,138 shares. Additionally, in December 2020, the board of directors approved to increase the number of shares of the Company’s common stock authorized for issuance under the 2019 Plan by 1,211,791 to 3,795,929 shares. In August 2022, the board of directors approved an increase in the shares authorized under the 2019 Equity Incentive Plan of 885,315 shares, for a total authorized amount of 4,681,244.
Awards granted under the 2019 Plan expire no later than 10 years from the date of grant. For incentive stock options and
non-statutory
stock options, the option exercise price will not be less than 100% of the estimated fair value on the date of grant. Options and restricted stock granted to employees typically vest over a four-year period but may be granted with different vesting terms.
 
F-21
Stock Option Repricing
Effective August 9, 2022, the Company’s board of directors repriced certain previously granted and still outstanding vested and unvested stock option awards under the 2019 Plan. As a result, the exercise price for these awards was lowered to $2.48 per share, which was the fair value of the Company’s common stock on August 9, 2022. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, 2,209,826 vested and unvested stock options outstanding as of August 9, 2022, with original exercise prices ranging from $4.68 to $7.56, were repriced. The repricing on August 9, 2022 resulted in incremental stock-based compensation expense of $1.0 million, of which $0.3 million related to vested stock option awards and was expensed on the repricing date, and $0.7 million related to unvested stock option awards is being amortized on a straight-line basis over the remaining weighted-average vesting period of those awards of approximately 2.9 years.
The following table summarizes the stock plan activity:
 
    
Available

for Grant
 
 
Stock
Options
Outstanding
 
 
Weighted-
Average Exercise
Price
 
  
Weighted-
Average
Contractual Term
(in years)
 
  
Aggregate
Intrinsic Value
(in thousands)
  
Outstanding - January 1, 2021
   
 
2,593,057
 
  
 
985,399
 
  
$
1.12
 
   
 
9.47
 
   
$
3,509
 
Options granted
   
 
(2,189,377
) 
  
 
2,189,377
 
  
$
4.71
 
   
 
9.38
 
   
Options exercised and vested
   
 
—  
 
  
 
(99,373
) 
  
$
2.26
 
   
 
8.77
 
   
  
 
 
    
 
 
          
Outstanding - December 31, 2021
   
 
403,680
 
  
 
3,075,403
 
  
$
3.64
 
   
 
9.11
 
   
$
9,657
 
Increase in option pool
   
 
885,315
 
          
Options granted
   
 
(391,653
) 
  
 
391,653
 
  
$
5.66
 
   
 
9.38
 
   
Options exercised and vested
   
 
—
 
  
 
(141,462
) 
  
$
3.72
 
   
 
8.09
 
   
Options cancelled and forfeited
   
 
8,923
 
  
 
(8,923
) 
  
$
4.68
 
   
 
8.23
 
   
  
 
 
    
 
 
          
Outstanding - December 31, 2022
   
 
906,265
 
  
 
3,316,671
 
  
$
2.20
 
   
 
8.26
 
   
$
1,194
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable - December 31, 2022
     
 
1,707,882
 
  
$
1.85
 
   
 
8.00
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vested and expected to vest - December 31, 2022
     
 
3,316,671
 
  
$
2.20
 
   
 
8.26
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The total intrinsic value of exercised and vested incentive awards during the year ended December 31, 2022 was $0.1 million and is calculated on the difference between the exercise price and the fair value of the Company’s common stock as of the exercise date.
The Company records stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, total compensation cost not yet recognized related to unvested stock options was $7.7 million, which is expected to be recognized over a weighted-average period of 2.43 years.
 
F-22
Restricted stock award activity
—Upon formation of the Company in June 2019, the Company issued 3.0 million shares in restricted common stock to the founders of the Company at $0.0003 per share. 25% of the shares vested immediately upon issuance, with the remaining shares vesting evenly over 36 or 48 months. Vesting may be accelerated upon a change in control, as defined in the holder agreements. If the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest. As of December 31, 2022 and 2021, there were 41,499 and 438,045 shares subject to repurchase, respectively.
Additionally, between 2019 and 2020, the Company issued a total of 197,262 shares of restricted stock to employees and consultants for aggregate consideration of $27,000. The purchase price of the restricted stock was the estimated fair value on the grant date. The restricted stock awards are subject to vesting over a period of four to five years, and vesting may be accelerated upon a change in control, as defined in the holder agreements.
If
 
the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest.
The following summarizes restricted stock activity:
 
    
Number of
Shares
 
  
Weighted-
Average
Grant Date Fair
Value
  
Unvested—December 31, 2020
   
 
160,935
 
   
$
0.14
 
Granted
   
 
—  
 
   
 
—  
 
Vested
   
 
(63,032
) 
   
 
0.14
 
Forfeited
   
 
—  
 
   
 
—  
 
  
 
 
     
Unvested—December 31, 2021
   
 
97,903
 
   
 
0.14
 
Granted
   
 
—  
 
   
 
—  
 
Vested
   
 
(47,446
) 
   
 
0.14
 
Forfeited
   
 
—  
 
   
 
—  
 
  
 
 
     
Unvested—December 31, 2022
   
 
50,457
 
   
$
0.14
 
  
 
 
     
The aggregate fair value of restricted stock that vested during the year ended December 31, 2022 was $0.1 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2022 was $0.14. Total intrinsic value of restricted stock as of December 31, 2022 was $0.2 million. As of December 31, 2022, total compensation cost not yet recognized related to unvested restricted stock was $4,000, which is expected to be recognized over a weighted-average period of 1.12 years.
The aggregate fair value of restricted stock that vested during the year ended December 31, 2021 was $0.3 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2021 was $0.14. Total intrinsic value of restricted stock as of December 31, 2021 was $3.6 million. As of December 31, 2021, total compensation cost not yet recognized related to unvested restricted stock was $7,000, which is expected to be recognized over a weighted-average period of 2.04 years.
 
F-23
Stock-based compensation expense
—The Company recorded stock-based compensation expense of $3.2 million and $1.9 million during the years ended December 31, 2022 and 2021, respectively.
Stock-based compensation expense is classified as follows (in thousands):
 
    
Year Ended December 31,
 
    
2022
 
  
2021
 
Research and development
   
$
1,893
 
   
$
1,019
 
General and administrative
   
 
1,298
 
   
 
905
 
  
 
 
     
 
 
  
Total stock-based compensation expense
   
$
3,191
 
   
$
1,924
 
 
 
 
 
 
 
 
 
 
 
F-24
The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used:
 
    
Year Ended December 31,
    
2022
  
2021
Stock price
   
$2.48 - $6.78  
   
$5.69 - $7.18
Expected term (years)
   
5.8 - 6.3 Years
   
6 Years
Expected volatility
   
80%
   
75% - 80%
Risk-free interest rate
   
1.60% - 3.00%
   
1.00% - 1.40%
Expected dividend yield
   
—
   
—
11. Income Taxes
The difference between the effective tax rate and the U.S. federal tax rate is as follows:
 
    
Year Ended
  
    
December 31,
  
    
2022
 
 
2021
  
Federal income tax
   
 
(21.0
)% 
  
 
(21.0
)% 
State income tax, less federal benefits
   
 
(6.7
)% 
  
 
(7.6
)% 
Permanent differences
   
 
1.5
% 
  
 
1.7
% 
Change in valuation allowance
   
 
26.7
% 
  
 
27.1
% 
Credits
   
 
(0.5
)% 
  
 
(0.4
)% 
Other
   
 
0.0
% 
  
 
0.2
% 
 
 
 
 
 
 
 
 
 
Effective tax rate
   
 
0.0
% 
  
 
0.0
% 
 
 
 
 
 
 
 
 
 
Significant components of the Company’s deferred income taxes consist of the following (in thousands):
 
    
As of December 31,
 
    
2022
 
  
2021
 
Deferred Tax Assets:
      
Intangible asset basis differences
   
$
43
 
   
$
47
 
Net operating loss carryforwards
   
 
12,894
 
   
 
8,918
 
Tax credit carryforwards
   
 
399
 
   
 
145
 
Capitalized research and development costs
   
 
5,422
 
   
 
—  
 
Other
   
 
1,017
 
   
 
530
 
  
 
 
     
 
 
  
Total deferred tax assets
   
 
19,775
 
   
 
9,640
 
Deferred Tax Liabilities:
      
Fixed asset basis difference
   
 
(49
) 
   
 
(33
) 
Goodwill differences
   
 
(175
) 
   
 
(129
) 
  
 
 
     
 
 
  
Total deferred tax liabilities
   
 
(224
) 
   
 
(162
) 
Valuation allowance
   
 
(19,551
) 
   
 
(9,478
) 
  
 
 
     
 
 
  
Net deferred tax assets
   
$
—  
 
   
$
—  
 
  
 
 
     
 
 
  
Realization of tax assets is dependent upon future earnings, the timing and amount of which are uncertain. Accordingly, the U.S. net deferred tax assets have been fully offset by a valuation allowance. The changes in the valuation allowance for the years ended December 31, 2022 and 2021 were $10.1 million and $6.7 million, respectively.
 
F-25
As of December 31, 2022, the Company had federal net operating loss carryforwards of approximately $39.5 million, which has no expiration for federal tax purposes. As of December 31, 2022, the Company had California net operating loss carryforwards of approximately $65.8 million, which will begin to expire in 2039 for California tax purposes. At December 31, 2022, the Company also had Colorado net operating loss carryforwards of approximately $4,000, which will begin to expire in 2041 for Colorado tax purposes.
 
F-26
Internal Revenue Code of 1986, as amended (IRC) Section 382 imposes limitations on the use of net operating loss carryforwards when the stock ownership of one or more 5% stockholders (stockholders owning more than 5% or more of the Company’s outstanding capital stock) has increased on a cumulative basis by more than 50 percentage points. There is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover. As of December 31, 2022, the Company has not completed an analysis whether an ownership change occurred under Section 382, which, if it did occur, could substantially limit its ability in the future to utilize its net operating loss and other tax carryforwards.
As of December 31, 2022, the Company had Federal research and development credit carryforwards of approximately $0.4 million, which will begin to expire in 2041. The Company had California research and development carryforwards of $0.2 million, which will not expire.
The Company adopted the provisions of FASB Accounting Standards Codification (ASC
740-10),
Accounting for Uncertainty in Income Taxes, upon the date of incorporation. ASC
740-10
prescribes a comprehensive model for the recognition, measurement presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. During the years ended December 31, 2022 and 2021, the Company had not recognized any
tax-related
penalties or interest. At December 31, 2022 the gross unrecognized tax benefit relating to research and development credits was $0.2 million, none of which if recognized would reduce the effective tax rate in a future period, due the Company’s full valuation allowance on U.S. net deferred tax assets. The Company does not expect that its uncertain tax positions will materially change in the next twelve months. The following table summarizes the changes to the Company’s unrecognized tax benefits (in thousands):
 
    
As of
 
    
December 31,
 
    
2022
 
  
2021
 
Balance, beginning of the period
   
$
47
 
   
$
7
 
Increase related to prior year positions
   
 
7
 
   
 
2
 
Increase related to current year positions
   
 
110
 
   
 
38
 
  
 
 
     
 
 
  
Balance, end of the period
   
$
164
 
   
$
47
 
  
 
 
     
 
 
  
All tax returns will remain open for examination by the federal and state taxing authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards or research and development credits.
On August 9, 2022 and August 16, 2022, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act and the Inflation Reduction Act (IRA), respectively, were signed into law. The CHIPS Act and IRA contain among other things, some income tax provisions that establish a corporate alternative minimum tax and provide tax incentives for semiconductor manufacturing and research. The Company has evaluated the current legislation and at this time, does not anticipate either to have a material impact on its financial statements.
The Tax Cuts and Jobs Act (TCJA) included a change in the treatment of research and development (R&D) expenditures for tax purposes under Section 174. Effective for tax years beginning after December 31, 2021, specified R&D expenditures must undergo a
5-year
amortization period for domestic spend and a
15-year
amortization period for foreign spend. Prior to the effective date (2021 tax year and prior), taxpayers were able to immediately expense R&D costs under Section 174(a) or had the option to capitalize and amortize R&D expenditures over a
5-year
recovery period under Section 174(b). The company has evaluated the current legislation at this time, and prepared the provision by following the treatment of R&D expenditures for tax purposes under Section 174.
 
F-27
12. 401(k) Savings Plan
The Company has a defined-contribution savings plan under IRC Section 401(k). The 401(k) Plan covers all employees who meet the defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. As of December 31, 2022 and 2021 the Company accrued no employee compensation costs for employer contributions payable to eligible employees.
13. Net Loss Per Share
Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts):
 
    
Year Ended December 31,
  
    
2022
 
  
2021
  
Numerator:
      
Net loss
   
$
(37,662
) 
   
$
(24,740
) 
 
 
 
 
 
 
 
 
 
Denominator:
      
Weighted-average common shares outstanding
   
 
3,548,829
 
   
 
3,335,786
 
Less: weighted-average unvested common stock issued upon early exercise of common stock options
   
 
(194,966
) 
   
 
(123,312
 )
 
Less: weighted-average unvested restricted shares of common stock
   
 
(229,589
) 
   
 
(906,364
 )
 
  
 
 
     
 
 
  
Weighted-average shares used to compute net loss per common share, basic and diluted
   
 
3,124,274
 
   
 
2,306,110
 
 
 
 
 
 
 
 
 
 
Net loss per share, basic and diluted
   
$
(12.05
) 
   
$
(10.73
) 
 
 
 
 
 
 
 
 
 
The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, and common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:
 
    
Year Ended
 
    
December 31,
 
    
2022
 
  
2021
 
Convertible preferred stock (as converted)
   
 
18,216,847
 
   
 
18,216,847
 
Stock options outstanding
   
 
3,316,671
 
   
 
3,075,403
 
Unvested restricted stock
   
 
91,953
 
   
 
535,945
 
  
 
 
     
 
 
  
Total
   
 
21,625,471
 
   
 
21,828,195
 
  
 
 
     
 
 
  
 
F-28
14. Subsequent Events
The Company evaluated subsequent events from December 31, 2022, the date of these financial statements, through June 23, 2023, which represents the date the financial statements were issued for events requiring recording or disclosure in the financial statements for the year ended December 31, 2022. The Company concluded that no events have occurred that would require recognition or disclosure in the financial statements, except as described below.
On February 23, 2023, Enliven closed the Merger with Imara Inc. Pursuant to the Merger Agreement, Merger Sub, a wholly owned subsidiary of Imara, merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Imara Inc. Immediately prior to the closing of the Merger, investors in the Financing purchased shares of Enliven’s common stock totaling $164.5 million. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc.
In connection with the merger, a reverse stock split of Imara’s common stock was effectuated at a ratio of 1 to 4. In addition, each share of the Company’s common stock outstanding, including shares of the Company’s common stock that were issued pursuant to the Financing, converted into the right to receive a number of shares of Imara’s common stock based on an agreed upon ratio by the parties of approximately 0.2951 shares of Imara’s common stock for each share of the Company’s common stock. Historical common share figures of Enliven have been retroactively restated based on the exchange ratio of approximately 0.2951.
 
F-29
EX-99.2 4 d514661dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

Explanatory Note

On October 13, 2022, Imara Inc. (“Imara” or the “Company”), Enliven Therapeutics, Inc. (“Enliven”), and a wholly owned subsidiary of Imara, Iguana Merger Sub, Inc. (“Merger Sub”) entered into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the Merger Agreement, among other matters, Merger Sub merged with and into Enliven, with Enliven becoming a wholly-owned subsidiary of Imara and the surviving corporation of the merger, which transaction is referred to as the Merger. Following the closing of the Merger, Imara changed its name to Enliven Therapeutics, Inc. and Enliven Therapeutics, Inc. changed its name to Enliven Inc.

As previously disclosed, on February 23, 2023, Imara and Enliven completed the Merger, pursuant to the Merger Agreement.

At the effective time of the Merger, each share of Enliven’s common stock outstanding immediately prior to the effective time of the Merger, including shares of Enliven’s common stock that were issued pursuant to the Enliven pre-closing financing (as defined below), were converted into the right to receive a number of shares of the Company’s common stock based on the exchange ratio. The final exchange ratio is approximately 0.2951 shares of Imara’s common stock for each share of Enliven’s common stock, which gives effect to the Reverse Stock Split (as defined below). Each share of Enliven’s convertible preferred stock outstanding immediately prior to the effective time of the Merger was converted into shares of Enliven’s common stock in accordance with its terms, which then converted into the right to receive shares of the Company’s common stock along with all other shares of Enliven’s common stock as described above. Under the exchange ratio formula in the Merger Agreement, the Enliven equity holders immediately before the effective time of the Merger owned approximately 84% of the outstanding capital stock of Imara on a fully-diluted basis, and the stockholders of Imara immediately before the effective time of the Merger owned approximately 16% of the outstanding capital stock of Imara on a fully-diluted basis.

The Merger

On February 23, 2023, the Company filed an amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the reverse stock split of its common stock, such that approximately every 4 shares of the Company’s common stock held by a stockholder immediately prior to the reverse stock split were combined and reclassified into 1 share of the Company’s common stock (the “Reverse Stock Split”). Except where otherwise indicated in these pro forma financial statements, all share and per share amounts of Imara have been adjusted retroactively to reflect the Reverse Stock Split as if it had occurred at the beginning of the earliest period presented for pro forma purposes only.

The Merger closed on February 23, 2023 pursuant to the Merger Agreement. At the closing of the Merger, the Company issued an aggregate of 34,426,351 shares of its common stock to the former Enliven stockholders, in exchange for all of the shares of Enliven common stock issued and outstanding immediately prior to the Merger, based on an exchange ratio of approximately 0.2951 with Enliven surviving as a wholly-owned subsidiary of the Company. In connection with the closing of the Merger, and in accordance with the terms of the Merger Agreement, the Company acquired net cash and cash equivalents from Imara of approximately $80.5 million. In addition, each outstanding and unexercised option to purchase shares of Enliven common stock granted to an individual who continued as a service provider to Enliven at the effective time of the Merger was assumed by the Company and converted into an option to purchase shares of the Company’s common stock, with necessary adjustments to reflect the exchange ratio.

The issuance of the shares of the Company’s common stock to the former stockholders of Enliven was registered with the SEC on the Company’s Registration Statement on Form S-4, as amended (File No. 333-268300).

Enliven Pre-closing Financing

On October 13, 2022, immediately prior to the execution and delivery of the Merger Agreement, Enliven entered into a common stock purchase agreement with certain investors, pursuant to which the investors agreed to purchase approximately 42.8 million shares of Enliven’s common stock, par value $0.0001 per share (the “Enliven pre-closing financing”).

On February 23, 2023, Enliven completed the pre-closing financing, in which Enliven issued approximately 42.8 million shares of Enliven common stock at a price of $3.84 per share, for aggregate gross proceeds of approximately $164.5 million, net of issuance costs of $4.7 million.

Unaudited Pro Forma Combined Financial Information

The following unaudited pro forma combined financial information gives effect to the Transaction Accounting Adjustments, which consist of the (i) Merger, (ii) the Enliven pre-closing financing, and (iii) the Reverse Stock Split.

In the unaudited pro forma combined financial statements, the Merger has been accounted for as a reverse recapitalization under U.S. generally accepted accounting principles (“U.S. GAAP”) because the assets of Imara as of the effective date of the Merger are primarily cash and other non-operating assets. Enliven was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (1) Enliven stockholders will own a substantial majority of the voting rights in the combined company; (2) Enliven will designate a majority (eight of nine) of the initial members of the board of directors of the combined company; and (3) Enliven’s senior management will hold all positions in senior management of the combined company.

As a result of Enliven being treated as the accounting acquirer, Enliven’s assets and liabilities are recorded at their pre-combination carrying amounts and the historical operations that are reflected in the unaudited pro forma combined financial information of Imara will be those of Enliven. Imara’s assets and liabilities will be measured and recognized at their fair values as of the effective date of the Merger, and combined with the assets, liabilities, and results of operations of Enliven after the consummation of the Merger. As a result, upon consummation of the Merger, the historical financial statements of Enliven will become the historical consolidated financial statements of the combined company.

The unaudited pro forma combined balance sheet data as of March 31, 2023 assumes that the Merger took place on March 31, 2023 and combines the Imara and Enliven historical balance sheets as of March 31, 2023. The unaudited pro forma combined statement of operations data for the three-month period ended March 31, 2023 and for the year ended December 31, 2022 gives effect to the Merger as if it took place on January 1, 2022 and combines the Imara and Enliven historical statement of operations for the periods presented.

The historical financial statements of Imara and Enliven have been adjusted to give pro forma effect to reflect the Transaction Accounting Adjustments in accordance with U.S. GAAP. The adjustments presented on the unaudited pro forma combined financial statements have been identified and presented to provide relevant information necessary for an accurate understanding of the combined company upon consummation of the Merger.

The unaudited pro forma combined financial information is based on assumptions and adjustments that are described in the accompanying notes, and is for illustrative purposes only. The unaudited pro forma combined financial information should not be relied upon as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the combined company will experience. The actual amounts recorded as of the completion of the Merger may differ materially from the information presented in these unaudited pro forma combined financial information as a result, if any, of the amount of cash used by Imara’s operations between the signing and closing of the Merger Agreement, and other changes in Imara’s assets and liabilities that occur prior to the completion of the Merger.

The unaudited pro forma combined financial information, including the notes thereto, should be read in conjunction with the separate historical consolidated financial statements of Imara and Enliven incorporated by reference in this information statement.

Unaudited Pro Forma Combined Balance Sheet

As of March 31, 2023

(in thousands)

 

     Enliven     IMARA      Transaction
Accounting
Adjustments		      Note 4      Pro Forma
Combined Total		  
Assets              

Current assets:

              

Cash and cash equivalents

    $ 292,102     $ —          —           $ 292,102  

Prepaid expense and other current assets

      5,901       —          —             5,901  
  

 

 

    

 

 

     

 

 

        

 

 

  

Total current assets

      298,003       —          —             298,003  

Property and equipment, net

      853       —          —             853  

Right-of-use asset

      551       —          —             551  

Restricted cash

      54       —          —             54  

Other assets

      3,405       —          —             3,405  
  

 

 

    

 

 

     

 

 

        

 

 

  

Total assets

    $ 302,866     $ —          —           $ 302,866  
  

 

 

    

 

 

     

 

 

        

 

 

  
Liabilities and stockholders’ equity              

Current liabilities:

              

Accounts payable

    $ 5,860     $ —        $ —           $ 5,860  

Accrued expense and other current liabilities

      5,082       —          —             5,082  
  

 

 

    

 

 

     

 

 

        

 

 

  

Total current liabilities

      10,942       —          —             10,942  

Long-term liabilities

      508       —          —             508  
  

 

 

    

 

 

     

 

 

        

 

 

  

Total liabilities

      11,450       —          —             11,450  
  

 

 

    

 

 

     

 

 

        

 

 

  

Stockholders’ equity (deficit):

              

Preferred stock

      —         —          —             —    

Common stock

      41       —          —             41  

Additional paid-in capital

      388,963       —          —             388,963  

Accumulated deficit

      (97,588 )      —          —             (97,588 ) 
  

 

 

    

 

 

     

 

 

        

 

 

  

Total stockholders’ equity

      291,416       —          —             291,416  
  

 

 

    

 

 

     

 

 

        

 

 

  

Total liabilities and stockholders’ equity

    $ 302,866     $ —        $ —           $ 302,866  
  

 

 

    

 

 

     

 

 

        

 

 

  

Unaudited Pro Forma Combined Statement of Operations

For the Three Months Ended March 31, 2023

(in thousands, except for share and per share amounts)

 

     Enliven     IMARA     Transaction
Accounting
Adjustments		      Note 4      Pro Forma
Combined Total		  

Operating expenses

             

Research and development

    $ 11,880     $ 104     $ —           $ 11,984  

General and administrative

      4,538       12,094       —             16,632  
  

 

 

    

 

 

    

 

 

        

 

 

  

Total operating expenses

      16,418       12,198       —             28,616  
  

 

 

    

 

 

    

 

 

        

 

 

  

Loss from operations

      (16,418 )      (12,198 )      —             (28,616 ) 

Interest income

      1,694       602       —             2,296  
  

 

 

    

 

 

    

 

 

        

 

 

  

Total other income (expense), net

      1,694       602       —             2,296  
  

 

 

    

 

 

    

 

 

        

 

 

  

Net loss and comrehensive loss

      (14,724 )      (11,596 )      —             (26,320 ) 
  

 

 

    

 

 

    

 

 

        

 

 

  

Net loss per share, basic and diluted

    $ (0.80 )    $ —       $ —           $ (1.42 ) 
  

 

 

    

 

 

    

 

 

        

 

 

  

Weighted-average shares outstanding, basic and diluted

      18,514,644       —         —             18,514,644  
  

 

 

    

 

 

    

 

 

        

 

 

  

Unaudited Pro Forma Combined Statement of Operations

For the Year Ended December 31, 2022

(in thousands, except for share and per share amounts)

 

     Enliven     IMARA     Transaction
Accounting
Adjustments		    

Note 4

    Pro Forma
Combined
Total		  

Operating expenses

            

Research and development

    $ 31,022     $ 18,940     $ (17,692 )    (d)    $ 32,270  

General and administrative

      7,769       15,330       3,564     (b)(c)      26,663  
  

 

 

    

 

 

    

 

 

       

 

 

  

Total operating expenses

      38,791       34,270       (14,128 )         58,933  
  

 

 

    

 

 

    

 

 

       

 

 

  

Gain on sale of asset

      —         35,000       —            35,000  
  

 

 

    

 

 

    

 

 

       

 

 

  

Loss from operations

      (38,791 )      730       14,128          (23,933 ) 

Other expense

      —         (97 )      —            (97 ) 

Interest income

      1,129       943       —            2,072  
  

 

 

    

 

 

    

 

 

       

 

 

  

Total other income (expense), net

      1,129       846       —            1,975  
  

 

 

    

 

 

    

 

 

       

 

 

  

Net loss (income) before income tax provision

      (37,662 )      1,576       14,128          (21,958 ) 

Income tax provision

      —         (88 )      —            (88 ) 
  

 

 

    

 

 

    

 

 

       

 

 

  

Net loss (income)

    $ (37,662 )    $ 1,488     $ 14,128        $ (22,046 ) 
  

 

 

    

 

 

    

 

 

       

 

 

  

Net loss (income) share attributable to common stockholders, basic and diluted

    $ (3.56 )    $ 0.06     $ —          $ (0.54 ) 
  

 

 

    

 

 

    

 

 

       

 

 

  

Weighted average common shares outstanding, basic and diluted

      10,586,983       26,385,567       3,632,417     (a)      40,604,967  
  

 

 

    

 

 

    

 

 

       

 

 

  

NOTES TO UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

1. Basis of Presentation

The unaudited pro forma combined financial information was prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of Article 11 of Regulation S-X. The unaudited pro forma combined balance sheet as of March 31, 2023 was prepared using the historical consolidated balance sheets of Imara and Enliven as of March 31, 2023. The unaudited pro forma combined statement of operations for the three months ended March 31, 2023 and for the year ended December 31, 2022 were prepared using the historical statements of operations and comprehensive loss of Imara and Enliven for the three months ended March 31, 2023 and for the year ended December 31, 2022, respectively, and gives effect to the Merger as if it occurred on January 1, 2022.

For accounting purposes, Enliven is considered to be the acquirer, and the Merger was accounted for as a reverse recapitalization of Imara by Enliven because upon the closing of the Merger, the pre-combination assets of Imara were primarily cash.

Under reverse recapitalization accounting, the assets and liabilities of Imara were recorded, as of the date of the Merger, at their fair value. No goodwill or intangible assets were recognized and any excess consideration transferred over the fair value of the net assets of Imara, following determination of the actual purchase consideration for Imara are reflected as a reduction to additional paid-in capital. Consequently, the financial statements of Enliven reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. The accompanying unaudited pro forma combined financial information is derived from the historical financial statements of Imara and Enliven, and includes adjustments to give pro forma effect to reflect the accounting for the transaction in accordance with U.S. GAAP. The historical financial statements of Enliven shall become the historical financial statements of the combined company.

To the extent there are significant changes to the business following completion of the Merger, the assumptions and estimates set forth in the unaudited pro forma consolidated financial information could change significantly. Accordingly, the pro forma adjustments are subject to further adjustment as additional information becomes available and as additional analyses are conducted following the completion of the Merger. There can be no assurances that these additional analyses will not result in material changes to the estimates of fair value.

2. Purchase Price

The accompanying unaudited pro forma combined financial information reflects a purchase price of approximately $168.8 million, which consists of the following (in thousands, except share and per share amounts):

 

Estimated number of common shares of the combined company to be owned by IMARA stockholders (1)

      6,625,176  

Multiplied by the fair value per share of IMARA common stock (2)

    $ 25.28  
  

 

 

  

Estimated fair value of IMARA common stock issued

      167,484  

Estimated fair value of stock options and restricted stock units attributable to precombination services (3)

      1,350  
  

 

 

  

Estimated purchase price

    $ 168,834  
  

 

 

  

 

(1)

Reflects the number of shares of the combined company that Imara equity holders owned as of the closing pursuant to the Merger Agreement. This amount is calculated for purposes of the unaudited pro forma combined financial information, based on the shares of Imara’s common stock outstanding as of February 23, 2023.

(2)

Reflects the assumed purchase price per share of Imara common stock, which is the closing price of Imara’s common stock on February 23, 2023.

(3)

Reflects the estimated acquisition-date fair value of the assumed Imara equity awards attributable to pre-combination services.

3. Shares of Imara Common Stock Issued to Enliven’s Stockholders upon Closing of the Merger

Prior to the Merger, all outstanding convertible preferred stock of Enliven were converted into common stock of Enliven. At the effective time of the Merger, all outstanding shares of Enliven’s common stock were converted into the right to receive shares of Imara common stock as consideration for the Merger, based on the exchange ratio. The final exchange ratio for purposes of the unaudited pro forma combined financial information was derived on a fully-diluted basis as of February 23, 2023 using a stipulated value of Enliven of approximately $489.1 million (including the Enliven pre-closing financing discussed above) and of Imara of approximately $90.5 million. Based on the exchange ratio of approximately 0.2951 determined in accordance with the terms of the Merger Agreement, Imara issued 34,426,394 shares of common stock to the stockholders of Enliven in the Merger, determined as follows:

 

     Shares  

Enliven:

   

Enliven common shareholders

      54,927,965  

Enliven convertible preferred stock

      61,730,064  
  

 

 

  

Total Enliven common equivalent shares pre-close

      116,658,029  

Exchange ratio

      0.2951  
  

 

 

  

Total Enliven merger common shares

      34,426,394  
  

 

 

  

The exchange ratio is calculated based on the Reverse Stock Split of Imara common stock.

4. Pro Forma Adjustments

The unaudited pro forma combined financial information includes pro forma adjustments that reflect Transaction Accounting Adjustments, as well as other adjustments deemed to be directly related to the Merger, irrespective of whether or not such adjustments are deemed to be recurring.

Based on Enliven management’s review of Imara’s summary of significant accounting policies, the nature and amount of any adjustments to the historical financial statements of Imara to conform to the accounting policies of Enliven are not expected to be significant.

The pro forma adjustments, based on preliminary estimates that may change significantly as additional information is obtained, are as follows:

 

(a)

The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net loss for the year ended December 31, 2022. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the total number of shares of common stock of the combined company outstanding as of the Merger closing date, including the shares to be issued in the Enliven pre-closing financing. The following table presents the calculation of the pro forma weighted average number of common stock outstanding after giving effect to the Reverse Stock Split for Imara shares and application of the exchange ratio for Enliven shares:

 

     December 31, 2022  

Historical Enliven weighted-average shares of common stock outstanding

      10,586,983  

Impact of Enliven’s convertible preferred stock assuming conversion as of January 1, 2022

      61,730,064  

Impact of Enliven’s common stock purchase agreement (Financing Transaction) assuming issuance as of January 1, 2022

      42,827,612  
  

 

 

  

Subtotal

      115,144,659  

Application of exchange ratio to historical Enliven weighted-average shares outstanding

      0.2951  
  

 

 

  

Adjusted Enliven weighted-average shares outstanding (after giving effect to the Exchange Ratio)

      33,979,790  

Historical IMARA weighted-average shares of common stock outstanding

      6,571,816  

Impact of IMARA common stock related to stock units that accelerated vesting, reflected as having occurred January 1, 2022

      53,361  
  

 

 

  

Total weighted average shares outstanding

      40,604,967  
  

 

 

  

 

(b)

To reflect the post combination stock-based compensation expense of $1.2 million, as a result of the accelerated vesting of certain Imara options, as a result of the Merger under the original award terms, as general and administrative expense on the unaudited pro forma combined statement of operations, and an increase in additional paid-in capital and accumulated deficit on the unaudited pro forma balance sheet.

 

(c)

To reflect Imara’s compensation expense of $2.4 million related to change-in-control severance payments resulting from pre-existing employment agreements that will be payable in cash in connection with the Merger but were not incurred as of December 31, 2022, as an increase to accrued expense and other current liabilities and accumulated deficit in the unaudited pro forma combined balance sheet. Imara’s compensation costs of $2.4 million are reflected as general and administrative expense in the unaudited pro forma combined statement of operations for the year ended December 31, 2022.

 

(d)

To reflect the elimination of direct external R&D expenses related to the IMR-687 program which were sold by Imara in an asset sale. Such R&D expenses were incurred and included in the Imara historical consolidated statement of operations for the year ended December 31, 2022.

EX-101.SCH 5 elvn-20230623.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Statements of Convertible Preferred Stock and Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Organization, Description of Business and Liquidity link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Common Stock link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - 401(k) Savings Plan link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Common Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Organization, Description of Business and Liquidity - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Convertible Preferred Stock - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Stock-Based Compensation - Summary of Stock Plan Activity (Details) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Income Taxes - Summary of Company's Deferred Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - 401(k) Savings Plan - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 elvn-20230623_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 elvn-20230623_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 elvn-20230623_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 elvn-20230623_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page
Jun. 23, 2023
Entity Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 23, 2023
Entity File Number 001-39247
Entity Registrant Name Enliven Therapeutics, Inc.
Entity Central Index Key 0001672619
Entity Tax Identification Number 81-1523849
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 6200 Lookout Road
Entity Address, City or Town Boulder
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80301
City Area Code 720
Local Phone Number 647-8519
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ELVN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS    
Cash and cash equivalents $ 75,536 $ 110,024
Prepaid expenses and other current assets 2,217 646
Total current assets 77,753 110,670
Property and equipment, net 890 492
Right-of-use asset 626 462
Deferred offering costs 3,975 1,651
Restricted cash 54 54
TOTAL ASSETS 83,298 113,329
Current liabilities:    
Accounts payable, net 3,438 2,521
Accrued expenses and other current liabilities 6,277 3,232
Total current liabilities 9,715 5,753
LONG TERM LIABILITIES    
Other non-current liabilities 659 714
Total liabilities 10,374 6,467
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY    
Common stock $0.0001 par value; 26,264,364 shares authorized at December 31, 2022 and December 31, 2021; 3,570,019 and 3,435,014 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively 1 1
Additional paid-in capital 6,038 2,314
Accumulated deficit (82,864) (45,202)
Total stockholders' deficit (76,825) (42,887)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT 83,298 113,329
Convertible Preferred Stock    
LONG TERM LIABILITIES    
Convertible preferred stock, $0.0001 par value; 61,730,064 shares authorized, issued and outstanding at December 31, 2022 and December 31, 2021, liquidation preference of $140,520 at December 31, 2022 and December 31, 2021 $ 149,749 $ 149,749
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Statement [Line Items]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 26,264,364 26,264,364
Common stock, shares issued 3,570,019 3,435,014
Common stock, shares outstanding 3,570,019 3,435,014
Convertible Preferred Stock    
Statement [Line Items]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 61,730,064 61,730,064
Preferred stock, shares issued 61,730,064 61,730,064
Preferred stock, shares outstanding 61,730,064 61,730,064
Preferred stock, liquidation preference, value $ 140,520 $ 140,520
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 31,022 $ 20,474
General and administrative 7,769 4,288
Total operating expenses 38,791 24,762
Loss from operations (38,791) (24,762)
Other income (expense), net    
Interest income 1,129 22
Total other income, net 1,129 22
Net loss and comprehensive loss $ (37,662) $ (24,740)
Net loss per share, basic $ (12.05) $ (10.73)
Net loss per share, diluted $ (12.05) $ (10.73)
Weighted-average shares outstanding, basic 3,124,274 2,306,110
Weighted-average shares outstanding, diluted 3,124,274 2,306,110
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Statement [Line Items]    
Beginning balance $ (42,887) $ (20,304)
Exercise of common stock options 246 136
Vesting of restricted stock and stock options 287 97
Stock-based compensation 3,191 1,924
Net loss (37,662) (24,740)
Ending balance (76,825) (42,887)
Preferred Stock | Convertible Preferred Stock    
Statement [Line Items]    
Beginning balance $ 149,749 $ 149,749
Beginning balance, shares 61,730,064 61,730,064
Ending balance $ 149,749 $ 149,749
Ending balance, shares 61,730,064 61,730,064
Common stock    
Statement [Line Items]    
Beginning balance $ 1 $ 1
Beginning balance, shares 3,435,014 3,257,927
Exercise of common stock options, shares 135,005 177,087
Ending balance $ 1 $ 1
Ending balance, shares 3,570,019 3,435,014
Additional Paid-in Capital    
Statement [Line Items]    
Beginning balance $ 2,314 $ 157
Exercise of common stock options 246 136
Vesting of restricted stock and stock options 287 97
Stock-based compensation 3,191 1,924
Ending balance 6,038 2,314
Accumulated Deficit    
Statement [Line Items]    
Beginning balance (45,202) (20,462)
Net loss (37,662) (24,740)
Ending balance $ (82,864) $ (45,202)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Statement of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (37,662) $ (24,740)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 215 115
Stock-based compensation 3,191 1,924
Write-off of deferred IPO costs 1,741  
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (1,590) (563)
Right-of-use asset 4 133
Accounts payable 411 1,734
Accrued expenses and other liabilities 1,613 2,263
Net cash used in operating activities (32,077) (19,134)
Cash flows from investing activities:    
Purchases of property and equipment (612) (191)
Net cash used in investing activities (612) (191)
Cash flows from financing activities:    
Issuance of convertible preferred stock, net of issuance costs   (226)
Deferred issuance costs related to merger / initial public offering (2,390) (1,480)
Issuance of common stock 591 690
Net cash provided by financing activities (1,799) (1,016)
Net decrease in cash, cash equivalents and restricted cash (34,488) (20,341)
Cash, cash equivalents and restricted cash at the beginning of the period 110,078 130,419
Cash, cash equivalents and restricted cash at the end of the period 75,590 110,078
Components of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 75,536 110,024
Restricted cash 54 54
Total cash, cash equivalents and restricted cash 75,590 110,078
Supplemental disclosure of non-cash investing and financing activities:    
Lease liability obtained in exchange for right of use asset 387 491
Accounts Payable    
Supplemental disclosure of non-cash investing and financing activities:    
Deferred issuance costs related to initial public offering included in accounts payable / liabilities   131
Deferred merger costs included in accounts payable / liabilities 656  
Accrued Liabilities    
Supplemental disclosure of non-cash investing and financing activities:    
Deferred issuance costs related to initial public offering included in accounts payable / liabilities   $ 39
Deferred merger costs included in accounts payable / liabilities $ 1,190  
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Organization, Description of Business and Liquidity
 12 Months Ended
Dec. 31, 2022
Organization Description Of Business And Liquidity [Abstract]  
Organization, Description of Business and Liquidity
1. Organization, Description of Business and Liquidity
Business
Enliven Therapeutics, Inc. (the Company) was incorporated in the State of Delaware on June 12, 2019 and is headquartered in Boulder, Colorado. The Company is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. The Company aims to address emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Its discovery process combines deep insights in clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs.
Since its inception, the Company has devoted substantially all of its efforts to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities. To date, the Company has funded its operations primarily through private placements of its convertible preferred stock.
On October 13, 2022, the Company entered into an agreement and plan of merger (Merger Agreement) with Imara Inc. (Imara), a Delaware corporation and Iguana Merger Sub, Inc., a wholly-owned subsidiary of Imara (Merger Sub). Pursuant to the Merger Agreement, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the merger (the Merger). Immediately prior to the closing of the Merger, certain new and current investors subscribed for the purchase of an aggregate of approximately $164.5 million of common stock of Enliven (the Financing). On February 23, 2023, Enliven closed the Merger with Imara Inc. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc.
Risks and uncertainties
The Company is subject to risks common to development-stage companies in the biotechnology industry including, but not limited to, risks of failure of preclinical studies and clinical trials, new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on third-party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, compliance with government regulations and the need to obtain additional financing.
The Company continues to closely monitor macroeconomic and geopolitical developments, including the global
COVID-19
pandemic, the Russia- Ukraine conflict and inflation. The extent of the impact of these developments on the Company’s business, operations and research and development timelines and plans remains uncertain, and will depend on numerous factors, including the impact, if any, on the Company’s personnel, responses of governmental entities, and the responses of third parties such as contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties with whom the Company does business. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s development activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the potential impact of these developments on its business and financial statements. To date, the Company has not experienced material business disruptions or incurred impairment losses in the carrying values of its assets as a result of these developments, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these financial statements.
 
Liquidity considerations
In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional capital. Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we may seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our capital requirements. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, that will occur.
The Company has incurred significant losses and negative cash flows from operations since inception. As of December 31, 2022, the Company had an accumulated deficit of $82.9 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $37.7 million and $24.7 million for the years ended December 31, 2022 and 2021, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash and cash equivalents of $75.5 million as of December 31, 2022 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.
Merger Agreement and Exchange Ratio
On October 13, 2022, the Company entered into the Merger Agreement with Imara, a Delaware corporation and Merger Sub. Pursuant to the Merger Agreement, among other matters, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the Merger. The Merger was intended to qualify for U.S. federal income tax purposes as a tax-free “reorganization” under the provisions of Section 368(a) of the Code and, in the event that former Enliven stockholders, including stockholders that participate in the Enliven
pre-closing
financing, are in “control” of Imara immediately after the effective time of the Merger (within the meaning of Section 368(c) of the Code), as a
non-taxable
exchange of shares of Enliven common stock for shares of Imara common stock within the meaning of Section 351(a) of the Code, with the result that Enliven stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes upon the exchange of Enliven common stock for Imara common stock pursuant to the Merger, except with respect to cash received in lieu of a fractional share of Imara common stock.
Upon the closing of the Merger on February 23, 2023, (a) each outstanding share of Company common stock (including common stock issued upon the conversion of the Company’s preferred stock, and shares issued in the Financing) was converted into the right to receive a number of shares of Imara common stock (Imara Common Stock) (after giving effect to the
1-for-4
reverse stock split of Imara Common Stock in connection with the Merger) equal to the exchange ratio per the Merger Agreement; and (b) each of the then outstanding Company stock option that had not previously been exercised prior to the closing of the Merger was assumed by Imara.
Immediately prior to the closing of the Merger, and in order to provide the Company with additional capital for its development programs, certain new and current investors purchased an aggregate of approximately $164.5 million of common stock of Enliven.
The Merger and Financing were completed on February 23, 2023. The Merger has been accounted for as a reverse recapitalization under U.S. GAAP because the assets of Imara as of the effective date of the Merger are primarily cash and other
non-operating
assets. Enliven was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (1) Enliven stockholders own a substantial majority of the voting rights in the combined company; (2) Enliven designated a majority (eight of nine) of the initial members of the board of directors of the combined company; and (3) Enliven’s senior management holds all positions in senior management
of
the combined company.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of presentation
The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB).
Use of estimates
The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and
stock-based
compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate.
Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations.
Restricted cash
The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets.
 
Concentrations of credit risk and
off-balance
sheet risk
The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances.
Fair value measurements
Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are as follows:
 
  •  
Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
 
  •  
Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and
 
  •  
Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.
The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities.
Deferred offering costs
Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively.
 
Property and equipment, net
Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.
The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of three to
five years
.
Impairment of long-lived assets
The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements.
Leases
The Company elected to early adopt ASU
No. 2016-02,
Leases (ASC 842) and its associated amendments as of January 1, 2020. In June 2020, the Company entered into a sublease agreement under which it leased laboratory and office facilities which the Company determined to be an operating lease. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding
right-of-use
asset (ROU) upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding
right-of-use
assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. As the Company’s lease does not provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and
non-lease
components.
Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other
non-current
liabilities.
Convertible preferred stock
The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur.
 
Research and development expenses
The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and
non-clinical
studies, costs to acquire, develop and manufacture supplies for preclinical and clinical testing and other studies, expenses incurred under agreements with contract research organizations, and salaries and related costs, including equity-based compensation, as well as depreciation and other allocated facility-related and overhead expenses. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.
The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and
non-clinical
study materials are manufactured by contract manufacturing organizations. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company’s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
Stock-based compensation
The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur.
The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified.
Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:
 
  •  
Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock.
 
  •  
Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the
mid-point
between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.
 
  •  
Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. 
 
  •  
Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards.
 
  •  
Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero.
The assumptions underlying these valuations represented the Company’s board and management’s best estimates,
which
involved inherent uncertainties and the application of management’s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its stock-based compensation expense could be materially different.
Income taxes
Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.
The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
Net loss per share
The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the
two-class
method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. The net loss attributable to common stockholders is not allocated to the convertible preferred shares as the holders of convertible preferred shares do not have a contractual obligation to share in losses. Cumulative dividends on preferred shares are added to net loss to arrive at net loss available to common stockholders.
Under the
two-class
method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted common stock as these shares are considered contingently issuable shares until they vest.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.
 
Segments
The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance.
Comprehensive income (loss)
Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. The Company did not have any items that required classification as other comprehensive income (loss).
Emerging growth company status
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently issued accounting pronouncements adopted
In December 2019, the FASB issued ASU
2019-12,
Simplifying the Accounting for Income Taxes (ASU
2019-12).
ASU
2019-12
eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance was effective for fiscal years beginning after December 15, 2021. The Company
adopted
ASU 2019-12
on
January 1, 2022
, and the adoption did not have a material impact.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements
3. Fair Value Measurements
The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):
 
    
As of December 31, 2022
  
    
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
  
Assets:
            
US Treasury backed money market funds
   
$
74,523
 
   
$
74,523
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total financial assets measured at fair value
   
$
74,523
 
   
$
74,523
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
As of December 31, 2021
 
    
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
Assets:
            
US Treasury backed money market funds
   
$
106,768
 
   
$
106,768
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total financial assets measured at fair value
   
$
106,768
 
   
$
106,768
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Leases
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Leases
4. Leases
Facility lease
In June 2020, the Company leased office and laboratory space under a sublease agreement for 6,782 square feet, which was set to expire on December 30, 2021. In March 2021, the Company amended its sublease agreement, increasing its leased space by 2,495 square feet to 9,277 square feet and monthly rent to $12,000. Upon the extension of the lease in March 2021, the lease was automatically extended to December 30, 2024. Additionally, in January 2022 the Company amended its sublease, which increased the leased space by an additional 8,893 square feet commencing on May 1, 2022, and the rental payments increased by an equally proportionate amount to reflect the increase in floor space. Further, in April 2022 the Company amended the sublease, which deferred the expansion for the additional space to July 1, 2022. The monthly rent is subject to annual increases through the lease term. The Company is required to pay base rent expense as well as its proportionate share of the facilities operating expenses. The
non-lease
components, consisting primarily of common area maintenance, are paid separately based on actual costs incurred. Therefore, the variable
non-lease
components were not included in the right of use asset and lease liability and are reflected as expense in the period incurred. The incremental borrowing rate used to calculate the Company’s right of use asset and lease liability is 4%. The incremental borrowing rate was estimated based on the Company’s estimated borrowing rate on a collateralized loan. As of December 31, 2022, the remaining lease liability and right of use asset were $0.6 million and $0.6 million, respectively. As of December 31, 2021, the remaining lease liability and right of use asset were $0.5 million and $0.5 million, respectively.
 
The Company recognized rent expense under the facility sublease for the years ended December 31, 2022 and 2021 of $0.2 million. As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands):

 
 
  
As of

December 31, 2022
 
Year ending December 31,
         
   
2023
   
$
329
 
2024
   
 
341
 
    
 
 
  
Total minimum lease payments
   
 
670
 
Less: amount representing interest
   
 
26
 
    
 
 
  
Present value of lease liabilities
   
 
644
 
Less: current portion of lease liabilities
   
 
323
 
    
 
 
  
Lease liabilities, noncurrent
   
$
321
 
    
 
 
  
During the years ended December 31, 2022 and 2021, the Company recognized $0.3 million and $0.2 million in variable lease costs, respectively.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net
5. Property and Equipment, Net
Property and equipment, net consisted of the following (dollars in thousands):
 
    
Estimated Useful Life
 
  
As of December 31,
 
    
in Years
 
  
2022
 
  
2021
 
Laboratory equipment
   
 
5
 
   
$
1,191
 
   
$
614
 
Computer equipment
   
 
3
 
   
 
73
 
   
 
38
 
             
 
 
     
 
 
  
             
 
1,264
 
   
 
652
 
Less: accumulated depreciation
            
 
(374
) 
   
 
(160
) 
             
 
 
     
 
 
  
Property and equipment, net
            
$
890
 
   
$
492
 
             
 
 
     
 
 
  
Depreciation expense for the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities
6. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
 
    
As of December 31,
 
    
2022
 
  
2021
 
Accrued employee compensation costs
   
$
2,130
 
   
$
1,027
 
Accrued research and development costs
   
 
1,918
 
   
 
1,637
 
Accrued deferred offering costs
   
 
1,190
 
   
 
39
 
Lease liabilities
   
 
323
 
   
 
159
 
Accrued legal and professional fees
   
 
269
 
   
 
176
 
Other
   
 
447
 
   
 
194
 
    
 
 
     
 
 
  
Accrued expenses and other current liabilities
   
$
6,277
 
   
$
3,232
 
 
 
 
 
 
 
 
 
 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
7. Commitments and Contingencies
Lease commitments
—The Company’s commitments related to lease agreements are disclosed in Note 4.
Litigation
—From time to time, the Company may be involved in legal proceedings or be subject to claims arising in the ordinary course of our business. The Company was not currently a party to any legal proceedings. Regardless of outcome, any proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.
Indemnification agreements
—In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company among other things to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its financial statements as of December 31, 2022 or 2021.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Common Stock
8. Common Stock
As of December 31, 2022 and 2021, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 26,264,364 shares of $0.0001 par value common stock, of which 3,570,019 and 3,435,014 shares were issued and outstanding, respectively. As of December 31, 2022 and 2021, there were 252,652 and 703,092 shares which were subject to repurchase, respectively. The liability related to shares subject to repurchase totaled $0.6 million as of December 31, 2022 and 2021, of which $0.3 million and $0.4 million were recorded as other
non-current
liabilities as of December 31, 2022 and 2021, respectively.
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any, subject to the preferential dividend rights of any convertible preferred stock. No dividends have been declared or paid by the Company through December 31, 2022.
In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any convertible preferred stock.
The Company had the following shares of common stock reserved for future issuance:
 
    
As of December 31,
  
    
2022
 
  
2021
  
Conversion of preferred stock
   
 
18,216,847
 
   
 
18,216,847
 
Issuance of common stock upon exercise of stock options
   
 
3,316,671
 
   
 
3,075,403
 
Options available for grant under stock plan
   
 
906,265
 
   
 
403,680
 
    
 
 
     
 
 
  
Total common stock reserved for future issuance
   
 
22,439,783
 
   
 
21,695,930
 
    
 
 
     
 
 
  
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Preferred Stock
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
 Convertible Preferred Stock
9. Convertible Preferred Stock
As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following:

 
 
  
 
 
  
 
 
  
 
 
  
Aggregate
 
  
Proceeds Net
 
 
  
 
 
  
Shares
 
  
Per Share
 
  
Liquidation
 
  
of Issuance
 
 
  
Authorized
 
  
Issued and
 
  
Liquidation
 
  
Amount
 
  
Costs
 
 
  
Shares
 
  
Outstanding
 
  
Preference
 
  
(in thousands)
 
  
(in thousands)
 
Series Seed convertible preferred stock
   
 
14,507,038
 
   
 
14,507,038
 
   
$
0.71
 
   
$
10,300
 
   
$
10,211
 
Series A convertible preferred stock
   
 
25,114,089
 
   
 
25,114,089
 
   
$
1.80
 
   
 
45,300
 
   
 
45,170
 
Series B convertible preferred stock
   
 
22,108,937
 
   
 
22,108,937
 
   
$
3.84
 
   
 
84,920
 
   
 
84,689
 
    
 
 
     
 
 
              
 
 
     
 
 
  
Total convertible preferred stock
   
 
61,730,064
 
   
 
61,730,064
 
            
$
140,520
 
   
$
140,070
 
    
 
 
     
 
 
              
 
 
     
 
 
  
No shares of convertible preferred stock were issued during the years ended December 31, 2022 and 2021.
 
The Company’s convertible preferred stock have the following rights, preferences, privileges and restrictions:
Voting
—On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of convertible preferred stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of convertible preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matters. Except as provided by law or by the other provisions of the Company’s Amended and Restated Certificate of Incorporation, holders of convertible preferred stock shall vote together with the holders of common stock as a single class and on an
as-converted
to common stock basis.
Dividends
—The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) in any calendar year unless the holders of the convertible preferred stock then outstanding shall first receive, or simultaneously receive, dividends on each outstanding share of convertible preferred stock in an amount for such calendar year equal to the greater of (i) the applicable dividend rate of $0.0426, $0.108226 and $0.2305 per share for the Series Seed, Series A and Series B, respectively, subject to adjustment in the event of any stock splits, stock dividends or similar changes in capitalization with respect to such class or series, and (ii) that dividend per share of such series of convertible preferred stock as would equal the product of (A) the dividend payable on each share of such series determined, if applicable, as if all shares of such series had been converted into common stock and (B) the number of shares of common stock issuable upon conversion of such series, in each case calculated on the record date for the determination of holders entitled to receive such dividend. The right to receive dividends on shares of convertible preferred stock shall not be cumulative, and no right to dividends shall accrue to holders of the convertible preferred stock by reason of the fact that dividends on such shares are not declared or paid.
Liquidation preference
—In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of the convertible preferred stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, and in the event of a deemed liquidation event, the holders of shares of convertible preferred stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such deemed liquidation event or out of the available proceeds, as applicable, on a pari passu basis among each other and before any payment shall be made to the holders of the common stock by reason of their ownership hereof, an amount equal to the greater of (i) one times the applicable original issue price of $0.71 per share of Series Seed, $1.803768 per share of Series A and $3.84098 per share of Series B, plus any dividends declared, but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of the convertible preferred stock had been converted into common stock immediately prior to such liquidation, dissolution, winding up or deemed liquidation event. If upon any such event, the assets of the Company available for distribution to the stockholders shall be insufficient to pay the holders of the convertible preferred stock the full amount, they shall be entitled to share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would be otherwise payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
After payment of the liquidation preference to the holders of convertible preferred stock, the remaining assets of the Company shall be distributed ratably to the holders of common stock on a fully converted basis.
Redemption
—The shares of convertible preferred stock shall not be redeemable by any holder.
Voluntary conversion
—Each share of convertible preferred stock shall be convertible, at the option of the holder thereof at any time and from time to time, without the payment of additional consideration by the holder thereof, into such number of fully paid and
non-assessable
shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price in effect at the time of conversion. The original issue price of the Series Seed, Series A and Series B convertible preferred shares is $0.71, $1.803768 and $3.84098, respectively. Such conversion price, and at the rate at which the convertible preferred shares may be converted into shares of common stock, shall be subject to adjustment for occurrences such as stock splits, certain dividends, mergers and distributions.
 
Automatic conversion
—Each share of convertible preferred stock will automatically be converted into shares of common stock, at the
then-effective
conversion rate of such shares upon either (i) the closing of the sale of shares of the Company’s common stock to the public in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, with proceeds of at least $75.0 million, or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the requisite holders, then all outstanding shares of convertible preferred stock shall automatically be converted into shares of common stock, at the then effective conversion rate.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2022
Compensation Related Costs [Abstract]  
Stock-Based Compensation
10. Stock-Based Compensation
Equity Incentive Plan
—In July 2019, the Company adopted the 2019 Equity Incentive Plan (the 2019 Plan) pursuant to which the Company’s board of directors may grant
non-statutory
stock options, stock appreciation rights, restricted stock, and restricted stock units to employees and
non-employees
and incentive stock options only to employees. The 2019 Plan initially authorized grants of awards of up to 374,076 shares. In April 2020, the board of directors increased the number of shares of the Company’s common stock authorized for issuance under the 2019 Plan by 2,210,062 to 2,584,138 shares. Additionally, in December 2020, the board of directors approved to increase the number of shares of the Company’s common stock authorized for issuance under the 2019 Plan by 1,211,791 to 3,795,929 shares. In August 2022, the board of directors approved an increase in the shares authorized under the 2019 Equity Incentive Plan of 885,315 shares, for a total authorized amount of 4,681,244.
Awards granted under the 2019 Plan expire no later than 10 years from the date of grant. For incentive stock options and
non-statutory
stock options, the option exercise price will not be less than 100% of the estimated fair value on the date of grant. Options and restricted stock granted to employees typically vest over a four-year period but may be granted with different vesting terms.
 
Stock Option Repricing
Effective August 9, 2022, the Company’s board of directors repriced certain previously granted and still outstanding vested and unvested stock option awards under the 2019 Plan. As a result, the exercise price for these awards was lowered to $2.48 per share, which was the fair value of the Company’s common stock on August 9, 2022. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, 2,209,826 vested and unvested stock options outstanding as of August 9, 2022, with original exercise prices ranging from $4.68 to $7.56, were repriced. The repricing on August 9, 2022 resulted in incremental stock-based compensation expense of $1.0 million, of which $0.3 million related to vested stock option awards and was expensed on the repricing date, and $0.7 million related to unvested stock option awards is being amortized on a straight-line basis over the remaining weighted-average vesting period of those awards of approximately 2.9 years.
The following table summarizes the stock plan activity:
 
    
Available

for Grant
 
 
Stock
Options
Outstanding
 
 
Weighted-
Average Exercise
Price
 
  
Weighted-
Average
Contractual Term
(in years)
 
  
Aggregate
Intrinsic Value
(in thousands)
  
Outstanding - January 1, 2021
   
 
2,593,057
 
  
 
985,399
 
  
$
1.12
 
   
 
9.47
 
   
$
3,509
 
Options granted
   
 
(2,189,377
) 
  
 
2,189,377
 
  
$
4.71
 
   
 
9.38
 
   
Options exercised and vested
   
 
—  
 
  
 
(99,373
) 
  
$
2.26
 
   
 
8.77
 
   
  
 
 
    
 
 
          
Outstanding - December 31, 2021
   
 
403,680
 
  
 
3,075,403
 
  
$
3.64
 
   
 
9.11
 
   
$
9,657
 
Increase in option pool
   
 
885,315
 
          
Options granted
   
 
(391,653
) 
  
 
391,653
 
  
$
5.66
 
   
 
9.38
 
   
Options exercised and vested
   
 
—
 
  
 
(141,462
) 
  
$
3.72
 
   
 
8.09
 
   
Options cancelled and forfeited
   
 
8,923
 
  
 
(8,923
) 
  
$
4.68
 
   
 
8.23
 
   
  
 
 
    
 
 
          
Outstanding - December 31, 2022
   
 
906,265
 
  
 
3,316,671
 
  
$
2.20
 
   
 
8.26
 
   
$
1,194
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable - December 31, 2022
     
 
1,707,882
 
  
$
1.85
 
   
 
8.00
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vested and expected to vest - December 31, 2022
     
 
3,316,671
 
  
$
2.20
 
   
 
8.26
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The total intrinsic value of exercised and vested incentive awards during the year ended December 31, 2022 was $0.1 million and is calculated on the difference between the exercise price and the fair value of the Company’s common stock as of the exercise date.
The Company records stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, total compensation cost not yet recognized related to unvested stock options was $7.7 million, which is expected to be recognized over a weighted-average period of 2.43 years.
 
Restricted stock award activity
—Upon formation of the Company in June 2019, the Company issued 3.0 million shares in restricted common stock to the founders of the Company at $0.0003 per share. 25% of the shares vested immediately upon issuance, with the remaining shares vesting evenly over 36 or 48 months. Vesting may be accelerated upon a change in control, as defined in the holder agreements. If the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest. As of December 31, 2022 and 2021, there were 41,499 and 438,045 shares subject to repurchase, respectively.
Additionally, between 2019 and 2020, the Company issued a total of 197,262 shares of restricted stock to employees and consultants for aggregate consideration of $27,000. The purchase price of the restricted stock was the estimated fair value on the grant date. The restricted stock awards are subject to vesting over a period of four to five years, and vesting may be accelerated upon a change in control, as defined in the holder agreements.
If
 
the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest.
The following summarizes restricted stock activity:
 
    
Number of
Shares
 
  
Weighted-
Average
Grant Date Fair
Value
  
Unvested—December 31, 2020
   
 
160,935
 
   
$
0.14
 
Granted
   
 
—  
 
   
 
—  
 
Vested
   
 
(63,032
) 
   
 
0.14
 
Forfeited
   
 
—  
 
   
 
—  
 
  
 
 
     
Unvested—December 31, 2021
   
 
97,903
 
   
 
0.14
 
Granted
   
 
—  
 
   
 
—  
 
Vested
   
 
(47,446
) 
   
 
0.14
 
Forfeited
   
 
—  
 
   
 
—  
 
  
 
 
     
Unvested—December 31, 2022
   
 
50,457
 
   
$
0.14
 
  
 
 
     
The aggregate fair value of restricted stock that vested during the year ended December 31, 2022 was $0.1 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2022 was $0.14. Total intrinsic value of restricted stock as of December 31, 2022 was $0.2 million. As of December 31, 2022, total compensation cost not yet recognized related to unvested restricted stock was $4,000, which is expected to be recognized over a weighted-average period of 1.12 years.
The aggregate fair value of restricted stock that vested during the year ended December 31, 2021 was $0.3 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2021 was $0.14. Total intrinsic value of restricted stock as of December 31, 2021 was $3.6 million. As of December 31, 2021, total compensation cost not yet recognized related to unvested restricted stock was $7,000, which is expected to be recognized over a weighted-average period of 2.04 years.
 
Stock-based compensation expense
—The Company recorded stock-based compensation expense of $3.2 million and $1.9 million during the years ended December 31, 2022 and 2021, respectively.
Stock-based compensation expense is classified as follows (in thousands):
 
    
Year Ended December 31,
 
    
2022
 
  
2021
 
Research and development
   
$
1,893
 
   
$
1,019
 
General and administrative
   
 
1,298
 
   
 
905
 
  
 
 
     
 
 
  
Total stock-based compensation expense
   
$
3,191
 
   
$
1,924
 
 
 
 
 
 
 
 
 
 
 
The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used:
 
    
Year Ended December 31,
    
2022
  
2021
Stock price
   
$2.48 - $6.78  
   
$5.69 - $7.18
Expected term (years)
   
5.8 - 6.3 Years
   
6 Years
Expected volatility
   
80%
   
75% - 80%
Risk-free interest rate
   
1.60% - 3.00%
   
1.00% - 1.40%
Expected dividend yield
   
—
   
—
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes
11. Income Taxes
The difference between the effective tax rate and the U.S. federal tax rate is as follows:
 
    
Year Ended
  
    
December 31,
  
    
2022
 
 
2021
  
Federal income tax
   
 
(21.0
)% 
  
 
(21.0
)% 
State income tax, less federal benefits
   
 
(6.7
)% 
  
 
(7.6
)% 
Permanent differences
   
 
1.5
% 
  
 
1.7
% 
Change in valuation allowance
   
 
26.7
% 
  
 
27.1
% 
Credits
   
 
(0.5
)% 
  
 
(0.4
)% 
Other
   
 
0.0
% 
  
 
0.2
% 
 
 
 
 
 
 
 
 
 
Effective tax rate
   
 
0.0
% 
  
 
0.0
% 
 
 
 
 
 
 
 
 
 
Significant components of the Company’s deferred income taxes consist of the following (in thousands):
 
    
As of December 31,
 
    
2022
 
  
2021
 
Deferred Tax Assets:
      
Intangible asset basis differences
   
$
43
 
   
$
47
 
Net operating loss carryforwards
   
 
12,894
 
   
 
8,918
 
Tax credit carryforwards
   
 
399
 
   
 
145
 
Capitalized research and development costs
   
 
5,422
 
   
 
—  
 
Other
   
 
1,017
 
   
 
530
 
  
 
 
     
 
 
  
Total deferred tax assets
   
 
19,775
 
   
 
9,640
 
Deferred Tax Liabilities:
      
Fixed asset basis difference
   
 
(49
) 
   
 
(33
) 
Goodwill differences
   
 
(175
) 
   
 
(129
) 
  
 
 
     
 
 
  
Total deferred tax liabilities
   
 
(224
) 
   
 
(162
) 
Valuation allowance
   
 
(19,551
) 
   
 
(9,478
) 
  
 
 
     
 
 
  
Net deferred tax assets
   
$
—  
 
   
$
—  
 
  
 
 
     
 
 
  
Realization of tax assets is dependent upon future earnings, the timing and amount of which are uncertain. Accordingly, the U.S. net deferred tax assets have been fully offset by a valuation allowance. The changes in the valuation allowance for the years ended December 31, 2022 and 2021 were $10.1 million and $6.7 million, respectively.
 
As of December 31, 2022, the Company had federal net operating loss carryforwards of approximately $39.5 million, which has no expiration for federal tax purposes. As of December 31, 2022, the Company had California net operating loss carryforwards of approximately $65.8 million, which will begin to expire in 2039 for California tax purposes. At December 31, 2022, the Company also had Colorado net operating loss carryforwards of approximately $4,000, which will begin to expire in 2041 for Colorado tax purposes.
 
Internal Revenue Code of 1986, as amended (IRC) Section 382 imposes limitations on the use of net operating loss carryforwards when the stock ownership of one or more 5% stockholders (stockholders owning more than 5% or more of the Company’s outstanding capital stock) has increased on a cumulative basis by more than 50 percentage points. There is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover. As of December 31, 2022, the Company has not completed an analysis whether an ownership change occurred under Section 382, which, if it did occur, could substantially limit its ability in the future to utilize its net operating loss and other tax carryforwards.
As of December 31, 2022, the Company had Federal research and development credit carryforwards of approximately $0.4 million, which will begin to expire in 2041. The Company had California research and development carryforwards of $0.2 million, which will not expire.
The Company adopted the provisions of FASB Accounting Standards Codification (ASC
740-10),
Accounting for Uncertainty in Income Taxes, upon the date of incorporation. ASC
740-10
prescribes a comprehensive model for the recognition, measurement presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. During the years ended December 31, 2022 and 2021, the Company had not recognized any
tax-related
penalties or interest. At December 31, 2022 the gross unrecognized tax benefit relating to research and development credits was $0.2 million, none of which if recognized would reduce the effective tax rate in a future period, due the Company’s full valuation allowance on U.S. net deferred tax assets. The Company does not expect that its uncertain tax positions will materially change in the next twelve months. The following table summarizes the changes to the Company’s unrecognized tax benefits (in thousands):
 
    
As of
 
    
December 31,
 
    
2022
 
  
2021
 
Balance, beginning of the period
   
$
47
 
   
$
7
 
Increase related to prior year positions
   
 
7
 
   
 
2
 
Increase related to current year positions
   
 
110
 
   
 
38
 
  
 
 
     
 
 
  
Balance, end of the period
   
$
164
 
   
$
47
 
  
 
 
     
 
 
  
All tax returns will remain open for examination by the federal and state taxing authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards or research and development credits.
On August 9, 2022 and August 16, 2022, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act and the Inflation Reduction Act (IRA), respectively, were signed into law. The CHIPS Act and IRA contain among other things, some income tax provisions that establish a corporate alternative minimum tax and provide tax incentives for semiconductor manufacturing and research. The Company has evaluated the current legislation and at this time, does not anticipate either to have a material impact on its financial statements.
The Tax Cuts and Jobs Act (TCJA) included a change in the treatment of research and development (R&D) expenditures for tax purposes under Section 174. Effective for tax years beginning after December 31, 2021, specified R&D expenditures must undergo a
5-year
amortization period for domestic spend and a
15-year
amortization period for foreign spend. Prior to the effective date (2021 tax year and prior), taxpayers were able to immediately expense R&D costs under Section 174(a) or had the option to capitalize and amortize R&D expenditures over a
5-year
recovery period under Section 174(b). The company has evaluated the current legislation at this time, and prepared the provision by following the treatment of R&D expenditures for tax purposes under Section 174.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.2
401(k) Savings Plan
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
401(k) Savings Plan
12. 401(k) Savings Plan
The Company has a defined-contribution savings plan under IRC Section 401(k). The 401(k) Plan covers all employees who meet the defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. As of December 31, 2022 and 2021 the Company accrued no employee compensation costs for employer contributions payable to eligible employees.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Share
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Net Loss Per Share
13. Net Loss Per Share
Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts):
 
    
Year Ended December 31,
  
    
2022
 
  
2021
  
Numerator:
      
Net loss
   
$
(37,662
) 
   
$
(24,740
) 
 
 
 
 
 
 
 
 
 
Denominator:
      
Weighted-average common shares outstanding
   
 
3,548,829
 
   
 
3,335,786
 
Less: weighted-average unvested common stock issued upon early exercise of common stock options
   
 
(194,966
) 
   
 
(123,312
 )
 
Less: weighted-average unvested restricted shares of common stock
   
 
(229,589
) 
   
 
(906,364
 )
 
  
 
 
     
 
 
  
Weighted-average shares used to compute net loss per common share, basic and diluted
   
 
3,124,274
 
   
 
2,306,110
 
 
 
 
 
 
 
 
 
 
Net loss per share, basic and diluted
   
$
(12.05
) 
   
$
(10.73
) 
 
 
 
 
 
 
 
 
 
The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, and common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:
 
    
Year Ended
 
    
December 31,
 
    
2022
 
  
2021
 
Convertible preferred stock (as converted)
   
 
18,216,847
 
   
 
18,216,847
 
Stock options outstanding
   
 
3,316,671
 
   
 
3,075,403
 
Unvested restricted stock
   
 
91,953
 
   
 
535,945
 
  
 
 
     
 
 
  
Total
   
 
21,625,471
 
   
 
21,828,195
 
  
 
 
     
 
 
  
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events
14. Subsequent Events
The Company evaluated subsequent events from December 31, 2022, the date of these financial statements, through June 23, 2023, which represents the date the financial statements were issued for events requiring recording or disclosure in the financial statements for the year ended December 31, 2022. The Company concluded that no events have occurred that would require recognition or disclosure in the financial statements, except as described below.
On February 23, 2023, Enliven closed the Merger with Imara Inc. Pursuant to the Merger Agreement, Merger Sub, a wholly owned subsidiary of Imara, merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Imara Inc. Immediately prior to the closing of the Merger, investors in the Financing purchased shares of Enliven’s common stock totaling $164.5 million. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc.
In connection with the merger, a reverse stock split of Imara’s common stock was effectuated at a ratio of 1 to 4. In addition, each share of the Company’s common stock outstanding, including shares of the Company’s common stock that were issued pursuant to the Financing, converted into the right to receive a number of shares of Imara’s common stock based on an agreed upon ratio by the parties of approximately 0.2951 shares of Imara’s common stock for each share of the Company’s common stock. Historical common share figures of Enliven have been retroactively restated based on the exchange ratio of approximately 0.2951.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB).
Use of estimates
Use of estimates
The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and
stock-based
compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate.
Cash and cash equivalents
Cash and cash equivalents
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations.
Restricted cash
Restricted cash
The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets.
Concentrations of credit risk and off-balance sheet risk
Concentrations of credit risk and
off-balance
sheet risk
The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances.
Fair value measurements
Fair value measurements
Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are as follows:
 
  •  
Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
 
  •  
Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and
 
  •  
Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.
The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities.
Deferred offering costs
Deferred offering costs
Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively.
Property and equipment, net
Property and equipment, net
Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.
The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of three to
five years
.
Impairment of long-lived assets
Impairment of long-lived assets
The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements.
Leases
Leases
The Company elected to early adopt ASU
No. 2016-02,
Leases (ASC 842) and its associated amendments as of January 1, 2020. In June 2020, the Company entered into a sublease agreement under which it leased laboratory and office facilities which the Company determined to be an operating lease. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding
right-of-use
asset (ROU) upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding
right-of-use
assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. As the Company’s lease does not provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and
non-lease
components.
Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other
non-current
liabilities.
Convertible preferred stock
Convertible preferred stock
The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur.
Research and development expenses
Research and development expenses
The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and
non-clinical
studies, costs to acquire, develop and manufacture supplies for preclinical and clinical testing and other studies, expenses incurred under agreements with contract research organizations, and salaries and related costs, including equity-based compensation, as well as depreciation and other allocated facility-related and overhead expenses. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.
The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and
non-clinical
study materials are manufactured by contract manufacturing organizations. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company’s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
Stock-based compensation
Stock-based compensation
The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur.
The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified.
Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:
 
  •  
Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock.
 
  •  
Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the
mid-point
between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.
 
  •  
Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. 
 
  •  
Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards.
 
  •  
Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero.
The assumptions underlying these valuations represented the Company’s board and management’s best estimates,
which
involved inherent uncertainties and the application of management’s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its stock-based compensation expense could be materially different.
Income taxes
Income taxes
Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes.
The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
Net loss per share
Net loss per share
The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the
two-class
method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. The net loss attributable to common stockholders is not allocated to the convertible preferred shares as the holders of convertible preferred shares do not have a contractual obligation to share in losses. Cumulative dividends on preferred shares are added to net loss to arrive at net loss available to common stockholders.
Under the
two-class
method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted common stock as these shares are considered contingently issuable shares until they vest.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.
Segments
Segments
The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance.
Comprehensive income (loss)
Comprehensive income (loss)
Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. The Company did not have any items that required classification as other comprehensive income (loss).
Emerging growth company status
Emerging growth company status
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently issued accounting pronouncements adopted
Recently issued accounting pronouncements adopted
In December 2019, the FASB issued ASU
2019-12,
Simplifying the Accounting for Income Taxes (ASU
2019-12).
ASU
2019-12
eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance was effective for fiscal years beginning after December 15, 2021. The Company
adopted
ASU 2019-12
on
January 1, 2022
, and the adoption did not have a material impact.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis
The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):
 
    
As of December 31, 2022
  
    
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
  
Assets:
            
US Treasury backed money market funds
   
$
74,523
 
   
$
74,523
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total financial assets measured at fair value
   
$
74,523
 
   
$
74,523
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
As of December 31, 2021
 
    
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
Assets:
            
US Treasury backed money market funds
   
$
106,768
 
   
$
106,768
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total financial assets measured at fair value
   
$
106,768
 
   
$
106,768
 
   
$
—  
 
   
$
—  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Summary of Future Minimum Lease Payments Under Operating Sublease As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands):
 
 
  
As of

December 31, 2022
 
Year ending December 31,
         
   
2023
   
$
329
 
2024
   
 
341
 
    
 
 
  
Total minimum lease payments
   
 
670
 
Less: amount representing interest
   
 
26
 
    
 
 
  
Present value of lease liabilities
   
 
644
 
Less: current portion of lease liabilities
   
 
323
 
    
 
 
  
Lease liabilities, noncurrent
   
$
321
 
    
 
 
  
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment, net consisted of the following (dollars in thousands):
 
    
Estimated Useful Life
 
  
As of December 31,
 
    
in Years
 
  
2022
 
  
2021
 
Laboratory equipment
   
 
5
 
   
$
1,191
 
   
$
614
 
Computer equipment
   
 
3
 
   
 
73
 
   
 
38
 
             
 
 
     
 
 
  
             
 
1,264
 
   
 
652
 
Less: accumulated depreciation
            
 
(374
) 
   
 
(160
) 
             
 
 
     
 
 
  
Property and equipment, net
            
$
890
 
   
$
492
 
             
 
 
     
 
 
  
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Summary Of Accrued Expenses And Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
 
    
As of December 31,
 
    
2022
 
  
2021
 
Accrued employee compensation costs
   
$
2,130
 
   
$
1,027
 
Accrued research and development costs
   
 
1,918
 
   
 
1,637
 
Accrued deferred offering costs
   
 
1,190
 
   
 
39
 
Lease liabilities
   
 
323
 
   
 
159
 
Accrued legal and professional fees
   
 
269
 
   
 
176
 
Other
   
 
447
 
   
 
194
 
    
 
 
     
 
 
  
Accrued expenses and other current liabilities
   
$
6,277
 
   
$
3,232
 
 
 
 
 
 
 
 
 
 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock (Tables)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Following Shares of Common Stock Reserved for Future Issuance
The Company had the following shares of common stock reserved for future issuance:
 
    
As of December 31,
  
    
2022
 
  
2021
  
Conversion of preferred stock
   
 
18,216,847
 
   
 
18,216,847
 
Issuance of common stock upon exercise of stock options
   
 
3,316,671
 
   
 
3,075,403
 
Options available for grant under stock plan
   
 
906,265
 
   
 
403,680
 
    
 
 
     
 
 
  
Total common stock reserved for future issuance
   
 
22,439,783
 
   
 
21,695,930
 
    
 
 
     
 
 
  
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Preferred Stock (Tables)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Schedule of Convertible Preferred Stock
As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following:

 
 
  
 
 
  
 
 
  
 
 
  
Aggregate
 
  
Proceeds Net
 
 
  
 
 
  
Shares
 
  
Per Share
 
  
Liquidation
 
  
of Issuance
 
 
  
Authorized
 
  
Issued and
 
  
Liquidation
 
  
Amount
 
  
Costs
 
 
  
Shares
 
  
Outstanding
 
  
Preference
 
  
(in thousands)
 
  
(in thousands)
 
Series Seed convertible preferred stock
   
 
14,507,038
 
   
 
14,507,038
 
   
$
0.71
 
   
$
10,300
 
   
$
10,211
 
Series A convertible preferred stock
   
 
25,114,089
 
   
 
25,114,089
 
   
$
1.80
 
   
 
45,300
 
   
 
45,170
 
Series B convertible preferred stock
   
 
22,108,937
 
   
 
22,108,937
 
   
$
3.84
 
   
 
84,920
 
   
 
84,689
 
    
 
 
     
 
 
              
 
 
     
 
 
  
Total convertible preferred stock
   
 
61,730,064
 
   
 
61,730,064
 
            
$
140,520
 
   
$
140,070
 
    
 
 
     
 
 
              
 
 
     
 
 
  
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Compensation Related Costs [Abstract]  
Summary of Stock Plan Activity
The following table summarizes the stock plan activity:
 
    
Available

for Grant
 
 
Stock
Options
Outstanding
 
 
Weighted-
Average Exercise
Price
 
  
Weighted-
Average
Contractual Term
(in years)
 
  
Aggregate
Intrinsic Value
(in thousands)
  
Outstanding - January 1, 2021
   
 
2,593,057
 
  
 
985,399
 
  
$
1.12
 
   
 
9.47
 
   
$
3,509
 
Options granted
   
 
(2,189,377
) 
  
 
2,189,377
 
  
$
4.71
 
   
 
9.38
 
   
Options exercised and vested
   
 
—  
 
  
 
(99,373
) 
  
$
2.26
 
   
 
8.77
 
   
  
 
 
    
 
 
          
Outstanding - December 31, 2021
   
 
403,680
 
  
 
3,075,403
 
  
$
3.64
 
   
 
9.11
 
   
$
9,657
 
Increase in option pool
   
 
885,315
 
          
Options granted
   
 
(391,653
) 
  
 
391,653
 
  
$
5.66
 
   
 
9.38
 
   
Options exercised and vested
   
 
—
 
  
 
(141,462
) 
  
$
3.72
 
   
 
8.09
 
   
Options cancelled and forfeited
   
 
8,923
 
  
 
(8,923
) 
  
$
4.68
 
   
 
8.23
 
   
  
 
 
    
 
 
          
Outstanding - December 31, 2022
   
 
906,265
 
  
 
3,316,671
 
  
$
2.20
 
   
 
8.26
 
   
$
1,194
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable - December 31, 2022
     
 
1,707,882
 
  
$
1.85
 
   
 
8.00
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vested and expected to vest - December 31, 2022
     
 
3,316,671
 
  
$
2.20
 
   
 
8.26
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of Restricted Stock Activity
The following summarizes restricted stock activity:
 
    
Number of
Shares
 
  
Weighted-
Average
Grant Date Fair
Value
  
Unvested—December 31, 2020
   
 
160,935
 
   
$
0.14
 
Granted
   
 
—  
 
   
 
—  
 
Vested
   
 
(63,032
) 
   
 
0.14
 
Forfeited
   
 
—  
 
   
 
—  
 
  
 
 
     
Unvested—December 31, 2021
   
 
97,903
 
   
 
0.14
 
Granted
   
 
—  
 
   
 
—  
 
Vested
   
 
(47,446
) 
   
 
0.14
 
Forfeited
   
 
—  
 
   
 
—  
 
  
 
 
     
Unvested—December 31, 2022
   
 
50,457
 
   
$
0.14
 
  
 
 
     
Summary of Stock-Based Compensation Expense
Stock-based compensation expense is classified as follows (in thousands):
 
    
Year Ended December 31,
 
    
2022
 
  
2021
 
Research and development
   
$
1,893
 
   
$
1,019
 
General and administrative
   
 
1,298
 
   
 
905
 
  
 
 
     
 
 
  
Total stock-based compensation expense
   
$
3,191
 
   
$
1,924
 
 
 
 
 
 
 
 
 
 
Summary of Stock-Based Compensation Fair Value Assumptions
The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used:
 
    
Year Ended December 31,
    
2022
  
2021
Stock price
   
$2.48 - $6.78  
   
$5.69 - $7.18
Expected term (years)
   
5.8 - 6.3 Years
   
6 Years
Expected volatility
   
80%
   
75% - 80%
Risk-free interest rate
   
1.60% - 3.00%
   
1.00% - 1.40%
Expected dividend yield
   
—
   
—
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Summary of Effective Tax Rate and The U.S. Federal Tax Rate
The difference between the effective tax rate and the U.S. federal tax rate is as follows:
 
    
Year Ended
  
    
December 31,
  
    
2022
 
 
2021
  
Federal income tax
   
 
(21.0
)% 
  
 
(21.0
)% 
State income tax, less federal benefits
   
 
(6.7
)% 
  
 
(7.6
)% 
Permanent differences
   
 
1.5
% 
  
 
1.7
% 
Change in valuation allowance
   
 
26.7
% 
  
 
27.1
% 
Credits
   
 
(0.5
)% 
  
 
(0.4
)% 
Other
   
 
0.0
% 
  
 
0.2
% 
 
 
 
 
 
 
 
 
 
Effective tax rate
   
 
0.0
% 
  
 
0.0
% 
 
 
 
 
 
 
 
 
 
Summary of Company's Deferred Income Taxes
Significant components of the Company’s deferred income taxes consist of the following (in thousands):
 
    
As of December 31,
 
    
2022
 
  
2021
 
Deferred Tax Assets:
      
Intangible asset basis differences
   
$
43
 
   
$
47
 
Net operating loss carryforwards
   
 
12,894
 
   
 
8,918
 
Tax credit carryforwards
   
 
399
 
   
 
145
 
Capitalized research and development costs
   
 
5,422
 
   
 
—  
 
Other
   
 
1,017
 
   
 
530
 
  
 
 
     
 
 
  
Total deferred tax assets
   
 
19,775
 
   
 
9,640
 
Deferred Tax Liabilities:
      
Fixed asset basis difference
   
 
(49
) 
   
 
(33
) 
Goodwill differences
   
 
(175
) 
   
 
(129
) 
  
 
 
     
 
 
  
Total deferred tax liabilities
   
 
(224
) 
   
 
(162
) 
Valuation allowance
   
 
(19,551
) 
   
 
(9,478
) 
  
 
 
     
 
 
  
Net deferred tax assets
   
$
—  
 
   
$
—  
 
  
 
 
     
 
 
  
Summary of Company's Unrecognized Tax Benefits The following table summarizes the changes to the Company’s unrecognized tax benefits (in thousands):
 
    
As of
 
    
December 31,
 
    
2022
 
  
2021
 
Balance, beginning of the period
   
$
47
 
   
$
7
 
Increase related to prior year positions
   
 
7
 
   
 
2
 
Increase related to current year positions
   
 
110
 
   
 
38
 
  
 
 
     
 
 
  
Balance, end of the period
   
$
164
 
   
$
47
 
  
 
 
     
 
 
  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Share (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Common Share
Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts):
 
    
Year Ended December 31,
  
    
2022
 
  
2021
  
Numerator:
      
Net loss
   
$
(37,662
) 
   
$
(24,740
) 
 
 
 
 
 
 
 
 
 
Denominator:
      
Weighted-average common shares outstanding
   
 
3,548,829
 
   
 
3,335,786
 
Less: weighted-average unvested common stock issued upon early exercise of common stock options
   
 
(194,966
) 
   
 
(123,312
 )
 
Less: weighted-average unvested restricted shares of common stock
   
 
(229,589
) 
   
 
(906,364
 )
 
  
 
 
     
 
 
  
Weighted-average shares used to compute net loss per common share, basic and diluted
   
 
3,124,274
 
   
 
2,306,110
 
 
 
 
 
 
 
 
 
 
Net loss per share, basic and diluted
   
$
(12.05
) 
   
$
(10.73
) 
 
 
 
 
 
 
 
 
 
Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect:
 
    
Year Ended
 
    
December 31,
 
    
2022
 
  
2021
 
Convertible preferred stock (as converted)
   
 
18,216,847
 
   
 
18,216,847
 
Stock options outstanding
   
 
3,316,671
 
   
 
3,075,403
 
Unvested restricted stock
   
 
91,953
 
   
 
535,945
 
  
 
 
     
 
 
  
Total
   
 
21,625,471
 
   
 
21,828,195
 
  
 
 
     
 
 
  
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Organization, Description of Business and Liquidity - Additional Information (Details)
$ in Thousands
 12 Months Ended
Jun. 23, 2023
Feb. 23, 2023
USD ($)
DIRECTOR
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Organization, Description of Business and Liquidity [Line Items]        
Entity incorporation date Jun. 12, 2019      
Reverse stock split   1-for-4    
Majority number of initial members of board of directors | DIRECTOR   8    
Common Stock Value   $ 164,500 $ 1 $ 1
Accumulated deficit     (82,864) (45,202)
Net loss     (37,662) (24,740)
Cash and cash equivalents     $ 75,536 $ 110,024
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
Segment
Dec. 31, 2021
USD ($)
Summary of Significant Accounting Policies [LineItems]    
Restricted cash $ 54,000 $ 54,000
Restricted cash collateral of sublease 54,000  
Losses recognized by uninsured balances 0  
Deferred offering costs capitalized $ 4,000,000 $ 1,700,000
Expected dividend yield 0.00%  
Number of operating segments | Segment 1  
Adoption of accounting standards update [true false] true  
Accounting standards update, adoption date Jan. 01, 2022  
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2019-12 [Member]  
Accounting standards update, immaterial effect [true false] true  
General and administrative expenses | IPO    
Summary of Significant Accounting Policies [LineItems]    
Deferred offering costs capitalized $ 1,700,000  
Minimum    
Summary of Significant Accounting Policies [LineItems]    
Property and equipment estimated useful lives 3 years  
Maximum    
Summary of Significant Accounting Policies [LineItems]    
Property and equipment estimated useful lives 5 years  
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Assets:    
Total financial assets measured at fair value $ 74,523 $ 106,768
U.S. Treasury Backed Money Market Funds    
Assets:    
Total financial assets measured at fair value 74,523 106,768
Level 1    
Assets:    
Total financial assets measured at fair value 74,523 106,768
Level 1 | U.S. Treasury Backed Money Market Funds    
Assets:    
Total financial assets measured at fair value 74,523 106,768
Level 2    
Assets:    
Total financial assets measured at fair value 0 0
Level 2 | U.S. Treasury Backed Money Market Funds    
Assets:    
Total financial assets measured at fair value 0 0
Level 3    
Assets:    
Total financial assets measured at fair value 0 0
Level 3 | U.S. Treasury Backed Money Market Funds    
Assets:    
Total financial assets measured at fair value $ 0 $ 0
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Additional Information (Details)
 1 Months Ended 12 Months Ended
Apr. 30, 2022
Jan. 31, 2022
ft²
Mar. 31, 2021
USD ($)
Jun. 30, 2020
ft²
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 01, 2021
ft²
Feb. 28, 2021
ft²
Leases [Abstract]                
Area of leased office and laboratory space | ft²       6,782        
Lease expiration date       Dec. 30, 2021        
Square feet of office space leased | ft²   8,893         9,277 2,495
Lease and rental expense     $ 12,000   $ 200,000 $ 200,000    
Lease renewal term for office space extended date     Dec. 30, 2024          
Lease commencement date Jul. 01, 2022 May 01, 2022            
Incremental borrowing rate of right of used assets and lease liabilities         4.00%      
Remaining lease liability         $ 600,000 500,000    
Remaining operating lease right of use asset         600,000 500,000    
Variable lease costs         $ 300,000 $ 200,000    
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Leases [Abstract]  
2023 $ 329
2024 341
Total minimum lease payments 670
Less: amount representing interest 26
Present value of lease liabilities 644
Less: current portion of lease liabilities 323
Lease liabilities, noncurrent $ 321
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 1,264 $ 652
Less: accumulated depreciation (374) (160)
Property and equipment, net 890 492
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 1,191 614
Property and equipment estimated useful lives 5  
Computer equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 73 $ 38
Property and equipment estimated useful lives 3  
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0.2 $ 0.1
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued employee compensation costs $ 2,130 $ 1,027
Accrued research and development costs 1,918 1,637
Accrued deferred offering costs 1,190 39
Lease liabilities 323 159
Accrued legal and professional fees 269 176
Other 447 194
Accrued expenses and other current liabilities $ 6,277 $ 3,232
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock - Additional Information (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Vote
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Class of Stock [Line Items]    
Common stock, shares authorized | shares 26,264,364 26,264,364
Common stock, par value | $ / shares $ 0.0001 $ 0.0001
Common stock, shares issued | shares 3,570,019 3,435,014
Common stock, shares outstanding | shares 3,570,019 3,435,014
Shares subject to repurchase | shares 252,652 703,092
Liability related to shares subject to repurchase | $ $ 600 $ 600
Number of vote by common stock holders | Vote 1  
Long-term liabilities    
Class of Stock [Line Items]    
Liability related to shares subject to repurchase | $ $ 300 $ 400
Dividend Declared    
Class of Stock [Line Items]    
Dividends | $ 0  
Dividend Paid    
Class of Stock [Line Items]    
Dividends | $ $ 0  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Class of Stock [Line Items]      
Conversion of preferred stock 18,216,847 18,216,847  
Issuance of common stock upon exercise of stock options 3,316,671 3,075,403  
Options available for grant under stock plans 906,265 403,680 2,593,057
Common stock reserved for future issuance 22,439,783 21,695,930  
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Preferred Stock - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Convertible Preferred Stock    
Class of Stock [Line Items]    
Preferred stock, shares authorized 61,730,064 61,730,064
Preferred stock, shares issued 61,730,064 61,730,064
Preferred stock, par value $ 0.0001 $ 0.0001
Sale of stock, consideration received per transaction $ 75.0  
Convertible Preferred Stock | Merger Agreement    
Class of Stock [Line Items]    
Preferred stock, shares issued 0 0
Series Seed Convertible Preferred Stock    
Class of Stock [Line Items]    
Preferred stock, shares authorized 14,507,038 14,507,038
Preferred stock dividend rate $ 0.0426  
Preferred stock, par value $ 0.71  
Series A Convertible Preferred Stock    
Class of Stock [Line Items]    
Preferred stock, shares authorized 25,114,089 25,114,089
Preferred stock dividend rate $ 0.108226  
Preferred stock, par value $ 1.803768  
Series B Convertible Preferred Stock    
Class of Stock [Line Items]    
Preferred stock, shares authorized 22,108,937 22,108,937
Preferred stock dividend rate $ 0.2305  
Preferred stock, par value $ 3.84098  
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Class of Stock [Line Items]    
Proceeds Net of Issuance Costs   $ (226)
Series Seed Convertible Preferred Stock    
Class of Stock [Line Items]    
Authorized Shares 14,507,038 14,507,038
Shares Issued and Outstanding 14,507,038 14,507,038
Per Share Liquidation Preference $ 0.71 $ 0.71
Aggregate Liquidation Amount $ 10,300 $ 10,300
Proceeds Net of Issuance Costs $ 10,211 $ 10,211
Series A Convertible Preferred Stock    
Class of Stock [Line Items]    
Authorized Shares 25,114,089 25,114,089
Shares Issued and Outstanding 25,114,089 25,114,089
Per Share Liquidation Preference $ 1.8 $ 1.8
Aggregate Liquidation Amount $ 45,300 $ 45,300
Proceeds Net of Issuance Costs $ 45,170 $ 45,170
Series B Convertible Preferred Stock    
Class of Stock [Line Items]    
Authorized Shares 22,108,937 22,108,937
Shares Issued and Outstanding 22,108,937 22,108,937
Per Share Liquidation Preference $ 3.84 $ 3.84
Aggregate Liquidation Amount $ 84,920 $ 84,920
Proceeds Net of Issuance Costs $ 84,689 $ 84,689
Total Convertible Preferred Stock    
Class of Stock [Line Items]    
Authorized Shares 61,730,064 61,730,064
Shares Issued and Outstanding 61,730,064 61,730,064
Aggregate Liquidation Amount $ 140,520 $ 140,520
Proceeds Net of Issuance Costs $ 140,070 $ 140,070
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended 19 Months Ended
Aug. 09, 2022
Dec. 31, 2020
Aug. 31, 2020
Apr. 30, 2020
Jun. 30, 2019
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jul. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Allocated share based compensation expense           $ 3,191,000 $ 1,924,000    
Incremental stock-based compensation expense           3,191,000 1,924,000    
Total compensation cost not yet recognized related to unvested stock options           $ 7,700,000      
Expected to be recognized over a weighted-average period           2 years 5 months 4 days      
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested Intrinsic Value           $ 100,000      
Share-Based Payment Award, Options, Outstanding, Intrinsic Value   $ 3,509,000       1,194,000 9,657,000 $ 3,509,000  
Stock Option Repricing                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Allocated share based compensation expense $ 1,000,000                
Minimum exercise price for repriced options $ 4.68                
Maximum exercise price for repriced options $ 7.56                
Repricing vested and unvested stock options outstanding 2,209,826                
Incremental stock-based compensation expense $ 1,000,000                
Incremental stock compensation expense for option repricing for vested stock options. 300,000                
Incremental stock compensation expense for option repricing for unvested stock options $ 700,000                
Remaining weighted-average vesting period 2 years 10 months 24 days                
Restricted Stock                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Share-Based Payment Award Options Vested in Period Fair Value           100,000 300,000    
Total compensation cost not yet recognized related to unvested stock options           $ 4,000 $ 7,000    
Expected to be recognized over a weighted-average period           1 year 1 month 13 days 2 years 14 days    
Shares subject to repurchase           41,499 438,045    
Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value           $ 0.14 $ 0.14    
Share-Based Payment Award, Options, Outstanding, Intrinsic Value           $ 200,000 $ 3,600,000    
Restricted Stock | Enliven Inc.                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Issued shares in restricted common stock to its founders         3,000,000        
Issued shares in restricted common stock to its founders , per share         $ 0.0003        
Restricted Stock | Enliven Inc. | Vested Upon Issuance                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Shares vested immediately upon issuance         25.00%        
Restricted Stock | Employees and Consultants | Enliven Inc.                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Restricted stock shares issued               197,262  
Restricted stock shares issued value               $ 27,000  
Maximum | Restricted Stock                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Award vesting period           5 years      
Maximum | Restricted Stock | Enliven Inc.                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Remaining shares vesting period         48 months        
Minimum | Restricted Stock                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Award vesting period           4 years      
Minimum | Restricted Stock | Enliven Inc.                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Remaining shares vesting period         36 months        
2019 Equity Incentive Plan                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of shares authorized     4,681,244            
Number of additional shares authorized     885,315            
Sharebased Compensation Arrangement By Sharebased Payment Award Exercise Price Of Common Stock Percent           100.00%      
2019 Equity Incentive Plan | Enliven Inc.                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of shares authorized   3,795,929   2,584,138       3,795,929  
Number of additional shares authorized   1,211,791   2,210,062          
2019 Equity Incentive Plan | Stock Option Repricing                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Excercise price for repriced options $ 2.48                
2019 Equity Incentive Plan | Maximum | Enliven Inc.                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Number of shares authorized                 374,076
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Stock Plan Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Compensation Related Costs [Abstract]      
Available for Grant, Beginning Balance 403,680 2,593,057  
Available for Grant, Options granted (391,653) (2,189,377)  
Available for Grant, Increase in option pool 885,315    
Available for Grant, Options cancelled and forfeited 8,923    
Available for Grant, Ending Balance 906,265 403,680 2,593,057
Stock Options Outstanding, Beginning Balance 3,075,403 985,399  
Stock Options Outstanding, Options granted 391,653 2,189,377  
Stock Options Outstanding, Options cancelled and forfeited (8,923)    
Stock Options Outstanding, Options exercised and vested (141,462) (99,373)  
Stock Options Outstanding, Exercisable 1,707,882    
Stock Options Outstanding, Vested and expected to vest 3,316,671    
Stock Options Outstanding, Ending Balance 3,316,671 3,075,403 985,399
Weighted-Average Exercise Price, Beginning Balance $ 3.64 $ 1.12  
Weighted-Average Exercise Price, Options granted 5.66 4.71  
Weighted-Average Exercise Price, Options exercised and vested 3.72 2.26  
Weighted- Average Exercise Price, Options cancelled and forfeited 4.68    
Weighted-Average Exercise Price, Ending Balance 2.2 $ 3.64 $ 1.12
Weighted- Average Exercise Price, Exercisable 1.85    
Weighted- Average Exercise Price, Vested and expected to vest $ 2.2    
Weighted- Average Contractual Term, Outstanding 8 years 3 months 3 days 9 years 1 month 9 days 9 years 5 months 19 days
Weighted- Average Contractual Term, Options granted 9 years 4 months 17 days 9 years 4 months 17 days  
Weighted- Average Contractual Term, Options exercised and vested 8 years 1 month 2 days 8 years 9 months 7 days  
Weighted- Average Contractual Term, Options cancelled and forfeited 8 years 2 months 23 days    
Weighted- Average Contractual Term, Exercisable 8 years    
Weighted- Average Contractual Term, Vested and expected to vest 8 years 3 months 3 days    
Aggregate Intrinsic Value, Options cancelled and forfeited    
Aggregate Intrinsic Value, Beginning Balance $ 9,657 $ 3,509  
Aggregate Intrinsic Value, Options granted    
Aggregate Intrinsic Value, Options exercised and vested    
Aggregate Intrinsic Value, Ending Balance 1,194 $ 9,657 $ 3,509
Aggregate Intrinsic Value, Vested and expected to vest    
Aggregate Intrinsic Value, Exercisable    
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of Shares, Unvested, Beginning Balance 97,903 160,935
Number of Shares, Vested (47,446) (63,032)
Number of Shares, Unvested, Ending Balance 50,457 97,903
Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance $ 0.14 $ 0.14
Weighted-Average Grant Date Fair Value, Vested 0.14 0.14
Weighted-Average Grant Date Fair Value, Unvested, Ending Balance $ 0.14 $ 0.14
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Allocated share based compensation expense $ 3,191 $ 1,924
Research and development    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Allocated share based compensation expense 1,893 1,019
General and administrative    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Allocated share based compensation expense $ 1,298 $ 905
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details) - Stock Options - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (years)   6 years
Expected volatility 80.00%  
Risk-free interest rate, minimum 1.60% 1.00%
Risk-free interest rate, maximum 3.00% 1.40%
Minimum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock Price $ 2.48 $ 5.69
Expected term (years) 5 years 9 months 18 days  
Expected volatility   75.00%
Maximum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock Price $ 6.78 $ 7.18
Expected term (years) 6 years 3 months 18 days  
Expected volatility   80.00%
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]    
Federal income tax (21.00%) (21.00%)
State income tax, less federal benefits (6.70%) (7.60%)
Permanent differences 1.50% 1.70%
Change in valuation allowance 26.70% 27.10%
Credits (0.50%) (0.40%)
Other 0.00% 0.20%
Effective tax rate 0.00% 0.00%
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes - Summary of Company's Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Components of Deferred Tax Assets and Liabilities [Abstract]    
Intangible asset basis differences $ 43 $ 47
Net operating loss carryforwards 12,894 8,918
Tax credit carryforwards 399 145
Capitalized research and development costs 5,422
Other 1,017 530
Total deferred tax assets 19,775 9,640
Deferred Tax Liabilities:    
Fixed asset basis difference (49) (33)
Goodwill differences (175) (129)
Total deferred tax liabilities (224) (162)
Valuation allowance (19,551) (9,478)
Net deferred tax assets
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Uncertainties [Abstract]    
Balance, beginning of the period $ 47 $ 7
Increase related to prior year positions 7 2
Increase related to current year positions 110 38
Balance, end of the period $ 164 $ 47
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Line Items]    
Changes in the valuation allowance $ 10,100,000 $ 6,700,000
Minimum change in percentage of stock holding 50.00%  
Income tax examination, description All tax returns will remain open for examination by the federal and state taxing authorities for three and four years  
Research Tax Credit Carryforward    
Income Tax Disclosure [Line Items]    
Income tax penalties expense $ 0 $ 0
Unrecognized tax benefits recognized, would affect the effective tax rate $ 200,000  
Minimum    
Income Tax Disclosure [Line Items]    
Percentage of stock holding 5.00%  
Post Tax Year 2021 | The Tax Cuts And Jobs Act    
Income Tax Disclosure [Line Items]    
Amortization period of specified research and development expenses domestic spend 5 years  
Amortization period of specified research and development expenses foreign spend 15 years  
Tax Year 2021 and Prior    
Income Tax Disclosure [Line Items]    
Amortization period of specified research and development expenses 5 years  
Domestic Tax Authority | Internal Revenue Service (IRS) | Not Expirable    
Income Tax Disclosure [Line Items]    
Operating loss carryforwards $ 39,500,000  
Domestic Tax Authority | Internal Revenue Service (IRS) | Tax Year 2041 | Research Tax Credit Carryforward    
Income Tax Disclosure [Line Items]    
Tax credit carryforward $ 400,000  
State and Local Jurisdiction | Internal Revenue Service (IRS) | Tax Year 2041 | Research Tax Credit Carryforward    
Income Tax Disclosure [Line Items]    
Tax credit carryforward expiration year 2041  
State and Local Jurisdiction | California Franchise Tax Board | Not Expirable | Research Tax Credit Carryforward    
Income Tax Disclosure [Line Items]    
Tax credit carryforward $ 200,000  
State and Local Jurisdiction | California Franchise Tax Board | Tax Year 2039    
Income Tax Disclosure [Line Items]    
Operating loss carryforwards $ 65,800,000  
Operating loss carryforwards expiration year 2039  
State and Local Jurisdiction | Colorado Tax Authority | Tax Year 2041    
Income Tax Disclosure [Line Items]    
Operating loss carryforwards $ 4,000  
Operating loss carryforwards expiration year 2041  
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.2
401(k) Savings Plan - Additional Information (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Retirement Benefits [Abstract]    
401(k) Savings Plan liability $ 0 $ 0
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Numerator:    
Net loss $ (37,662) $ (24,740)
Denominator:    
Weighted-Average Common Shares Outstanding 3,548,829 3,335,786
Less: weighted-average unvested common stock issued upon early exercise of common stock options (194,966) (123,312)
Less: weighted-average unvested restricted shares of common stock (229,589) (906,364)
Weighted-average shares outstanding, basic 3,124,274 2,306,110
Weighted-average shares outstanding, diluted 3,124,274 2,306,110
Net loss per share, basic $ (12.05) $ (10.73)
Net loss per share, diluted $ (12.05) $ (10.73)
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Earnings Per Share Basic [Line Items]    
Convertible preferred stock (as converted) 21,625,471 21,828,195
Convertible Preferred Stock (as converted)    
Earnings Per Share Basic [Line Items]    
Convertible preferred stock (as converted) 18,216,847 18,216,847
Stock Options Outstanding    
Earnings Per Share Basic [Line Items]    
Convertible preferred stock (as converted) 3,316,671 3,075,403
Unvested Restricted Stock    
Earnings Per Share Basic [Line Items]    
Convertible preferred stock (as converted) 91,953 535,945
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events - Additional Information (Details) - USD ($)
$ in Thousands
Feb. 23, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]      
Common stock value $ 164,500 $ 1 $ 1
Reverse stock split 1-for-4    
Business acquisition, exchange ratio 0.2951%    
XML 65 d514661d8k_htm.xml IDEA: XBRL DOCUMENT 0001672619 2022-12-31 0001672619 2021-12-31 0001672619 2022-01-01 2022-12-31 0001672619 2021-01-01 2021-12-31 0001672619 2023-06-23 2023-06-23 0001672619 2020-06-30 0001672619 2020-06-01 2020-06-30 0001672619 2023-02-23 2023-02-23 0001672619 2021-02-28 0001672619 2021-03-01 0001672619 2022-01-31 0001672619 2021-03-01 2021-03-31 0001672619 2022-01-01 2022-01-31 0001672619 2022-04-01 2022-04-30 0001672619 2023-02-23 0001672619 2020-01-01 2020-12-31 0001672619 2020-12-31 0001672619 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 elvn:UnvestedRestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001672619 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 elvn:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0001672619 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001672619 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001672619 srt:MaximumMember 2022-01-01 2022-12-31 0001672619 srt:MinimumMember 2022-01-01 2022-12-31 0001672619 us-gaap:DividendPaidMember 2022-01-01 2022-12-31 0001672619 us-gaap:DividendDeclaredMember 2022-01-01 2022-12-31 0001672619 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001672619 us-gaap:AccountsPayableMember 2022-01-01 2022-12-31 0001672619 us-gaap:AccruedLiabilitiesMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:TaxYearTwoThousandAndThirtyNineMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember elvn:ColoradoTaxAuthorityMember elvn:TaxYearTwoThousandFortyOneMember 2022-01-01 2022-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember elvn:TaxYearTwoThousandFortyOneMember 2022-01-01 2022-12-31 0001672619 us-gaap:ResearchMember 2022-01-01 2022-12-31 0001672619 elvn:PostTaxYearTwoThousandAndTwentyOneMember elvn:TheTaxCutsAndJobsActMember 2022-01-01 2022-12-31 0001672619 elvn:TaxYearTwoThousandTwentyOneAndPriorMember 2022-01-01 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:LaboratoryEquipmentMember 2022-12-31 0001672619 us-gaap:ComputerEquipmentMember 2022-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2022-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2022-12-31 0001672619 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-12-31 0001672619 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-12-31 0001672619 elvn:MergerAgreementMember us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:IPOMember 2022-12-31 0001672619 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0001672619 us-gaap:RestrictedStockMember 2022-12-31 0001672619 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember elvn:NotExpirableMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember elvn:TaxYearTwoThousandAndThirtyNineMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember elvn:ColoradoTaxAuthorityMember elvn:TaxYearTwoThousandFortyOneMember 2022-12-31 0001672619 srt:MinimumMember 2022-12-31 0001672619 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember elvn:TaxYearTwoThousandFortyOneMember 2022-12-31 0001672619 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:ResearchMember elvn:NotExpirableMember 2022-12-31 0001672619 us-gaap:ResearchMember 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:LaboratoryEquipmentMember 2021-12-31 0001672619 us-gaap:ComputerEquipmentMember 2021-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2021-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2021-12-31 0001672619 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-12-31 0001672619 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-12-31 0001672619 elvn:MergerAgreementMember us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001672619 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0001672619 us-gaap:RestrictedStockMember 2021-12-31 0001672619 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001672619 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 elvn:UnvestedRestrictedStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:AccountsPayableMember 2021-01-01 2021-12-31 0001672619 us-gaap:AccruedLiabilitiesMember 2021-01-01 2021-12-31 0001672619 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001672619 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001672619 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesSeedConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 elvn:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001672619 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001672619 us-gaap:ResearchMember 2021-01-01 2021-12-31 0001672619 srt:MaximumMember elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2019-07-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-04-30 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-04-01 2020-04-30 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember elvn:EnlivenIncMember 2020-12-01 2020-12-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2020-08-01 2020-08-31 0001672619 elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2020-08-31 0001672619 elvn:StockOptionRepricingMember 2022-08-09 2022-08-09 0001672619 elvn:StockOptionRepricingMember elvn:TwoThousandAndNineteenEquityIncentivePlanMember 2022-08-09 2022-08-09 0001672619 us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 srt:MinimumMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 srt:MaximumMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2019-06-30 0001672619 elvn:EmployeesAndConsultantsMember us-gaap:RestrictedStockMember elvn:EnlivenIncMember 2019-06-01 2020-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001672619 us-gaap:CommonStockMember 2022-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001672619 us-gaap:RetainedEarningsMember 2022-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001672619 us-gaap:CommonStockMember 2020-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001672619 us-gaap:RetainedEarningsMember 2020-12-31 0001672619 us-gaap:RestrictedStockMember 2020-12-31 0001672619 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001672619 us-gaap:CommonStockMember 2021-12-31 0001672619 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001672619 us-gaap:RetainedEarningsMember 2021-12-31 iso4217:USD utr:sqft shares utr:Year pure utr:Month iso4217:USD shares elvn:DIRECTOR elvn:Segment elvn:Vote false 0001672619 CO 8-K 2023-06-23 Enliven Therapeutics, Inc. DE 001-39247 81-1523849 6200 Lookout Road Boulder 80301 720 647-8519 false false false false Common Stock, par value $0.001 per share ELVN NASDAQ true false P4Y P3Y http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201912Member 1-for-4 75536000 110024000 2217000 646000 77753000 110670000 890000 492000 626000 462000 3975000 1651000 54000 54000 83298000 113329000 3438000 2521000 6277000 3232000 9715000 5753000 659000 714000 10374000 6467000 0.0001 0.0001 61730064 61730064 61730064 61730064 61730064 61730064 140520000 140520000 149749000 149749000 0.0001 0.0001 26264364 26264364 3570019 3570019 3435014 3435014 1000 1000 6038000 2314000 -82864000 -45202000 -76825000 -42887000 83298000 113329000 31022000 20474000 7769000 4288000 38791000 24762000 -38791000 -24762000 1129000 22000 1129000 22000 -37662000 -24740000 -12.05 -12.05 -10.73 -10.73 3124274 3124274 2306110 2306110 61730064 149749000 3257927 1000 157000 -20462000 -20304000 177087 136000 136000 97000 97000 1924000 1924000 -24740000 -24740000 61730064 149749000 3435014 1000 2314000 -45202000 -42887000 135005 246000 246000 287000 287000 3191000 3191000 -37662000 -37662000 61730064 149749000 3570019 1000 6038000 -82864000 -76825000 -37662000 -24740000 215000 115000 3191000 1924000 1741000 1590000 563000 -4000 -133000 411000 1734000 1613000 2263000 -32077000 -19134000 612000 191000 -612000 -191000 -226000 2390000 1480000 591000 690000 -1799000 -1016000 -34488000 -20341000 110078000 130419000 75590000 110078000 75536000 110024000 54000 54000 75590000 110078000 131000 39000 656000 1190000 387000 491000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization, Description of Business and Liquidity </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business </div></div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Enliven Therapeutics, Inc. (the Company) was incorporated in the State of Delaware on June 12, 2019 and is headquartered in Boulder, Colorado. The Company is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. The Company aims to address emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Its discovery process combines deep insights in clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities. To date, the Company has funded its operations primarily through private placements of its convertible preferred stock. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October 13, 2022, the Company entered into an agreement and plan of merger (Merger Agreement) with Imara Inc. (Imara), a Delaware corporation and Iguana Merger Sub, Inc., a wholly-owned subsidiary of Imara (Merger Sub). Pursuant to the Merger Agreement, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the merger (the Merger). Immediately prior to the closing of the Merger, certain new and current investors subscribed for the purchase of an aggregate of approximately $164.5 million of common stock of Enliven (the Financing). On February 23, 2023, Enliven closed the Merger with Imara Inc. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and uncertainties </div></div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to development-stage companies in the biotechnology industry including, but not limited to, risks of failure of preclinical studies and clinical trials, new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on third-party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, compliance with government regulations and the need to obtain additional financing. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company continues to closely monitor macroeconomic and geopolitical developments, including the global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Russia- Ukraine conflict and inflation. The extent of the impact of these developments on the Company’s business, operations and research and development timelines and plans remains uncertain, and will depend on numerous factors, including the impact, if any, on the Company’s personnel, responses of governmental entities, and the responses of third parties such as contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties with whom the Company does business. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s development activities, financial condition and results of operations, including its ability to obtain financing. The Company is monitoring the potential impact of these developments on its business and financial statements. To date, the Company has not experienced material business disruptions or incurred impairment losses in the carrying values of its assets as a result of these developments, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these financial statements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity considerations </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional capital. Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we may seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our capital requirements. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, that will occur. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since inception. As of December 31, 2022, the Company had an accumulated deficit of $82.9 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $37.7 million and $24.7 million for the years ended December 31, 2022 and 2021, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash and cash equivalents of $75.5 million as of December 31, 2022 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the financial statements are issued. </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Calibri;font-weight:bold"><div style="font-style:italic;display:inline;">Merger Agreement and Exchange Ratio </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On October 13, 2022, the Company entered into the Merger Agreement with Imara, a Delaware corporation and Merger Sub. Pursuant to the Merger Agreement, among other matters, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the Merger. The Merger was intended to qualify for U.S. federal income tax purposes as a tax-free “reorganization” under the provisions of Section 368(a) of the Code and, in the event that former Enliven stockholders, including stockholders that participate in the Enliven <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-closing</div> financing, are in “control” of Imara immediately after the effective time of the Merger (within the meaning of Section 368(c) of the Code), as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-taxable</div> exchange of shares of Enliven common stock for shares of Imara common stock within the meaning of Section 351(a) of the Code, with the result that Enliven stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes upon the exchange of Enliven common stock for Imara common stock pursuant to the Merger, except with respect to cash received in lieu of a fractional share of Imara common stock. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the closing of the Merger on February 23, 2023, (a) each outstanding share of Company common stock (including common stock issued upon the conversion of the Company’s preferred stock, and shares issued in the Financing) was converted into the right to receive a number of shares of Imara common stock (Imara Common Stock) (after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-4</div> reverse stock split of Imara Common Stock in connection with the Merger) equal to the exchange ratio per the Merger Agreement; and (b) each of the then outstanding Company stock option that had not previously been exercised prior to the closing of the Merger was assumed by Imara. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately prior to the closing of the Merger, and in order to provide the Company with additional capital for its development programs, certain new and current investors purchased an aggregate of approximately $164.5 million of common stock of Enliven. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger and Financing were completed on February 23, 2023. The Merger has been accounted for as a reverse recapitalization under U.S. GAAP because the assets of Imara as of the effective date of the Merger are primarily cash and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> assets. Enliven was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (1) Enliven stockholders own a substantial majority of the voting rights in the combined company; (2) Enliven designated a majority (eight of nine) of the initial members of the board of directors of the combined company; and (3) Enliven’s senior management holds all positions in senior management <div style="display:inline;">of</div> the combined company. </div> 2019-06-12 164500000 -82900000 -37700000 -24700000 75500000 1-for-4 164500000 8 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of presentation </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB). </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of estimates </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-based</div> compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted cash </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of credit risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value measurements </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The three levels of the fair value hierarchy are as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred offering costs </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment, net </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of <span style="-sec-ix-hidden:hidden82544289">three</span> to <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">five years</div>. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of long-lived assets </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company elected to early adopt ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-02,</div> Leases (ASC 842) and its associated amendments as of January 1, 2020. In June 2020, the Company entered into a sublease agreement under which it leased laboratory and office facilities which the Company determined to be an operating lease. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset (ROU) upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. As the Company’s lease does not provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible preferred stock </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, costs to acquire, develop and manufacture supplies for preclinical and clinical testing and other studies, expenses incurred under agreements with contract research organizations, and salaries and related costs, including equity-based compensation, as well as depreciation and other allocated facility-related and overhead expenses. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> study materials are manufactured by contract manufacturing organizations. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company’s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-point</div> between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="break-inside: avoid; font-size: 0px;"> <td style="width: 5%;"></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions underlying these valuations represented the Company’s board and management’s best estimates, <div style="letter-spacing: 0px; top: 0px;;display:inline;">which</div> involved inherent uncertainties and the application of management’s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its stock-based compensation expense could be materially different. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss per share </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. The net loss attributable to common stockholders is not allocated to the convertible preferred shares as the holders of convertible preferred shares do not have a contractual obligation to share in losses. Cumulative dividends on preferred shares are added to net loss to arrive at net loss available to common stockholders. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted common stock as these shares are considered contingently issuable shares until they vest. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive income (loss) </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company did not have any items that required classification as other comprehensive income (loss). </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging growth company status </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently issued accounting pronouncements adopted </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> Simplifying the Accounting for Income Taxes (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance was effective for fiscal years beginning after December 15, 2021. The Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">adopted</div> <span style="-sec-ix-hidden:hidden82544226">ASU 2019-12</span><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> on <div style="letter-spacing: 0px; top: 0px;;display:inline;">January 1, 2022</div>, and the adoption did not have a material impact. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of presentation </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB). </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of estimates </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-based</div> compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted cash </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets. </div></div> 54000 54000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of credit risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. </div></div> 0 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value measurements </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The three levels of the fair value hierarchy are as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred offering costs </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively. </div></div> 1700000 4000000 1700000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment, net </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of <span style="-sec-ix-hidden:hidden82544289">three</span> to <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">five years</div>. </div></div> P5Y <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of long-lived assets </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company elected to early adopt ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-02,</div> Leases (ASC 842) and its associated amendments as of January 1, 2020. In June 2020, the Company entered into a sublease agreement under which it leased laboratory and office facilities which the Company determined to be an operating lease. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset (ROU) upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. As the Company’s lease does not provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible preferred stock </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, costs to acquire, develop and manufacture supplies for preclinical and clinical testing and other studies, expenses incurred under agreements with contract research organizations, and salaries and related costs, including equity-based compensation, as well as depreciation and other allocated facility-related and overhead expenses. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> study materials are manufactured by contract manufacturing organizations. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company’s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-point</div> between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="break-inside: avoid; font-size: 0px;"> <td style="width: 5%;"></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: Calibri; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions underlying these valuations represented the Company’s board and management’s best estimates, <div style="letter-spacing: 0px; top: 0px;;display:inline;">which</div> involved inherent uncertainties and the application of management’s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of its stock-based compensation expense could be materially different. </div></div> 0 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss per share </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. Convertible preferred stock is a participating security in distributions of the Company. The net loss attributable to common stockholders is not allocated to the convertible preferred shares as the holders of convertible preferred shares do not have a contractual obligation to share in losses. Cumulative dividends on preferred shares are added to net loss to arrive at net loss available to common stockholders. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method, basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted common stock as these shares are considered contingently issuable shares until they vest. </div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. </div></div> 1 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive income (loss) </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company did not have any items that required classification as other comprehensive income (loss). </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging growth company status </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently issued accounting pronouncements adopted </div></div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> Simplifying the Accounting for Income Taxes (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance was effective for fiscal years beginning after December 15, 2021. The Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">adopted</div> <span style="-sec-ix-hidden:hidden82544226">ASU 2019-12</span><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> on <div style="letter-spacing: 0px; top: 0px;;display:inline;">January 1, 2022</div>, and the adoption did not have a material impact. </div> true 2022-01-01 true <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Fair Value Measurements </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%; font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US Treasury backed money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total financial assets measured at fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: Calibri; font-size: 0px;"></td> <td colspan="16" style="height: 12pt; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US Treasury backed money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total financial assets measured at fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%; font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 3%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US Treasury backed money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total financial assets measured at fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">74,523</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: Calibri; font-size: 0px;"></td> <td colspan="16" style="height: 12pt; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US Treasury backed money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total financial assets measured at fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">106,768</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> </table> 74523000 74523000 0 0 74523000 74523000 0 0 106768000 106768000 0 0 106768000 106768000 0 0 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Leases </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Facility lease </div></div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2020, the Company leased office and laboratory space under a sublease agreement for 6,782 square feet, which was set to expire on December 30, 2021. In March 2021, the Company amended its sublease agreement, increasing its leased space by 2,495 square feet to 9,277 square feet and monthly rent to $12,000. Upon the extension of the lease in March 2021, the lease was automatically extended to December 30, 2024. Additionally, in January 2022 the Company amended its sublease, which increased the leased space by an additional 8,893 square feet commencing on May 1, 2022, and the rental payments increased by an equally proportionate amount to reflect the increase in floor space. Further, in April 2022 the Company amended the sublease, which deferred the expansion for the additional space to July 1, 2022. The monthly rent is subject to annual increases through the lease term. The Company is required to pay base rent expense as well as its proportionate share of the facilities operating expenses. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, consisting primarily of common area maintenance, are paid separately based on actual costs incurred. Therefore, the variable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components were not included in the right of use asset and lease liability and are reflected as expense in the period incurred. The incremental borrowing rate used to calculate the Company’s right of use asset and lease liability is 4%. The incremental borrowing rate was estimated based on the Company’s estimated borrowing rate on a collateralized loan. As of December 31, 2022, the remaining lease liability and right of use asset were $0.6 million and $0.6 million, respectively. As of December 31, 2021, the remaining lease liability and right of use asset were $0.5 million and $0.5 million, respectively. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized rent expense under the facility sublease for the years ended December 31, 2022 and 2021 of $0.2 million. As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands): </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"></td> <td style="width: 16%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31,</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: Calibri; font-size: 0px;"> </td> <td colspan="4" style="height: 6pt; font-family: Calibri; font-size: 0px;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">329</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">341</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">670</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: amount representing interest</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">644</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion of lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">323</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, noncurrent</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">321</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended December 31, 2022 and 2021, the Company recognized $0.3 million and $0.2 million in variable lease costs, respectively. </div></div> 6782 2021-12-30 2495 9277 12000 2024-12-30 8893 2022-05-01 2022-07-01 0.04 600000 600000 500000 500000 200000 200000 As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands): <br/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"></td> <td style="width: 16%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31,</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: Calibri; font-size: 0px;"> </td> <td colspan="4" style="height: 6pt; font-family: Calibri; font-size: 0px;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">329</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">341</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">670</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: amount representing interest</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">644</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion of lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">323</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, noncurrent</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">321</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 329000 341000 670000 26000 644000 323000 321000 300000 200000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Property and Equipment, Net </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (dollars in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 67%; font-family: Calibri;"></td> <td style="width: 8%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 8%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">in Years</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,191</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">614</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">73</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,264</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">652</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(374</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(160</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">890</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">492</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (dollars in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 67%; font-family: Calibri;"></td> <td style="width: 8%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 8%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">in Years</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,191</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">614</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">73</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,264</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">652</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(374</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(160</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">890</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">492</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 5 1191000 614000 3 73000 38000 1264000 652000 374000 160000 890000 492000 200000 100000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Accrued Expenses and Other Current Liabilities </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued employee compensation costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,130</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,027</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued research and development costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,918</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,637</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued deferred offering costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,190</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">39</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">323</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">159</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal and professional fees</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">269</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">176</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">447</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">194</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">6,277</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,232</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued employee compensation costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,130</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,027</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued research and development costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,918</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,637</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued deferred offering costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,190</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">39</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">323</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">159</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal and professional fees</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">269</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">176</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">447</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">194</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">6,277</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,232</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> 2130000 1027000 1918000 1637000 1190000 39000 323000 159000 269000 176000 447000 194000 6277000 3232000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Commitments and Contingencies </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease commitments</div></div></div></div>—The Company’s commitments related to lease agreements are disclosed in Note 4. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation</div></div></div></div>—From time to time, the Company may be involved in legal proceedings or be subject to claims arising in the ordinary course of our business. The Company was not currently a party to any legal proceedings. Regardless of outcome, any proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification agreements</div></div></div></div>—In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company among other things to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its financial statements as of December 31, 2022 or 2021. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Common Stock </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of December 31, 2022 and 2021, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 26,264,364 shares of $0.0001 par value common stock, of which 3,570,019 and 3,435,014 shares were issued and outstanding, respectively. As of December 31, 2022 and 2021, there were 252,652 and 703,092 shares which were subject to repurchase, respectively. The liability related to shares subject to repurchase totaled $0.6 million as of December 31, 2022 and 2021, of which $0.3 million and $0.4 million were recorded as other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as of December 31, 2022 and 2021, respectively. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any, subject to the preferential dividend rights of any convertible preferred stock. No dividends have been declared or paid by the Company through December 31, 2022. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any convertible preferred stock. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following shares of common stock reserved for future issuance: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%; font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock upon exercise of stock options</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,075,403</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options available for grant under stock plan</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">906,265</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">403,680</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total common stock reserved for future issuance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">22,439,783</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">21,695,930</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 26264364 26264364 0.0001 0.0001 3570019 3570019 3435014 3435014 252652 703092 600000 600000 300000 400000 1 0 0 <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had the following shares of common stock reserved for future issuance: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%; font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock upon exercise of stock options</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,075,403</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options available for grant under stock plan</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">906,265</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">403,680</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total common stock reserved for future issuance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">22,439,783</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">21,695,930</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 18216847 18216847 3316671 3075403 906265 403680 22439783 21695930 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Convertible Preferred Stock </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following: </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proceeds Net</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Per Share</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidation</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Issuance</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Authorized</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued and</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidation</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Costs</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preference</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series Seed convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">14,507,038</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">14,507,038</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.71</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">10,300</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">10,211</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">25,114,089</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">25,114,089</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.80</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">45,300</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">45,170</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">22,108,937</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">22,108,937</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3.84</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">84,920</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">84,689</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">61,730,064</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">61,730,064</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">140,520</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">140,070</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No shares of convertible preferred stock were issued during the years ended December 31, 2022 and 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s convertible preferred stock have the following rights, preferences, privileges and restrictions: </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting</div></div></div></div>—On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of convertible preferred stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of convertible preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matters. Except as provided by law or by the other provisions of the Company’s Amended and Restated Certificate of Incorporation, holders of convertible preferred stock shall vote together with the holders of common stock as a single class and on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> to common stock basis. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends</div></div></div></div>—The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) in any calendar year unless the holders of the convertible preferred stock then outstanding shall first receive, or simultaneously receive, dividends on each outstanding share of convertible preferred stock in an amount for such calendar year equal to the greater of (i) the applicable dividend rate of $0.0426, $0.108226 and $0.2305 per share for the Series Seed, Series A and Series B, respectively, subject to adjustment in the event of any stock splits, stock dividends or similar changes in capitalization with respect to such class or series, and (ii) that dividend per share of such series of convertible preferred stock as would equal the product of (A) the dividend payable on each share of such series determined, if applicable, as if all shares of such series had been converted into common stock and (B) the number of shares of common stock issuable upon conversion of such series, in each case calculated on the record date for the determination of holders entitled to receive such dividend. The right to receive dividends on shares of convertible preferred stock shall not be cumulative, and no right to dividends shall accrue to holders of the convertible preferred stock by reason of the fact that dividends on such shares are not declared or paid. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation preference</div></div></div></div>—In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of the convertible preferred stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, and in the event of a deemed liquidation event, the holders of shares of convertible preferred stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such deemed liquidation event or out of the available proceeds, as applicable, on a pari passu basis among each other and before any payment shall be made to the holders of the common stock by reason of their ownership hereof, an amount equal to the greater of (i) one times the applicable original issue price of $0.71 per share of Series Seed, $1.803768 per share of Series A and $3.84098 per share of Series B, plus any dividends declared, but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of the convertible preferred stock had been converted into common stock immediately prior to such liquidation, dissolution, winding up or deemed liquidation event. If upon any such event, the assets of the Company available for distribution to the stockholders shall be insufficient to pay the holders of the convertible preferred stock the full amount, they shall be entitled to share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would be otherwise payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After payment of the liquidation preference to the holders of convertible preferred stock, the remaining assets of the Company shall be distributed ratably to the holders of common stock on a fully converted basis. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption</div></div></div></div>—The shares of convertible preferred stock shall not be redeemable by any holder. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voluntary conversion</div></div></div></div>—Each share of convertible preferred stock shall be convertible, at the option of the holder thereof at any time and from time to time, without the payment of additional consideration by the holder thereof, into such number of fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of common stock as is determined by dividing the applicable original issue price by the applicable conversion price in effect at the time of conversion. The original issue price of the Series Seed, Series A and Series B convertible preferred shares is $0.71, $1.803768 and $3.84098, respectively. Such conversion price, and at the rate at which the convertible preferred shares may be converted into shares of common stock, shall be subject to adjustment for occurrences such as stock splits, certain dividends, mergers and distributions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Automatic conversion</div></div></div></div>—Each share of convertible preferred stock will automatically be converted into shares of common stock, at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">then-effective</div> conversion rate of such shares upon either (i) the closing of the sale of shares of the Company’s common stock to the public in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, with proceeds of at least $75.0 million, or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the requisite holders, then all outstanding shares of convertible preferred stock shall automatically be converted into shares of common stock, at the then effective conversion rate. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following: </div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> <td style="width: 3%; vertical-align: bottom;"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proceeds Net</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Per Share</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidation</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Issuance</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Authorized</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued and</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidation</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Costs</div></div></div></div></td> <td style="vertical-align: bottom;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preference</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series Seed convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">14,507,038</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">14,507,038</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.71</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">10,300</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">10,211</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">25,114,089</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">25,114,089</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.80</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">45,300</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">45,170</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">22,108,937</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">22,108,937</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3.84</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">84,920</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">84,689</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total convertible preferred stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">61,730,064</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">61,730,064</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: top; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">140,520</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: top;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: top;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">140,070</div></td> <td style="vertical-align: top; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> 61730064 61730064 14507038 14507038 14507038 14507038 0.71 0.71 10300000 10300000 10211000 10211000 25114089 25114089 25114089 25114089 1.8 1.8 45300000 45300000 45170000 45170000 22108937 22108937 22108937 22108937 3.84 3.84 84920000 84920000 84689000 84689000 61730064 61730064 61730064 61730064 140520000 140520000 140070000 140070000 0 0 0.0426 0.108226 0.2305 0.71 1.803768 3.84098 0.71 1.803768 3.84098 75000000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Stock-Based Compensation </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Incentive Plan</div></div></div></div>—In July 2019, the Company adopted the 2019 Equity Incentive Plan (the 2019 Plan) pursuant to which the Company’s board of directors may grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, and restricted stock units to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and incentive stock options only to employees. The 2019 Plan initially authorized grants of awards of up to 374,076 shares. In April 2020, the board of directors increased the number of shares of the Company’s common stock authorized for issuance under the 2019 Plan by 2,210,062 to 2,584,138 shares. Additionally, in December 2020, the board of directors approved to increase the number of shares of the Company’s common stock authorized for issuance under the 2019 Plan by 1,211,791 to 3,795,929 shares. In August 2022, the board of directors approved an increase in the shares authorized under the 2019 Equity Incentive Plan of 885,315 shares, for a total authorized amount of 4,681,244. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Awards granted under the 2019 Plan expire no later than 10 years from the date of grant. For incentive stock options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options, the option exercise price will not be less than 100% of the estimated fair value on the date of grant. Options and restricted stock granted to employees typically vest over a four-year period but may be granted with different vesting terms. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Repricing </div></div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective August 9, 2022, the Company’s board of directors repriced certain previously granted and still outstanding vested and unvested stock option awards under the 2019 Plan. As a result, the exercise price for these awards was lowered to $2.48 per share, which was the fair value of the Company’s common stock on August 9, 2022. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, 2,209,826 vested and unvested stock options outstanding as of August 9, 2022, with original exercise prices ranging from $4.68 to $7.56, were repriced. The repricing on August 9, 2022 resulted in incremental stock-based compensation expense of $1.0 million, of which $0.3 million related to vested stock option awards and was expensed on the repricing date, and $0.7 million related to unvested stock option awards is being amortized on a straight-line basis over the remaining weighted-average vesting period of those awards of approximately 2.9 years. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the stock plan activity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Available</div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">for Grant</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Stock<br/>Options<br/>Outstanding</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/>Average Exercise<br/>Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/>Average<br/>Contractual Term<br/>(in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding - January 1, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,593,057</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">985,399</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.12</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,509</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(2,189,377</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,189,377</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">4.71</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised and vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(99,373</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.77</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding - December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">403,680</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,075,403</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3.64</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.11</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9,657</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in option pool</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">885,315</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(391,653</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">391,653</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">5.66</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised and vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(141,462</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3.72</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.09</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options cancelled and forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8,923</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(8,923</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">4.68</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.23</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding - December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">906,265</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2.20</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,194</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable - December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,707,882</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.85</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.00</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest - December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2.20</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total intrinsic value of exercised and vested incentive awards during the year ended December 31, 2022 was $0.1 million and is calculated on the difference between the exercise price and the fair value of the Company’s common stock as of the exercise date. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, total compensation cost not yet recognized related to unvested stock options was $7.7 million, which is expected to be recognized over a weighted-average period of 2.43 years. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock award activity</div></div></div><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">—Upon formation of the Company in June 2019, the Company issued 3.0 million shares in restricted common stock to the founders of the Company at $0.0003 per share. 25% of the shares vested immediately upon issuance, with the remaining shares vesting evenly over 36 or 48 months. Vesting may be accelerated upon a change in control, as defined in the holder agreements. If the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest. As of December 31, 2022 and 2021, there were 41,499 and 438,045 shares subject to repurchase, respectively.</div><div style="font-style:italic;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, between 2019 and 2020, the Company issued a total of 197,262 shares of restricted stock to employees and consultants for aggregate consideration of $27,000. The purchase price of the restricted stock was the estimated fair value on the grant date. The restricted stock awards are subject to vesting over a period of <span style="-sec-ix-hidden:hidden82544405">four</span> to five years, and vesting may be accelerated upon a change in control, as defined in the holder agreements.<br/>If<div style="display:inline;"> </div>the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following summarizes restricted stock activity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%; font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 6%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Number of<br/>Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/>Average<br/>Grant Date Fair<br/>Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested—December 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">160,935</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(63,032</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested—December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">97,903</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(47,446</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested—December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">50,457</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate fair value of restricted stock that vested during the year ended December 31, 2022 was $0.1 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2022 was $0.14. Total intrinsic value of restricted stock as of December 31, 2022 was $0.2 million. As of December 31, 2022, total compensation cost not yet recognized related to unvested restricted stock was $4,000, which is expected to be recognized over a weighted-average period of 1.12 years. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate fair value of restricted stock that vested during the year ended December 31, 2021 was $0.3 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2021 was $0.14. Total intrinsic value of restricted stock as of December 31, 2021 was $3.6 million. As of December 31, 2021, total compensation cost not yet recognized related to unvested restricted stock was $7,000, which is expected to be recognized over a weighted-average period of 2.04 years. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-based compensation expense</div></div></div></div>—The Company recorded stock-based compensation expense of $3.2 million and $1.9 million during the years ended December 31, 2022 and 2021, respectively. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense is classified as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,893</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,019</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,298</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">905</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,191</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,924</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%; font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December 31,</div></div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$2.48 - $6.78  </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$5.69 - $7.18</div></div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.8 - 6.3 Years</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">6 Years</div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">80%</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">75% - 80%</div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.60% - 3.00%</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.00% - 1.40%</div></div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—</div></td> </tr> </table> 374076 2210062 2584138 1211791 3795929 885315 4681244 1 2.48 2209826 4.68 7.56 1000000 300000 700000 P2Y10M24D <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the stock plan activity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Available</div><br/><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">for Grant</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Stock<br/>Options<br/>Outstanding</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/>Average Exercise<br/>Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/>Average<br/>Contractual Term<br/>(in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding - January 1, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,593,057</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">985,399</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.12</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,509</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(2,189,377</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,189,377</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">4.71</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised and vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(99,373</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.77</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding - December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">403,680</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,075,403</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3.64</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.11</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9,657</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in option pool</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">885,315</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(391,653</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">391,653</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">5.66</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9.38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised and vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(141,462</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3.72</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.09</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options cancelled and forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8,923</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(8,923</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">4.68</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.23</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding - December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">906,265</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2.20</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,194</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable - December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,707,882</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.85</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.00</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest - December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2.20</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0pt; line-height: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> 2593057 985399 1.12 P9Y5M19D 3509000 2189377 2189377 4.71 P9Y4M17D -99373 2.26 P8Y9M7D 403680 3075403 3.64 P9Y1M9D 9657000 885315 391653 391653 5.66 P9Y4M17D -141462 3.72 P8Y1M2D 8923 8923 4.68 P8Y2M23D 906265 3316671 2.2 P8Y3M3D 1194000 1707882 1.85 P8Y 3316671 2.2 P8Y3M3D 100000 7700000 P2Y5M4D 3000000 0.0003 0.25 P36M P48M 41499 438045 197262 27000 P5Y <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following summarizes restricted stock activity: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%; font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 6%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Number of<br/>Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/>Average<br/>Grant Date Fair<br/>Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested—December 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">160,935</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(63,032</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested—December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">97,903</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(47,446</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested—December 31, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">50,457</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.14</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> </table> 160935 0.14 63032 0.14 97903 0.14 47446 0.14 50457 0.14 100000 0.14 200000 4000 P1Y1M13D 300000 0.14 3600000 7000 P2Y14D 3200000 1900000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense is classified as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,893</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,019</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,298</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">905</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,191</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,924</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> 1893000 1019000 1298000 905000 3191000 1924000 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%; font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December 31,</div></div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$2.48 - $6.78  </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$5.69 - $7.18</div></div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.8 - 6.3 Years</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">6 Years</div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">80%</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">75% - 80%</div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.60% - 3.00%</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.00% - 1.40%</div></div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—</div></td> </tr> </table> 2.48 6.78 5.69 7.18 P5Y9M18D P6Y3M18D P6Y 0.80 0.75 0.80 0.016 0.03 0.01 0.014 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;">11. Income Taxes </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the effective tax rate and the U.S. federal tax rate is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%; font-family: Calibri;"></td> <td style="width: 5%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal income tax</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(21.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(21.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income tax, less federal benefits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(6.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(7.6</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">26.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">27.1</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(0.5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(0.4</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant components of the Company’s deferred income taxes consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%; font-family: Calibri;"></td> <td style="width: 8%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Assets:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: Calibri; font-size: 0px;"></td> <td colspan="4" style="height: 6pt; font-family: Calibri; font-size: 0px;"></td> <td colspan="4" style="height: 6pt; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset basis differences</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">43</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">12,894</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8,918</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">399</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">145</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capitalized research and development costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">5,422</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,017</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">530</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">19,775</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9,640</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed asset basis difference</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(49</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(33</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill differences</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(175</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(129</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(224</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(162</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(19,551</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(9,478</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Realization of tax assets is dependent upon future earnings, the timing and amount of which are uncertain. Accordingly, the U.S. net deferred tax assets have been fully offset by a valuation allowance. The changes in the valuation allowance for the years ended December 31, 2022 and 2021 were $10.1 million and $6.7 million, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022, the Company had federal net operating loss carryforwards of approximately $39.5 million, which has no expiration for federal tax purposes. As of December 31, 2022, the Company had California net operating loss carryforwards of approximately $65.8 million, which will begin to expire in 2039 for California tax purposes. At December 31, 2022, the Company also had Colorado net operating loss carryforwards of approximately $4,000, which will begin to expire in 2041 for Colorado tax purposes. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-align: center; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code of 1986, as amended (IRC) Section 382 imposes limitations on the use of net operating loss carryforwards when the stock ownership of one or more 5% stockholders (stockholders owning more than 5% or more of the Company’s outstanding capital stock) has increased on a cumulative basis by more than 50 percentage points. There is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover. As of December 31, 2022, the Company has not completed an analysis whether an ownership change occurred under Section 382, which, if it did occur, could substantially limit its ability in the future to utilize its net operating loss and other tax carryforwards. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022, the Company had Federal research and development credit carryforwards of approximately $0.4 million, which will begin to expire in 2041. The Company had California research and development carryforwards of $0.2 million, which will not expire. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted the provisions of FASB Accounting Standards Codification (ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10),</div> Accounting for Uncertainty in Income Taxes, upon the date of incorporation. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10</div> prescribes a comprehensive model for the recognition, measurement presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. During the years ended December 31, 2022 and 2021, the Company had not recognized any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-related</div> penalties or interest. At December 31, 2022 the gross unrecognized tax benefit relating to research and development credits was $0.2 million, none of which if recognized would reduce the effective tax rate in a future period, due the Company’s full valuation allowance on U.S. net deferred tax assets. The Company does not expect that its uncertain tax positions will materially change in the next twelve months. The following table summarizes the changes to the Company’s unrecognized tax benefits (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of</div></div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of the period</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to prior year positions</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year positions</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">110</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, end of the period</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">164</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All tax returns will remain open for examination by the federal and state taxing authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards or research and development credits. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 9, 2022 and August 16, 2022, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act and the Inflation Reduction Act (IRA), respectively, were signed into law. The CHIPS Act and IRA contain among other things, some income tax provisions that establish a corporate alternative minimum tax and provide tax incentives for semiconductor manufacturing and research. The Company has evaluated the current legislation and at this time, does not anticipate either to have a material impact on its financial statements. </div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Tax Cuts and Jobs Act (TCJA) included a change in the treatment of research and development (R&amp;D) expenditures for tax purposes under Section 174. Effective for tax years beginning after December 31, 2021, specified R&amp;D expenditures must undergo a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> amortization period for domestic spend and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div> amortization period for foreign spend. Prior to the effective date (2021 tax year and prior), taxpayers were able to immediately expense R&amp;D costs under Section 174(a) or had the option to capitalize and amortize R&amp;D expenditures over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> recovery period under Section 174(b). The company has evaluated the current legislation at this time, and prepared the provision by following the treatment of R&amp;D expenditures for tax purposes under Section 174. </div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the effective tax rate and the U.S. federal tax rate is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%; font-family: Calibri;"></td> <td style="width: 5%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal income tax</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(21.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(21.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income tax, less federal benefits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(6.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(7.6</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">26.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">27.1</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(0.5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(0.4</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">)% </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.2</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">0.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"> </div></div> </td> </tr> </table> 0.21 0.21 -0.067 -0.076 0.015 0.017 0.267 0.271 -0.005 -0.004 0 0.002 0 0 <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant components of the Company’s deferred income taxes consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%; font-family: Calibri;"></td> <td style="width: 8%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Assets:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: Calibri; font-size: 0px;"></td> <td colspan="4" style="height: 6pt; font-family: Calibri; font-size: 0px;"></td> <td colspan="4" style="height: 6pt; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset basis differences</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">43</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">12,894</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">8,918</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">399</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">145</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capitalized research and development costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">5,422</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">1,017</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">530</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">19,775</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">9,640</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed asset basis difference</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(49</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(33</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill differences</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(175</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(129</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(224</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(162</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(19,551</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(9,478</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 43000 47000 12894000 8918000 399000 145000 5422000 1017000 530000 19775000 9640000 49000 33000 175000 129000 224000 162000 19551000 9478000 10100000 6700000 39500000 65800000 2039 4000 2041 0.05 0.05 0.50 400000 2041 200000 0 0 200000 The following table summarizes the changes to the Company’s unrecognized tax benefits (in thousands): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%; font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 4%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">As of</div></div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of the period</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to prior year positions</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year positions</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">110</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">38</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, end of the period</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">164</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 47000 7000 7000 2000 110000 38000 164000 47000 All tax returns will remain open for examination by the federal and state taxing authorities for three and four years P5Y P15Y P5Y <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. 401(k) Savings Plan </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has a defined-contribution savings plan under IRC Section 401(k). The 401(k) Plan covers all employees who meet the defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. As of December 31, 2022 and 2021 the Company accrued no employee compensation costs for employer contributions payable to eligible employees. </div></div> 0 0 <div style="font-family: Calibri; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Net Loss Per Share </div></div></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%; font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 6%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(37,662</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(24,740</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average common shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,548,829</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,335,786</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: weighted-average unvested common stock issued upon early exercise of common stock options</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(194,966</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(123,312</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: weighted-average unvested restricted shares of common stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(229,589</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(906,364</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares used to compute net loss per common share, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,124,274</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,306,110</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(12.05</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(10.73</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, and common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%; font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid black;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid black;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible preferred stock (as converted)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,075,403</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">91,953</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">535,945</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">21,625,471</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">21,828,195</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%; font-family: Calibri;"></td> <td style="width: 7%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 6%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(37,662</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(24,740</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average common shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,548,829</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,335,786</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: weighted-average unvested common stock issued upon early exercise of common stock options</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(194,966</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(123,312</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: weighted-average unvested restricted shares of common stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(229,589</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(906,364</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares used to compute net loss per common share, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,124,274</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2,306,110</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(12.05</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">(10.73</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black; line-height: 0pt; font-size: 0pt;;text-align:right;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;"> <div style="font-family: Calibri; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> -37662000 -24740000 3548829 3335786 -194966 -123312 229589 906364 3124274 3124274 2306110 2306110 -12.05 -12.05 -10.73 -10.73 The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: arial; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 74%; font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="width: 2%; vertical-align: bottom; font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> <td style="font-family: Calibri;"></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid black;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-weight:bold;display:inline;width:100%;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid black;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"><div style="font-weight:bold;display:inline;width:100%;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible preferred stock (as converted)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">18,216,847</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,316,671</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">3,075,403</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">91,953</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">535,945</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: arial; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">21,625,471</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;">21,828,195</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-family: Calibri; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: Calibri; font-size: 0px;"></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 18216847 18216847 3316671 3075403 91953 535945 21625471 21828195 <div style="font-family: Calibri; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. Subsequent Events </div></div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events from December 31, 2022, the date of these financial statements, through June 23, 2023, which represents the date the financial statements were issued for events requiring recording or disclosure in the financial statements for the year ended December 31, 2022. The Company concluded that no events have occurred that would require recognition or disclosure in the financial statements, except as described below. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 23, 2023, Enliven closed the Merger with Imara Inc. Pursuant to the Merger Agreement, Merger Sub, a wholly owned subsidiary of Imara, merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Imara Inc. Immediately prior to the closing of the Merger, investors in the Financing purchased shares of Enliven’s common stock totaling $164.5 million. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc. </div></div><div style="font-family: Calibri; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: Calibri; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the merger, a reverse stock split of Imara’s common stock was effectuated at a ratio of <span style="-sec-ix-hidden:hidden82544585">1 to 4</span>. In addition, each share of the Company’s common stock outstanding, including shares of the Company’s common stock that were issued pursuant to the Financing, converted into the right to receive a number of shares of Imara’s common stock based on an agreed upon ratio by the parties of approximately 0.2951 shares of Imara’s common stock for each share of the Company’s common stock. Historical common share figures of Enliven have been retroactively restated based on the exchange ratio of approximately 0.2951. </div></div> 164500000 0.002951 0.002951 EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 142 289 1 false 48 0 false 10 false false R1.htm 1001 - Document - Cover Page Sheet http://www.enliventherapeutics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Balance Sheets Sheet http://www.enliventherapeutics.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Balance Sheets (Parenthetical) Sheet http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Statements of Operations and Comprehensive Loss Sheet http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Statements of Convertible Preferred Stock and Stockholders' Deficit Sheet http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit Statements of Convertible Preferred Stock and Stockholders' Deficit Statements 5 false false R6.htm 1006 - Statement - Statement of Cash Flows Sheet http://www.enliventherapeutics.com/role/StatementOfCashFlows Statement of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Organization, Description of Business and Liquidity Sheet http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidity Organization, Description of Business and Liquidity Notes 7 false false R8.htm 1008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - Fair Value Measurements Sheet http://www.enliventherapeutics.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 1010 - Disclosure - Leases Sheet http://www.enliventherapeutics.com/role/Leases Leases Notes 10 false false R11.htm 1011 - Disclosure - Property and Equipment, Net Sheet http://www.enliventherapeutics.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 1012 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 12 false false R13.htm 1013 - Disclosure - Commitments and Contingencies Sheet http://www.enliventherapeutics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 1014 - Disclosure - Common Stock Sheet http://www.enliventherapeutics.com/role/CommonStock Common Stock Notes 14 false false R15.htm 1015 - Disclosure - Convertible Preferred Stock Sheet http://www.enliventherapeutics.com/role/ConvertiblePreferredStock Convertible Preferred Stock Notes 15 false false R16.htm 1016 - Disclosure - Stock-Based Compensation Sheet http://www.enliventherapeutics.com/role/StockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 1017 - Disclosure - Income Taxes Sheet http://www.enliventherapeutics.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 1018 - Disclosure - 401(k) Savings Plan Sheet http://www.enliventherapeutics.com/role/KSavingsPlan 401(k) Savings Plan Notes 18 false false R19.htm 1019 - Disclosure - Net Loss Per Share Sheet http://www.enliventherapeutics.com/role/NetLossPerShare Net Loss Per Share Notes 19 false false R20.htm 1020 - Disclosure - Subsequent Events Sheet http://www.enliventherapeutics.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 1021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 1022 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.enliventherapeutics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.enliventherapeutics.com/role/FairValueMeasurements 22 false false R23.htm 1023 - Disclosure - Leases (Tables) Sheet http://www.enliventherapeutics.com/role/LeasesTables Leases (Tables) Tables http://www.enliventherapeutics.com/role/Leases 23 false false R24.htm 1024 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.enliventherapeutics.com/role/PropertyAndEquipmentNet 24 false false R25.htm 1025 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilities 25 false false R26.htm 1026 - Disclosure - Common Stock (Tables) Sheet http://www.enliventherapeutics.com/role/CommonStockTables Common Stock (Tables) Tables http://www.enliventherapeutics.com/role/CommonStock 26 false false R27.htm 1027 - Disclosure - Convertible Preferred Stock (Tables) Sheet http://www.enliventherapeutics.com/role/ConvertiblePreferredStockTables Convertible Preferred Stock (Tables) Tables http://www.enliventherapeutics.com/role/ConvertiblePreferredStock 27 false false R28.htm 1028 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.enliventherapeutics.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.enliventherapeutics.com/role/StockBasedCompensation 28 false false R29.htm 1029 - Disclosure - Income Taxes (Tables) Sheet http://www.enliventherapeutics.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.enliventherapeutics.com/role/IncomeTaxes 29 false false R30.htm 1030 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.enliventherapeutics.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.enliventherapeutics.com/role/NetLossPerShare 30 false false R31.htm 1031 - Disclosure - Organization, Description of Business and Liquidity - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails Organization, Description of Business and Liquidity - Additional Information (Details) Details 31 false false R32.htm 1032 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 32 false false R33.htm 1033 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 33 false false R34.htm 1034 - Disclosure - Leases - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 34 false false R35.htm 1035 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details) Sheet http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details) Details 35 false false R36.htm 1036 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 36 false false R37.htm 1037 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 37 false false R38.htm 1038 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details) Sheet http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details) Details 38 false false R39.htm 1039 - Disclosure - Common Stock - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails Common Stock - Additional Information (Details) Details 39 false false R40.htm 1040 - Disclosure - Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details) Sheet http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details) Details 40 false false R41.htm 1041 - Disclosure - Convertible Preferred Stock - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails Convertible Preferred Stock - Additional Information (Details) Details 41 false false R42.htm 1042 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) Sheet http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) Details 42 false false R43.htm 1043 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 43 false false R44.htm 1044 - Disclosure - Stock-Based Compensation - Summary of Stock Plan Activity (Details) Sheet http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails Stock-Based Compensation - Summary of Stock Plan Activity (Details) Details 44 false false R45.htm 1045 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Sheet http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Details 45 false false R46.htm 1046 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Sheet http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Details 46 false false R47.htm 1047 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details) Sheet http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details) Details 47 false false R48.htm 1048 - Disclosure - Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details) Sheet http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details) Details 48 false false R49.htm 1049 - Disclosure - Income Taxes - Summary of Company's Deferred Income Taxes (Details) Sheet http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails Income Taxes - Summary of Company's Deferred Income Taxes (Details) Details 49 false false R50.htm 1050 - Disclosure - Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details) Sheet http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySUnrecognizedTaxBenefitsDetails Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details) Details 50 false false R51.htm 1051 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 51 false false R52.htm 1052 - Disclosure - 401(k) Savings Plan - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/KSavingsPlanAdditionalInformationDetails 401(k) Savings Plan - Additional Information (Details) Details 52 false false R53.htm 1053 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) Sheet http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) Details 53 false false R54.htm 1054 - Disclosure - Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details) Sheet http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details) Details 54 false false R55.htm 1055 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 55 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d514661dex991.htm 2094, 2108 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityReverseStockSplit - d514661d8k.htm 7, d514661dex991.htm 7 d514661d8k.htm d514661dex991.htm d514661dex231.htm d514661dex992.htm elvn-20230623.xsd elvn-20230623_cal.xml elvn-20230623_def.xml elvn-20230623_lab.xml elvn-20230623_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d514661d8k.htm d514661dex991.htm": { "axisCustom": 0, "axisStandard": 23, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 496, "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 142, "dts": { "calculationLink": { "local": [ "elvn-20230623_cal.xml" ] }, "definitionLink": { "local": [ "elvn-20230623_def.xml" ] }, "inline": { "local": [ "d514661d8k.htm", "d514661dex991.htm" ] }, "labelLink": { "local": [ "elvn-20230623_lab.xml" ] }, "presentationLink": { "local": [ "elvn-20230623_pre.xml" ] }, "schema": { "local": [ "elvn-20230623.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 450, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 4, "http://xbrl.sec.gov/dei/2022": 3, "total": 7 }, "keyCustom": 55, "keyStandard": 234, "memberCustom": 17, "memberStandard": 29, "nsprefix": "elvn", "nsuri": "http://www.enliventherapeutics.com/20230623", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d514661d8k.htm", "contextRef": "P06_23_2023To06_23_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.enliventherapeutics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d514661d8k.htm", "contextRef": "P06_23_2023To06_23_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Leases", "menuCat": "Notes", "order": "10", "role": "http://www.enliventherapeutics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Property and Equipment, Net", "menuCat": "Notes", "order": "11", "role": "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "12", "role": "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "13", "role": "http://www.enliventherapeutics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Common Stock", "menuCat": "Notes", "order": "14", "role": "http://www.enliventherapeutics.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "elvn:ConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Convertible Preferred Stock", "menuCat": "Notes", "order": "15", "role": "http://www.enliventherapeutics.com/role/ConvertiblePreferredStock", "shortName": "Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "elvn:ConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "16", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "17", "role": "http://www.enliventherapeutics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - 401(k) Savings Plan", "menuCat": "Notes", "order": "18", "role": "http://www.enliventherapeutics.com/role/KSavingsPlan", "shortName": "401(k) Savings Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "19", "role": "http://www.enliventherapeutics.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.enliventherapeutics.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://www.enliventherapeutics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.enliventherapeutics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.enliventherapeutics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Property and Equipment, Net (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "elvn:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Common Stock (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.enliventherapeutics.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "elvn:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "elvn:ConvertiblePreferredStockTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPreferredUnitsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Convertible Preferred Stock (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockTables", "shortName": "Convertible Preferred Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "elvn:ConvertiblePreferredStockTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPreferredUnitsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.enliventherapeutics.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "us-gaap:PreferredStockSharesIssued", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.enliventherapeutics.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "elvn:OrganizationDescriptionOfBusinessAndLiquidityTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P06_23_2023To06_23_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Organization, Description of Business and Liquidity - Additional Information (Details)", "menuCat": "Details", "order": "31", "role": "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails", "shortName": "Organization, Description of Business and Liquidity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "elvn:OrganizationDescriptionOfBusinessAndLiquidityTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P06_23_2023To06_23_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "32", "role": "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "0", "lang": null, "name": "elvn:RestrictedCashCollateralOfSublease", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "menuCat": "Details", "order": "33", "role": "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn06_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "elvn:AreaOfLeasedOfficeAndLaboratorySpace", "reportCount": 1, "unique": true, "unitRef": "Unit_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Leases - Additional Information (Details)", "menuCat": "Details", "order": "34", "role": "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn06_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "elvn:AreaOfLeasedOfficeAndLaboratorySpace", "reportCount": 1, "unique": true, "unitRef": "Unit_sqft", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details)", "menuCat": "Details", "order": "35", "role": "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails", "shortName": "Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "menuCat": "Details", "order": "36", "role": "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "menuCat": "Details", "order": "37", "role": "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details)", "menuCat": "Details", "order": "38", "role": "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Common Stock - Additional Information (Details)", "menuCat": "Details", "order": "39", "role": "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails", "shortName": "Common Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "INF", "lang": null, "name": "elvn:CommonStockNumberOfSharesSubjectToRepurchase", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "elvn:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details)", "menuCat": "Details", "order": "40", "role": "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails", "shortName": "Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "elvn:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Convertible Preferred Stock - Additional Information (Details)", "menuCat": "Details", "order": "41", "role": "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "shortName": "Convertible Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "-5", "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2021To12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "42", "role": "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails", "shortName": "Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfPreferredUnitsTextBlock", "elvn:ConvertiblePreferredStockTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022_SeriesSeedConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "elvn:PreferredStockSharesIssuedAndOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "43", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "elvn:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Stock-Based Compensation - Summary of Stock Plan Activity (Details)", "menuCat": "Details", "order": "44", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails", "shortName": "Stock-Based Compensation - Summary of Stock Plan Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2021_RestrictedStockMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "menuCat": "Details", "order": "45", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2020_RestrictedStockMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "menuCat": "Details", "order": "46", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details)", "menuCat": "Details", "order": "47", "role": "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details)", "menuCat": "Details", "order": "48", "role": "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails", "shortName": "Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Income Taxes - Summary of Company's Deferred Income Taxes (Details)", "menuCat": "Details", "order": "49", "role": "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails", "shortName": "Income Taxes - Summary of Company's Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Statements of Convertible Preferred Stock and Stockholders' Deficit", "menuCat": "Statements", "order": "5", "role": "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "shortName": "Statements of Convertible Preferred Stock and Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "50", "role": "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Income Taxes - Additional Information (Details)", "menuCat": "Details", "order": "51", "role": "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "div", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - 401(k) Savings Plan - Additional Information (Details)", "menuCat": "Details", "order": "52", "role": "http://www.enliventherapeutics.com/role/KSavingsPlanAdditionalInformationDetails", "shortName": "401(k) Savings Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "div", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn12_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)", "menuCat": "Details", "order": "53", "role": "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails", "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "0", "lang": null, "name": "elvn:WeightedAverageCommonSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details)", "menuCat": "Details", "order": "54", "role": "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "PAsOn02_23_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Subsequent Events - Additional Information (Details)", "menuCat": "Details", "order": "55", "role": "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P02_23_2023To02_23_2023", "decimals": "INF", "lang": null, "name": "elvn:BusinessAcquisitionExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Statement of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.enliventherapeutics.com/role/StatementOfCashFlows", "shortName": "Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "elvn:OrganizationDescriptionOfBusinessAndLiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - Organization, Description of Business and Liquidity", "menuCat": "Notes", "order": "7", "role": "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidity", "shortName": "Organization, Description of Business and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "elvn:OrganizationDescriptionOfBusinessAndLiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "9", "role": "http://www.enliventherapeutics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d514661dex991.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage", "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Entity incorporation date" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage", "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "elvn_AccruedDeferredOfferingCostCurrent": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "elvn_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued deferred offering cost current.", "label": "Accrued Deferred Offering Cost Current", "terseLabel": "Accrued deferred offering costs" } } }, "localname": "AccruedDeferredOfferingCostCurrent", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "elvn_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "elvn_AccruedResearchAndDevelopmentCostCurrent": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "elvn_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development cost current.", "label": "Accrued Research And Development Cost Current", "terseLabel": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostCurrent", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "elvn_AmortizationPeriodForSpecifiedResearchAndDevelopmentExpenditures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization period for specified research and development expenditures.", "label": "Amortization Period For Specified Research And Development Expenditures", "terseLabel": "Amortization period of specified research and development expenses" } } }, "localname": "AmortizationPeriodForSpecifiedResearchAndDevelopmentExpenditures", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "elvn_AmortizationPeriodForSpecifiedResearchAndDevelopmentExpendituresDomestic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization period for specified research and development expenditures domestic.", "label": "Amortization Period For Specified Research And Development Expenditures Domestic", "terseLabel": "Amortization period of specified research and development expenses domestic spend" } } }, "localname": "AmortizationPeriodForSpecifiedResearchAndDevelopmentExpendituresDomestic", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "elvn_AmortizationPeriodForSpecifiedResearchAndDevelopmentExpendituresForeign": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization period for specified research and development expenditures foreign.", "label": "Amortization Period For Specified Research And Development Expenditures Foreign", "terseLabel": "Amortization period of specified research and development expenses foreign spend" } } }, "localname": "AmortizationPeriodForSpecifiedResearchAndDevelopmentExpendituresForeign", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "elvn_AmountOfLossRecognizedByUninsuredBalances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Loss Recognized by Uninsured Balances", "label": "Amount of Loss Recognized by Uninsured Balances", "terseLabel": "Losses recognized by uninsured balances" } } }, "localname": "AmountOfLossRecognizedByUninsuredBalances", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_AreaOfLeasedOfficeAndLaboratorySpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of leased office and laboratory space.", "label": "Area Of Leased Office And Laboratory Space", "terseLabel": "Area of leased office and laboratory space" } } }, "localname": "AreaOfLeasedOfficeAndLaboratorySpace", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "elvn_AreaOfLeasedOfficeSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of leased office space.", "label": "Area Of Leased Office Space", "terseLabel": "Square feet of office space leased" } } }, "localname": "AreaOfLeasedOfficeSpace", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "elvn_BusinessAcquisitionExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition, exchange ratio.", "label": "Business Acquisition Exchange Ratio", "terseLabel": "Business acquisition, exchange ratio" } } }, "localname": "BusinessAcquisitionExchangeRatio", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "elvn_ColoradoTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Colorado Tax Authority [Member]", "terseLabel": "Colorado Tax Authority" } } }, "localname": "ColoradoTaxAuthorityMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_CommonStockLiabilityRelatedToSharesSubjectToRepurchase": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common Stock Liability Related to Shares Subject to Repurchase", "label": "Common Stock Liability Related to Shares Subject to Repurchase", "terseLabel": "Liability related to shares subject to repurchase" } } }, "localname": "CommonStockLiabilityRelatedToSharesSubjectToRepurchase", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_CommonStockNumberOfSharesSubjectToRepurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Number of Shares Subject to Repurchase", "label": "Common Stock Number of Shares Subject to Repurchase", "terseLabel": "Shares subject to repurchase" } } }, "localname": "CommonStockNumberOfSharesSubjectToRepurchase", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "elvn_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentrations of credit risk and off-balance sheet risk.", "label": "Concentrations Of Credit Risk And Off Balance Sheet Risk [Policy Text Block]", "terseLabel": "Concentrations of credit risk and off-balance sheet risk" } } }, "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "elvn_ConvertiblePreferredStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock.", "label": "Convertible Preferred Stock [Policy Text Block]", "terseLabel": "Convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockPolicyTextBlock", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "elvn_ConvertiblePreferredStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred Stock text block..", "label": "Convertible Preferred Stock [Text Block]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockTextBlock", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "elvn_DeferredIssuanceCostsRelatedToInitialPublicOfferingIncludedInLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred issuance costs related to initial public offering included in liabilities.", "label": "Deferred Issuance Costs Related To Initial Public Offering Included In Liabilities", "terseLabel": "Deferred issuance costs related to initial public offering included in accounts payable / liabilities" } } }, "localname": "DeferredIssuanceCostsRelatedToInitialPublicOfferingIncludedInLiabilities", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "elvn_DeferredOfferingCostsNonCurrent": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering cost non current.", "label": "Deferred Offering Costs Non Current", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsNonCurrent", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "elvn_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging growth company status.", "label": "Emerging Growth Company Status [Policy Text Block]", "terseLabel": "Emerging growth company status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "elvn_EmployeeServiceShareBasedCompensationSharesSubjectToRepurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Service Share Based Compensation Shares Subject To Repurchase", "label": "Employee Service Share Based Compensation Shares Subject To Repurchase", "terseLabel": "Shares subject to repurchase" } } }, "localname": "EmployeeServiceShareBasedCompensationSharesSubjectToRepurchase", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "elvn_EmployeesAndConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and consultants.", "label": "Employees and Consultants [Member]", "terseLabel": "Employees and Consultants" } } }, "localname": "EmployeesAndConsultantsMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_EnlivenIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Enliven Inc.", "label": "Enliven Inc. [Member]", "terseLabel": "Enliven Inc." } } }, "localname": "EnlivenIncMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_IncomeTaxDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Line Items]" } } }, "localname": "IncomeTaxDisclosureLineItems", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "elvn_IncomeTaxDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Table]" } } }, "localname": "IncomeTaxDisclosureTable", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "elvn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease, right-of-use asset.", "label": "Increase (Decrease) in Operating Lease, Right-of-use Asset", "negatedLabel": "Right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "elvn_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory Equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "elvn_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "elvn_LeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "elvn_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Current", "label": "Lease Liability Current", "verboseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilityCurrent", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "elvn_LesseeOperatingLeaseExtendedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease extended date.", "label": "Lessee Operating Lease Extended Date", "terseLabel": "Lease renewal term for office space extended date" } } }, "localname": "LesseeOperatingLeaseExtendedDate", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "elvn_MajorityNumberOfInitialMembersOfBoardOfDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Majority number of initial members of board of directors.", "label": "Majority Number Of Initial Members Of Board Of Directors", "terseLabel": "Majority number of initial members of board of directors" } } }, "localname": "MajorityNumberOfInitialMembersOfBoardOfDirectors", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "elvn_MergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger agreement.", "label": "Merger Agreement [Member]", "terseLabel": "Merger Agreement" } } }, "localname": "MergerAgreementMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_MinimumChangeInPercentageOfStockHolding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum change in percentage of stock holding.", "label": "Minimum Change In Percentage Of Stock Holding", "terseLabel": "Minimum change in percentage of stock holding" } } }, "localname": "MinimumChangeInPercentageOfStockHolding", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "elvn_NotExpirableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Not Expirable [Member]", "terseLabel": "Not Expirable" } } }, "localname": "NotExpirableMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_NumberOfVoteByCommonStockHolders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote by common stock holders.", "label": "Number Of Vote By Common Stock Holders", "terseLabel": "Number of vote by common stock holders" } } }, "localname": "NumberOfVoteByCommonStockHolders", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "elvn_OperatingLeaseRemainingRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease remaining right of use asset.", "label": "Operating Lease Remaining Right of Use Asset", "terseLabel": "Remaining operating lease right of use asset" } } }, "localname": "OperatingLeaseRemainingRightOfUseAsset", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "Operating loss carryforwards expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "elvn_OperatingRemainingLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating remaining lease liability.", "label": "Operating Remaining Lease Liability", "terseLabel": "Remaining lease liability" } } }, "localname": "OperatingRemainingLeaseLiability", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_OrganizationDescriptionOfBusinessAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization description of business and liquidity.", "label": "Organization Description Of Business And Liquidity [Abstract]" } } }, "localname": "OrganizationDescriptionOfBusinessAndLiquidityAbstract", "nsuri": "http://www.enliventherapeutics.com/20230623", "xbrltype": "stringItemType" }, "elvn_OrganizationDescriptionOfBusinessAndLiquidityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, description of business and liquidity.", "label": "Organization, Description of Business and Liquidity [Line Items]" } } }, "localname": "OrganizationDescriptionOfBusinessAndLiquidityLineItems", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "elvn_OrganizationDescriptionOfBusinessAndLiquidityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, Description of Business and Liquidity.", "label": "Organization, Description of Business and Liquidity [Table]" } } }, "localname": "OrganizationDescriptionOfBusinessAndLiquidityTable", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "elvn_OrganizationDescriptionOfBusinessAndLiquidityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, description of business and liquidity.", "label": "Organization Description Of Business And Liquidity [Text Block]", "terseLabel": "Organization, Description of Business and Liquidity" } } }, "localname": "OrganizationDescriptionOfBusinessAndLiquidityTextBlock", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" ], "xbrltype": "textBlockItemType" }, "elvn_PercentageOfStockHolding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of stock holding.", "label": "Percentage Of Stock Holding", "terseLabel": "Percentage of stock holding" } } }, "localname": "PercentageOfStockHolding", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "elvn_PostTaxYearTwoThousandAndTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Post Tax Year Two Thousand And Twenty One [Member]", "verboseLabel": "Post Tax Year 2021" } } }, "localname": "PostTaxYearTwoThousandAndTwentyOneMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_PreferredStockSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock shares issued and outstanding.", "label": "Preferred Stock Shares Issued And Outstanding", "terseLabel": "Shares Issued and Outstanding" } } }, "localname": "PreferredStockSharesIssuedAndOutstanding", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "elvn_RestrictedCashCollateralOfSublease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted cash collateral of sublease.", "label": "Restricted Cash Collateral Of Sublease", "terseLabel": "Restricted cash collateral of sublease" } } }, "localname": "RestrictedCashCollateralOfSublease", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "terseLabel": "Following Shares of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "elvn_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock member.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "elvn_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock member.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "elvn_SeriesSeedConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series seed convertible preferred stock member.", "label": "Series Seed Convertible Preferred Stock [Member]", "terseLabel": "Series Seed Convertible Preferred Stock" } } }, "localname": "SeriesSeedConvertiblePreferredStockMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncrementalStockCompensationExpenseForOptionRepricingForUnvestedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award incremental stock compensation expense for option repricing for unvested stock options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Incremental Stock Compensation Expense For Option Repricing For Unvested Stock Options", "terseLabel": "Incremental stock compensation expense for option repricing for unvested stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncrementalStockCompensationExpenseForOptionRepricingForUnvestedStockOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncrementalStockCompensationExpenseForOptionRepricingForVestedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award incremental stock compensation expense for option repricing for vested stock options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Incremental Stock Compensation Expense For Option Repricing For Vested Stock Options", "terseLabel": "Incremental stock compensation expense for option repricing for vested stock options." } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncrementalStockCompensationExpenseForOptionRepricingForVestedStockOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndForfeitedWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "share based compensation arrangement by share based payment award options cancelled and forfeited weighted average remaining contractual term 2.", "label": "Share based Compensation Arrangement By Share based Payment Award Options cancelled and forfeited Weighted Average Remaining Contractual Term 2", "terseLabel": "Weighted- Average Contractual Term, Options cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndForfeitedWeightedAverageRemainingContractualTerm2", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "durationItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options exercised and vested in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested In Period", "terseLabel": "Stock Options Outstanding, Options exercised and vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriod", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "share based compensation arrangement by share based payment award options exercised and vested intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested Intrinsic Value", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedIntrinsicValue", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement By Share based payment award options exercised and vested weighted average remaining contractual term2.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised and Vested Weighted Average Remaining Contractual Term 2", "terseLabel": "Weighted- Average Contractual Term, Options exercised and vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedWeightedAverageRemainingContractualTerm2", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "durationItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options grants average remaining contractual term.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants Average Remaining Contractual Term", "terseLabel": "Weighted- Average Contractual Term, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsAverageRemainingContractualTerm", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "durationItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Contractual Term.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Contractual Term", "terseLabel": "Weighted- Average Contractual Term, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTerm", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "durationItemType" }, "elvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionRepricingVestedAndUnvestedStockOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, stock option repricing, vested and unvested stock options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Option Repricing Vested And Unvested Stock Options Outstanding", "terseLabel": "Repricing vested and unvested stock options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionRepricingVestedAndUnvestedStockOptionsOutstanding", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "elvn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options exercised and vested in period weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercised And Vested In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercised and vested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "elvn_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExcercisePriceForRepricedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation shares authorized under stock option plans excercise price for repriced options.", "label": "Share-based Compensation Shares Authorized Under Stock Option Plans Excercise Price For Repriced Options", "terseLabel": "Excercise price for repriced options" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExcercisePriceForRepricedOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "elvn_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansMaximumExercisePriceForRepricedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation shares authorized under stock option plans maximum exercise price for repriced options.", "label": "Share-based Compensation Shares Authorized Under Stock Option Plans Maximum Exercise Price For Repriced Options.", "terseLabel": "Maximum exercise price for repriced options" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansMaximumExercisePriceForRepricedOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "elvn_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansMinimumExercisePriceForRepricedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation shares authorized under stock option plans minimum exercise price for repriced options.", "label": "Share-Based Compensation Shares Authorized Under Stock Option Plans Minimum Exercise Price For Repriced Options", "terseLabel": "Minimum exercise price for repriced options" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansMinimumExercisePriceForRepricedOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "elvn_SharebasedCompensationArrangementBySharebasedPaymentAwardExercisePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "sharebased compensation arrangement by sharebased payment award exercise price of common stock percent.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Exercise Price Of Common Stock Percent", "terseLabel": "Sharebased Compensation Arrangement By Sharebased Payment Award Exercise Price Of Common Stock Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExercisePriceOfCommonStockPercent", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "elvn_SharebasedcompensationarrangementbysharebasedpaymentawardsharesoptionsCancelledAndForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShareBased compensation arrangement by Sharebased payment award shares options cancelled and forfeited.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOptions cancelled and forfeited", "terseLabel": "Available for Grant, Options cancelled and forfeited" } } }, "localname": "SharebasedcompensationarrangementbysharebasedpaymentawardsharesoptionsCancelledAndForfeited", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "elvn_StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Upon Exercise of Stock Options Outstanding", "label": "Stock Issued During Period Shares Upon Exercise of Stock Options Outstanding", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "elvn_StockOptionRepricingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option Repricing.", "label": "Stock Option Repricing [Member]", "terseLabel": "Stock Option Repricing" } } }, "localname": "StockOptionRepricingMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary of Significant Accounting Policies Line Items", "terseLabel": "Summary of Significant Accounting Policies [LineItems]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "elvn_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies table.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "elvn_TaxCreditCarryforwardExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforward expiration year.", "label": "Tax Credit Carryforward Expiration Year", "terseLabel": "Tax credit carryforward expiration year" } } }, "localname": "TaxCreditCarryforwardExpirationYear", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "elvn_TaxYearTwoThousandAndThirtyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tax Year Two Thousand And Thirty Nine [Member]", "verboseLabel": "Tax Year 2039" } } }, "localname": "TaxYearTwoThousandAndThirtyNineMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_TaxYearTwoThousandFortyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tax Year Two Thousand Forty One [Member]", "verboseLabel": "Tax Year 2041" } } }, "localname": "TaxYearTwoThousandFortyOneMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_TaxYearTwoThousandTwentyOneAndPriorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tax Year Two Thousand Twenty One And Prior [Member]", "verboseLabel": "Tax Year 2021 and Prior" } } }, "localname": "TaxYearTwoThousandTwentyOneAndPriorMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_TheTaxCutsAndJobsActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Tax Cuts And Jobs Act [Member]", "terseLabel": "The Tax Cuts And Jobs Act" } } }, "localname": "TheTaxCutsAndJobsActMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_TwoThousandAndNineteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Nineteen Equity Incentive Plan.", "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "localname": "TwoThousandAndNineteenEquityIncentivePlanMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "elvn_UnvestedRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock.", "label": "Unvested Restricted Stock [Member]", "terseLabel": "Unvested Restricted Stock" } } }, "localname": "UnvestedRestrictedStockMember", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "elvn_VestingOfRestrictedStockAndStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of restricted stock and stock options.", "label": "Vesting Of Restricted Stock And Stock Options", "terseLabel": "Vesting of restricted stock and stock options" } } }, "localname": "VestingOfRestrictedStockAndStockOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "elvn_WeightedAverageCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average common shares outstanding.", "label": "Weighted-Average Common Shares Outstanding" } } }, "localname": "WeightedAverageCommonSharesOutstanding", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "elvn_WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average unvested common stock issued upon early exercise of common stock options.", "label": "Weighted-Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options", "verboseLabel": "Less: weighted-average unvested common stock issued upon early exercise of common stock options" } } }, "localname": "WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "elvn_WriteOffOfDeferredIpoCosts": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off\u00a0of deferred IPO costs.", "label": "Write Off Of Deferred IPO costs", "terseLabel": "Write-off\u00a0of deferred IPO costs" } } }, "localname": "WriteOffOfDeferredIpoCosts", "nsuri": "http://www.enliventherapeutics.com/20230623", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r267", "r409", "r417", "r435", "r436", "r445", "r451", "r457", "r489", "r532", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r267", "r409", "r417", "r435", "r436", "r445", "r451", "r457", "r489", "r532", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r218", "r219", "r220", "r221", "r250", "r267", "r295", "r296", "r297", "r408", "r409", "r417", "r435", "r436", "r445", "r451", "r457", "r485", "r489", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r250", "r267", "r295", "r296", "r297", "r408", "r409", "r417", "r435", "r436", "r445", "r451", "r457", "r485", "r489", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r482", "r529" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r152", "r153", "r154", "r200", "r201", "r207", "r208", "r209", "r210", "r212", "r213", "r304", "r305", "r306", "r327", "r328", "r337", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r382", "r383", "r385", "r386", "r387", "r396", "r397", "r398", "r399", "r400", "r401", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r456" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable, net" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "elvn_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued employee compensation costs" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "elvn_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued legal and professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r48", "r127" ], "calculation": { "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r456" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 10.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r304", "r305", "r306", "r474", "r475", "r476", "r527" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r152", "r153", "r154", "r155", "r165", "r200", "r201", "r207", "r208", "r209", "r210", "r212", "r213", "r304", "r305", "r306", "r325", "r326", "r327", "r328", "r337", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r382", "r383", "r385", "r386", "r387", "r388", "r396", "r397", "r398", "r399", "r400", "r401", "r411", "r412", "r413", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r78", "r79", "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Allocated share based compensation expense", "verboseLabel": "Incremental stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Convertible preferred stock (as converted)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r108", "r129", "r146", "r187", "r195", "r197", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r340", "r342", "r365", "r456", "r487", "r488", "r530" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r123", "r133", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r340", "r342", "r365", "r456", "r487", "r488", "r530" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total financial assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r336", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r91", "r92", "r336", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "California Franchise Tax Board" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r31", "r125", "r438" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r32", "r99" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r26", "r31", "r33" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Components of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r26", "r98" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r117", "r118", "r151", "r200", "r201", "r204", "r205", "r206", "r207", "r208", "r325", "r337", "r338", "r344", "r346", "r347", "r357", "r366", "r368", "r369", "r370", "r373", "r374", "r382", "r384", "r385", "r386", "r387", "r396", "r397", "r411", "r412", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Adoption of accounting standards update [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r117", "r118", "r200", "r201", "r204", "r205", "r206", "r207", "r208", "r325", "r337", "r338", "r339", "r344", "r346", "r347", "r348", "r351", "r357", "r366", "r368", "r369", "r370", "r373", "r374", "r382", "r384", "r385", "r386", "r387", "r396", "r397", "r411", "r412", "r418", "r419", "r478" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r152", "r164", "r202", "r211", "r329" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Accounting standards update, immaterial effect [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r130", "r131", "r132", "r146", "r168", "r169", "r171", "r173", "r180", "r181", "r203", "r222", "r224", "r225", "r226", "r229", "r230", "r232", "r233", "r236", "r240", "r248", "r365", "r437", "r466", "r472", "r479" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r104", "r112" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r52", "r216", "r217", "r431", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r474", "r475", "r527" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r56" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r456" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 9.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Common stock value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock $0.0001 par value; 26,264,364 shares authorized at December 31, 2022 and December 31, 2021; 3,570,019 and 3,435,014 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively", "verboseLabel": "Common Stock Value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation Related Costs [Abstract]" } } }, "localname": "CompensationRelatedCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r232", "r233", "r236" ], "lang": { "en-us": { "role": { "definitionGuidance": "Total Convertible Preferred Stock", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock", "verboseLabel": "Convertible Preferred Stock (as converted)" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails", "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r3", "r4", "r57", "r60", "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "verboseLabel": "Conversion of preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r1", "r2", "r101", "r107", "r319" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs capitalized" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible asset basis differences" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r90", "r522" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Capitalized research and development costs" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r521" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r521" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r90", "r522" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r90", "r522" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r88", "r90", "r522" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r320" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r90", "r522" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Goodwill differences" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "verboseLabel": "Deferred Tax Liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r90", "r522" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Fixed asset basis difference" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r29", "r46" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r29", "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r272", "r300", "r301", "r303", "r307", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendDeclaredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.", "label": "Dividend Declared [Member]", "terseLabel": "Dividend Declared" } } }, "localname": "DividendDeclaredMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings to shareholders either in cash, property, or capital stock.", "label": "Dividend Paid [Member]", "terseLabel": "Dividend Paid" } } }, "localname": "DividendPaidMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r64", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r140", "r156", "r157", "r158", "r159", "r160", "r166", "r168", "r171", "r172", "r173", "r177", "r355", "r356", "r414", "r416", "r440" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share Basic [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r140", "r156", "r157", "r158", "r159", "r160", "r168", "r171", "r172", "r173", "r177", "r355", "r356", "r414", "r416", "r440" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r174", "r175", "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r311" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r147", "r311", "r331" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Federal income tax" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r519", "r523" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r519", "r523" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r519", "r523" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income tax, less federal benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r519", "r523" ], "calculation": { "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "terseLabel": "Credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndTheUSFederalTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total compensation cost not yet recognized related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected to be recognized over a weighted-average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Stock Options Outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r56", "r119", "r137", "r138", "r139", "r148", "r149", "r150", "r153", "r161", "r163", "r179", "r210", "r249", "r304", "r305", "r306", "r327", "r328", "r354", "r375", "r376", "r377", "r378", "r379", "r380", "r401", "r420", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r358", "r359", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r95", "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r231", "r252", "r253", "r254", "r255", "r256", "r257", "r359", "r405", "r406", "r407", "r443", "r444", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r358", "r359", "r360", "r361", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r231", "r252", "r257", "r359", "r405", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r231", "r252", "r257", "r359", "r406", "r443", "r444", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r231", "r252", "r253", "r254", "r255", "r256", "r257", "r359", "r407", "r443", "r444", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r231", "r252", "r253", "r254", "r255", "r256", "r257", "r405", "r406", "r407", "r443", "r444", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r362", "r364" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r21" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "verboseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r44", "r50" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r147", "r312", "r317", "r323", "r330", "r332", "r333", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income Tax Examination, Description", "terseLabel": "Income tax examination, description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r136", "r309", "r310", "r317", "r318", "r322", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Uncertainties [Abstract]" } } }, "localname": "IncomeTaxUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r28" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r470" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r28" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Lease and rental expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Incremental borrowing rate of right of used assets and lease liabilities" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r394" ], "calculation": { "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r394" ], "calculation": { "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r394" ], "calculation": { "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r341", "r342", "r343", "r365", "r441", "r487", "r530", "r531" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r102", "r110", "r456", "r473", "r483", "r528" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r124", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r341", "r342", "r343", "r365", "r456", "r487", "r530", "r531" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r142" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r142" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r26", "r27", "r30" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r19", "r30", "r105", "r114", "r122", "r134", "r135", "r139", "r146", "r152", "r156", "r157", "r158", "r159", "r162", "r163", "r170", "r187", "r194", "r196", "r198", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r356", "r365", "r442", "r487" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit", "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently issued accounting pronouncements adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashMergerRelatedCosts": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.", "label": "Noncash Merger Related Costs", "terseLabel": "Deferred merger costs included in accounts payable / liabilities" } } }, "localname": "NoncashMergerRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r187", "r194", "r196", "r198", "r442" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Less: current portion of lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingSubleaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r389" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "elvn_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other\u00a0non-current\u00a0liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r25" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Deferred issuance costs related to merger / initial public offering" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r141", "r524", "r525", "r526" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r250", "r251", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "401(k) Savings Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/KSavingsPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r103", "r113", "r491", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.", "label": "Postemployment Benefits Liability", "terseLabel": "401(k) Savings Plan liability" } } }, "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/KSavingsPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "terseLabel": "Preferred stock dividend rate" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r4", "r57", "r58", "r472", "r490" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Per Share Liquidation Preference" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r144", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock, Liquidation Preference, Value", "terseLabel": "Preferred stock, liquidation preference, value", "verboseLabel": "Aggregate Liquidation Amount" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r232" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Authorized Shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r232" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r456" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Convertible preferred stock, $0.0001 par value; 61,730,064 shares authorized, issued and outstanding at December 31, 2022 and December 31, 2021, liquidation preference of $140,520 at December 31, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r469" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds Net of Issuance Costs", "verboseLabel": "Issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r51", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property and equipment estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r47", "r126" ], "calculation": { "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r49", "r111", "r415", "r456" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r49", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r80", "r115", "r538" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r467", "r471", "r539", "r541" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r430", "r468", "r471" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r64", "r109", "r424", "r429", "r456" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 11.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r119", "r148", "r149", "r150", "r153", "r161", "r163", "r210", "r304", "r305", "r306", "r327", "r328", "r354", "r420", "r422" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r393", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Lease liability obtained in exchange for right of use asset" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Sale of stock, consideration received per transaction" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary Of Accrued Expenses And Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of Company's Deferred Income Taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Loss Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r36", "r39", "r168", "r169", "r171" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareAntiDilutivePotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Summary of Effective Tax Rate and The U.S. Federal Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r75", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments Under Operating Sublease" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPreferredUnitsTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners.", "label": "Schedule of Preferred Units [Table Text Block]", "terseLabel": "Schedule of Convertible Preferred Stock" } } }, "localname": "ScheduleOfPreferredUnitsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r269", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r69", "r70", "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Plan Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Fair Value Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r53", "r54", "r55", "r57", "r58", "r59", "r61", "r62", "r63", "r64", "r130", "r131", "r132", "r180", "r232", "r233", "r234", "r236", "r240", "r246", "r248", "r445", "r466", "r472" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r28" ], "calculation": { "http://www.enliventherapeutics.com/role/StatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Issued shares in restricted common stock to its founders" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "terseLabel": "Issued shares in restricted common stock to its founders , per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, Unvested, Ending Balance", "periodStartLabel": "Number of Shares, Unvested, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Unvested, Ending Balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Remaining shares vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Available for Grant, Ending Balance", "periodStartLabel": "Available for Grant, Beginning Balance", "terseLabel": "Options available for grant under stock plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Stock Options Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercised and vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Stock Options Outstanding, Options cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Options cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options cancelled and forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock Options Outstanding, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance", "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance", "terseLabel": "Share-Based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock Options Outstanding, Ending Balance", "periodStartLabel": "Stock Options Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Stock Options Outstanding, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)", "terseLabel": "Available for Grant, Increase in option pool" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "negatedLabel": "Available for Grant, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails", "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vested Upon Issuance" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Shares vested immediately upon issuance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockBasedCompensationFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- Average Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining weighted-average vesting period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- Average Contractual Term, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationSummaryOfStockPlanActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "verboseLabel": "Share-Based Payment Award Options Vested in Period Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r34", "r143" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r130", "r131", "r132", "r146", "r168", "r169", "r171", "r173", "r180", "r181", "r203", "r222", "r224", "r225", "r226", "r229", "r230", "r232", "r233", "r236", "r240", "r248", "r365", "r437", "r466", "r472", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/ConvertiblePreferredStockScheduleOfConvertiblePreferredStockDetails", "http://www.enliventherapeutics.com/role/StatementOfCashFlows", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r56", "r119", "r137", "r138", "r139", "r148", "r149", "r150", "r153", "r161", "r163", "r179", "r210", "r249", "r304", "r305", "r306", "r327", "r328", "r354", "r375", "r376", "r377", "r378", "r379", "r380", "r401", "r420", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/StatementOfCashFlows", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r148", "r149", "r150", "r179", "r410" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/BalanceSheetsParenthetical", "http://www.enliventherapeutics.com/role/StatementOfCashFlows", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r56", "r64" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Restricted stock shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r56", "r64", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of common stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r4", "r5", "r56", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Restricted stock shares issued value" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r56", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r43", "r456", "r473", "r483", "r528" ], "calculation": { "http://www.enliventherapeutics.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets", "http://www.enliventherapeutics.com/role/StatementsOfConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r67", "r145", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r247", "r249", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/OrganizationDescriptionOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r381", "r403" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r381", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r381", "r403" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r402", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/CommonStockFollowingSharesOfCommonStockReservedForFutureIssuanceDetails", "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r82", "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of Company's Unrecognized Tax Benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r152", "r153", "r154", "r155", "r165", "r200", "r201", "r207", "r208", "r209", "r210", "r212", "r213", "r304", "r305", "r306", "r325", "r326", "r327", "r328", "r337", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r382", "r383", "r385", "r386", "r387", "r388", "r396", "r397", "r398", "r399", "r400", "r401", "r411", "r412", "r413", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r439", "r446", "r448", "r540" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Backed Money Market Funds" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r308", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, end of the period", "periodStartLabel": "Balance, beginning of the period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": { "auth_ref": [ "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense", "terseLabel": "Income tax penalties expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase related to current year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increase related to prior year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesSummaryOfCompanySUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits recognized, would affect the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r40", "r41", "r42", "r182", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Changes in the valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r392", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r167", "r173" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r166", "r173" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.enliventherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedLabel": "Less: weighted-average unvested restricted shares of common stock" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.enliventherapeutics.com/role/NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 73 0001193125-23-173796-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-173796-xbrl.zip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end